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Human physiological systems, especially the cardiovascular and musculo-skeletal systems, 
are well-known to decondition during spaceflight.  Several countermeasures that are in use today 
have been rigorously developed over the decades to combat this deconditioning.  However, these 
countermeasures are system specific and have proven to be only partially effective.  Artificial 
gravity has been persistently discussed as a countermeasure that potentially has salutary effects 
on all physiological systems, though few ground-based studies have been performed in 
comparison to other countermeasures.  The current analysis attempts to elucidate the 
effectiveness of artificial gravity by directly comparing results of previously published and 
unpublished deconditioning studies with those of more traditional, ground-based 
countermeasures (i.e. resistive exercise, aerobic exercise, lower body negative pressure, or some 
variation of these).  Animal studies were also evaluated to supplement the knowledge base and to 
fill gaps in the human countermeasure literature.  Designs of published studies, such as study 
duration, deconditioning paradigm, subject selection criteria, measurements taken, etc., were 
confounding variables; however, studies that had some measure of consistency between these 
variables were compared, although notable differences were cited in the analysis and discussion.  
Results indicate that for prolonged spaceflight an artificial gravity-based countermeasure may 
provide benefits equivalent to traditional countermeasures for the cardiovascular system.  Too 
few comparable, human studies have been performed to draw any conclusions for the musculo-
skeletal system, although animal studies show some positive results.  Gaps in the current 
knowledge of artificial gravity are identified and guidance for future deconditioning studies is 
offered.  Based on the results of this study, a comprehensive artificial gravity protocol is 
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As humankind prepares to venture from the safety of low-earth orbit (LEO) to more 
ambitious and novel destinations, countermeasures for microgravity and partial gravity 
deconditioning of astronauts will play a vital role in mission success.  For a hypothetical three 
year, round-trip mission to Mars, astronauts would need to maintain nearly a pre-flight level of 
fitness on the outbound one-year segment in order to safely endure a Martian landing and 
gravitational stress (3/8G).  In addition, astronauts would also need to maintain a high level of 
fitness on the return one-year voyage in order to endure a more violent Earth reentry and 
gravitational stress.  Regardless of which celestial destination humans will next embark, 
countermeasures to physiological deconditioning of humans will undoubtedly remain a high 
priority.  
1.1 Effects of Spaceflight on Human Physiology 
Spaceflight deconditioning has been a well-documented problem since orthostatic 
hypotension was first observed following the final two Mercury missions.  This deconditioning 
affects many physiological systems with effects that manifest at different time scales for the 
astronaut; some are realized upon entering microgravity while others take weeks in microgravity 
to become noticeable.  The following sections give a brief introduction to body systems and how 
these systems are affected by spaceflight. 
1.1.1 Cardiovascular System and Deconditioning 
The cardiovascular system is a profoundly intricate body system that has several critical 
functions.  Its primary tasks are to perfuse the body with oxygenated blood (the brain and central 
nervous system receive highest priority), to act as a communicative medium to different parts of 
the body, to remove waste and to meet metabolic needs of the human system.  In an 
oversimplified model, the cardiovascular system can be thought of as the heart, which acts as the 
pump, the pulmonary exchange, and the peripheral vasculature (Figure 1).  Within the heart, 
blood enters the right atrium from the vasculature and then enters the right ventricle.  Blood then 
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proceeds through the pulmonary loop to conduct gas exchange with the alveoli in the lungs and 
then flows to the left atrium and left ventricle and exits to the peripheral vasculature.  This 
vasculature consists of the collective arteries, which are – in order of decreasing size – the aorta, 
arteries, arterioles, pre-capillaries, and capillaries, and carry oxygenated erythrocytes, and the 
veins, which are – in order of increasing size – the venules, veins, and vena cava, and carry 
carbon dioxide waste.  Vasculature structure from the inside-out consists of an endothelium 
lining, which is a permeable membrane, smooth muscle cells, which can constrict and relax the 
vessel, and a collagen outer lining.  All of the vasculature, except the true capillary and venule, 
has these structures in varying degrees, which is shown in Figure 2. 
 





Figure 2.  Vasculature composition and cross-section  
The cardiovascular system has several methods of coping with systematic stress.  One of the 
primary mechanisms of mediating stress, such as moving from a supine to an upright position, is 
the baroreceptor reflex (also known as the baroreflex).  The baroreceptors are pressure sensors 
located in several areas of the body, including the aortic arch and the carotid arteries.  Unloading 
of these receptors in response to standing triggers the baroreflex, which initiates an autonomic 
nervous system response that increases heart rate, vasoconstriction and venous constriction, in 
order to maintain arterial blood pressure. 
Within minutes of entering the microgravity environment, blood and body fluids, which are 
normally pooled in the lower extremities in a gravitational environment, shift into the thorax and 
upper extremities (Figure 3).  This fluid shift is the reason astronauts exhibit „chicken legs‟ and 
„puffy face‟ and causes an increase in central venous pressure, which in turn increases cardiac 
stroke volume and cardiac output.  An increased transmural pressure in microgravity along with 
this cardiac distension results in plasma volume migrating from intravascular to extravascular 
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compartments (Beckers et al. 2006).  Plasma volume reduction on the order of 17% has been 
observed on the first day of spaceflight, thus leading to an increase in hematocrit.  This triggers a 
decrease in the level of erythropoietin, which is a regulating hormone of red blood cells, and 
results in a decrease in hematocrit over the first few days to a week (Buckey 2006).  However, 
hematocrit ultimately remains elevated from pre-flight levels. 
 
Figure 3.  Fluid shift in space. a) Normal 1G fluid distribution, b) Initial fluid shift in space, 
c) fluid shift from long duration spaceflight, d) fluid distribution upon return to Earth 
(Vernikos 1996) 
Long term adaptation in space has several implications for the astronaut.  Loss of plasma 
volume and elevated hematocrit persist throughout the spaceflight.  The cardiac muscle 
atrophies, which results in lower stroke volume and lower cardiac output.  For the arterial 
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vasculature, the lack of a gravitational stress results in increased vasoconstriction in space, which 
results in a reduction of vasoconstrictive reserve upon return to Earth.  This adaptation could 
contribute to the lower total peripheral resistance rise seen upon standing in astronauts post-flight 
versus pre-flight (Zhang et al. 2008).   
Orthostatic intolerance is observed in a number of astronauts returning from spaceflight; 
depending on how the orthostatic tolerance is defined, the incident rate of astronauts is as high as 
63% (Buckey 2006).  The exact mechanism for orthostatic intolerance has yet to be determined; 
however, it is most likely a combination of the adaptive changes above, including decreased 
plasma volume, stroke volume, and increased total peripheral resistance.  Moreover, data has 
shown that astronauts who are orthostatic intolerant exhibit a significantly lower norepinephrine 
response to standing than their tolerance counterparts (Fritsch-Yelle et al. 1996). 
Finally, aerobic capacity is affected by spaceflight.  Upon return to Earth, astronauts have 
exhibited a decrease in maximal oxygen uptake despite maintaining fitness in space with the use 
of countermeasures.  This decrease in oxygen uptake may occur as a result of the detrimental 
changes listed above.  
1.1.2 Muscular Physiology Deconditioning 
Skeletal muscle fibers are divided into predominately three groups: slow twitch (type I), 
fast-twitch non-fatigueable (type IIa), and fast-twitch fatigueable (type IIx).  Muscle groups that 
have a majority of slow twitch fibers are usually postural muscles that support the weight of the 
body in a 1G environment (e.g. soleus and gastrocnemius), whereas muscle groups with a 
majority of fast-twitch fibers are explosive muscles that are useful, for example, in sprinting (e.g. 
vasti group and rectus femoris). 
Postural muscles play a small role in the locomotion of astronauts in space.  In the absence 
of gravity, locomotion is performed by small bursts of muscle activation, followed by „flying‟ 
through the spacecraft, and then again small muscle bursts to arrest the astronaut.  Thus, 
antigravity muscles, which are predominantly extensor muscles such as the plantar flexors 
(soleus and gastrocnemius) and quadriceps (vastus lateralis, vastus intermedius, vastus medialis, 
and rectus femoris), atrophy initially to a greater extent than flexor muscle groups.  After long-
18 
 
duration flight, the extensors and flexors exhibit similar levels of atrophy (Fitts et al. 2000).  
Whole muscles also show evidence of a reduction of peak force and power after spaceflight.  The 
anatomical location of these muscle groups is shown in Figure 4, with the rectus femoris (not 
shown) located just anterior to the vastus intermedius. 
  
Figure 4.  Leg muscles of the left leg (anterior view)  
Atrophy of the muscles begins with an imbalance of muscle protein homeostasis.  During 
spaceflight, there is a decrease in rate of protein synthesis while the rate of breakdown remains 
the same.  This imbalance causes a decrease in fiber cross-sectional area (CSA), which 
ultimately results in atrophy of the whole muscle.   
Several changes take place within the muscle fiber itself.  Contractile proteins are lost 
disproportionately compared to other cellular proteins and actin molecules are lost to a larger 
extent than myosin molecules (Fitts et al. 2000).  This results in a decrease in force per CSA and 
an increase in the shortening velocities of the fibers.  In addition, slow-twitch fibers have a 
tendency to transition from a slow type I to fast type II fiber. 
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1.1.3 Bone Physiology and Deconditioning 
The human skeleton is composed of a collagen protein matrix as well as a mineral matrix of 
calcium carbonate.  Long bones of the body have an outer, dense region called the cortical bone 
while the inner trabecular region is of a much lower density matrix.  In a 1G environment, bone 
health is maintained through a process called remodeling, where osteoblast (used in bone 
formation) and osteoclast (used in bone resorption) activities are coupled and are constantly 
occurring.  Conversely, modeling is the adaptive process of bone that – according to Frost‟s 
mechanostat – tries to maintain bone mass to keep bone strain within an acceptable daily range 
(Frost 1997).  Modeling usually takes place on the periosteal, or outer surface of the bone, while 
the majority of remodeling occurs on the endosteal, or inner surface of the bone.  The aging 
process of bone of a normal ambulatory human results in an expansion of the endosteal as well 
as an expansion (to a lesser extent) of the periosteal so the section modulus of the bone is 
constant.  This process is shown in Figure 5A. 
During spaceflight, normal bone homeostasis is disturbed due to the absence of gravity.  
Osteoclast activity has been found to increase, while osteoblast activity decreases.  This 
imbalance results in a net loss of bone mineral density (BMD).  Furthermore, without gravity and 
stress on the bone, no modeling takes place in space.  The aging process of bone in space is an 
expansion of the endosteal while the periosteal remains constant, which results in a decrease in 
section modulus and decrease in bone strength.  This process is shown graphically in Figure 5B. 
Because of the absence of gravity in space, the normal load bearing sections of the skeleton 
will have the greatest loss of bone mineral density (BMD).  These sections include the hip, 
lumbar spine, and calcaneus.  Bone loss rates for various anatomical regions of the body are 
shown in Figure 6.  It is interesting to note that the upper regions of the body may increase bone 
mass.  This phenomenon might result from an increase in extracellular pressure due to fluid shift, 





Figure 5.  Bone changes due to A) normal aging – periosteal and endosteal expansion and 
B) spaceflight – only endosteal expansion 
 









1.1.4 Vestibular Physiology and Deconditioning 
The vestibular system plays a crucial role in balance control of the body, such as in normal 
locomotion or running.  It lies in the inner ear and is comprised of two organs: the semicircular 
canals and the otoliths.  The semicircular canals are three, roughly orthogonal, fluid-filled canals 
that detect angular acceleration of the head; however, due to the inherent design of the canals, the 
signal transmitted to the brain closely follows angular velocity.  The otoliths consist of the utricle 
and the saccule, which are two roughly orthogonal planes of calcium carbonate stones embedded 
in a sensory epithelium.  The otoliths detect linear acceleration, which includes gravity as well as 
linear acceleration from translational movement.  Because of this dual role, certain ambiguities – 
somatogravic illusions – arise that the otoliths cannot resolve.  For instance, pitching the head 
backwards to 45° past vertical will have the same otolith response as accelerating forward at a 
specific acceleration with the head upright, as seen in Figure 7.  This ambiguity is resolved by a 
number of mechanisms, including any visual cues, prolonged acceleration (interpreted as tilt), or 
a history of prior motions. 
 
Figure 7.  Tilt-translation ambiguity of the otoliths.  Backward head tilt has the same effect 
as forward acceleration (Previc and Ercoline 2004) 
In spaceflight, one important adaptation of the vestibular system is the otolith tilt-translation 
reinterpretation (OTTR).  Because there is an absence of gravity in space, the otoliths must adapt 
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by interpreting any acceleration as translation of the body instead of tilt.  While this adaptation is 
perfectly suitable for spaceflight, it has detrimental effects with the reintroduction of a gravity 
field.  Upon return to Earth, several astronauts have experienced translational acceleration with a 
given head tilt (Parker et al. 1985).  In addition to OTTR during spaceflight, the central nervous 
system may also reduce the weighting of the otoliths and rely more heavily on the visual scene to 
determine orientation.  Post-flight, experiments performed on a rotating chair have determined 
that astronauts tend to overestimate tilt (Clement et al. 2003). 
Finally, there exists some evidence that the sensitivity of the otolith afferents increases after 
spaceflight.  This phenomenon was observed in oyster toadfish that flew on STS-90 (Neurolab) 
and STS-95.  Otolith sensitivity was reduced to the pre-flight baseline 30 hours post-flight 






2.1 Evolution of Countermeasures 
Countermeasures for spaceflight deconditioning have continually evolved throughout the 
human experience in space.  This evolution has in part followed the continual refinement of how 
the human body adapts to life in space.  The following two sections present an overview of 
countermeasures on spacecraft through the 1990‟s and the countermeasures used in the 
International Space Station (ISS) era. 
2.1.1 Countermeasures from the Advent of Spaceflight through the 1990s 
The first manned spaceflights of Project Mercury witnessed medical advisors who were 
concerned not with how the astronauts‟ bodies would adapt to spaceflight, but rather if the 
human body could even survive in space.  There persisted a debate among the scientific 
community on whether astronauts could breathe in space, swallow in space, and so forth.  The 
first few Mercury spaceflights, however, quelled these concerns.   
Following Mercury-Atlas 8 and more dramatically after Mercury-Atlas 9, astronauts Walter 
Schirra and Gordon Cooper, respectively, experienced an exaggerated increase in heart rate and 
decrease in blood pressure upon standing from their capsule.  This orthostatic hypertension after 
the final two flights of the Mercury Project gave scientists their first indication that the human 
body changes with spaceflight.  Projects Gemini and Apollo soon followed Mercury, and 
astronauts were given a bungee device with which to exercise in space.  Because of the small 
size of the capsules, this bungee exercise was performed from the astronaut‟s seat by pushing on 
the bungee with the feet and restraining it with the hands.  This „exercise‟ was not intended to be 
a countermeasure, but rather a diagnostic tool to obtain a time-course history of the 
cardiovascular changes in space.  In addition, bone mineral density of Apollo astronauts was 
measured pre- and post-flight in the hand and foot by single-photon densitometers and was found 
to have decreased substantially, which indicated bone adaptations might take place during flight. 
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Skylab was the first American spacecraft to truly have countermeasures for spaceflight 
deconditioning.  Though because astronauts did not want to feel like guinea pigs in medical 
experiments and due to potential personal inconvenience, they strongly objected to a prescribed 
exercise plan.  Exercise was therefore not regulated on Skylab, but astronauts were still required 
to report how long and how hard they exercised and they were required to undergo periodic 
fitness tests (Compton and Benson 1983).  Skylab 2 was equipped with an upright cycle 
ergometer device as the primary countermeasure, which could be peddled with either the hands 
or feet (Figure 8).  Though the cycle ergometer was adequate for aerobic exercise, it did not 
provide the appropriate forces to maintain muscle mass.  Skylab 3 introduced additional 
countermeasure devices, the MK-I and MK-II (Figure 9), to perform isokinetic exercises.  These 
exercises provided appropriate forces to the upper body; however, the force transmitted to the 
legs was still less than 1G equivalent (Thornton and Rummel 1977).  Skylab 4 added a treadmill 
to the countermeasure gamut, although this treadmill was passive due to severe weight 
constraints.  The astronaut was restrained by bungees and ran on a low friction Teflon sheet, as 
shown in Figure 10.  Skylab also had a Lower Body Negative Pressure (LBNP) device, which 
was used to periodically test the integrity of the cardiovascular system.  A subsequent analysis of 
the Skylab data revealed that the periodic LBNP use did not significantly improve the post-flight 
performance of astronauts (Nicogossian et al. 1988).  [LBNP is a device that fits around the 
lower half of the body and evacuates some air to create a partial vacuum around the lower 
extremities.  This in turn causes blood to pool in the lower extremities as it would normally in 
1G to create cardiovascular stress.] 
 




Figure 9.  MK-I exercise device and exercises.  MK-II was similar in design to MK-I. 
(Thornton and Rummel 1977) 
 
Figure 10.  Skylab passive treadmill device (Thornton and Rummel 1977) 
Early shuttle missions had only a few countermeasures because of the small size of the cabin 
as well as the short duration (8-10 days) of the missions.  Astronauts made use of a treadmill, 
although the tread length was extremely short due to stowage requirements, and a cycle 
ergometer.  When a series of Extended Duration Orbiter (EDO) missions began with STS-50 in 
1992, a broader range of countermeasures was developed to assess their effectiveness in 16-day 
missions.  These countermeasures included a cycle ergometer (Figure 11), an EDO treadmill, 
which had a longer running surface and more comfortable harness than the shuttle treadmill, a 
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collapsible LBNP device (Figure 12), and a rowing device, which was similar to the MK-I and 
MK-II devices of Skylab. 
 
Figure 11.  Deployed EDO cycle ergometer (Sawin et al. 1999) 
 
Figure 12.  Collapsible LBNP device (Sawin et al. 1999) 
The Russians have also developed a series of countermeasures to deal with the problem of 
space deconditioning, especially countermeasures with respect to long-duration spaceflight since 
that has been the focus of their space program.  The devices developed for their space stations 
include: a treadmill with bungee cords and restraints for running, walking, or jumping; a cycle 
ergometer; the „Penguin‟ suit, which is a suit that exerts forces on the body through elastic cords 
and is worn throughout the 8-hour workday (Figure 13); an LBNP device; and the „Tonus-2‟ 
system, which is a multichannel device for electrically stimulating muscle (Kozlovskaya et al. 
1995).  The intensity and use of the countermeasure regime has depended in which of the three 
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flight segments the astronauts were.  During the first flight segment, exercise was relatively light 
and mainly performed on the cycle ergometer.  The second phase of flight utilized all the 
countermeasures except for the LBNP device and exercise was performed on a 3+1 schedule (3 
days of exercise, 1 day of rest).  During the final stage of flight (4-6 weeks before landing), 
cosmonauts performed exercise at the highest intensity, and, in addition, a steadily increasing 
LBNP regiment was applied (Kozlovskaya et al. 1995). 
 
Figure 13.  Penguin suit (Clement 2003) 
 
2.1.2 Current Countermeasures and Protocols on the International Space 
Station 
From this evolution of space exercise, a suite of countermeasures has been developed for use 
on the ISS.  Current facilities include: the advanced resistive exercise device (ARED), which 
replaced the interim resistive exercise device and is capable of exercising the arms and legs 
(Figure 14); the cycle ergometer with vibration isolation system (CEVIS), which is very similar 
to the EDO ergometer; and the T-2 treadmill with vibration isolation system (TVIS) (also known 
as COLBERT).  In addition, Russian cosmonauts continue to wear the Penguin suit and also 
continue to utilize the LBNP device that they maintain.  Finally, some non-traditional 
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countermeasures have made a debut on the ISS; namely, a trial phase has begun using the 
bisphosphonates alendronate and zoledronic acid as a pharmaceutical countermeasures for bone. 
 
Figure 14.  Advanced resistive exercise device (Bentley et al. 2006) 
2.2 Artificial Gravity 
One potential countermeasure approach that has been persistently discussed is artificial 
gravity (AG), which was first conceived by Konstantin Tsiolkovsky for application in space well 
before the space age (Clement and Bukley 2007).  AG has the potential to be a comprehensive 
multi-system countermeasure for human deconditioning because it directly supplies the missing 
stimulus – gravity – in space.  AG can be supplied via two distinct methods: 1) a large, 
continuously rotating spacecraft or 2) a short-radius centrifuge (SRC) within a conventional 
spacecraft.   
2.2.1 Continuous, Rotating Spacecraft 
A rotating spacecraft would be ideal from a countermeasure standpoint because it could 
provide a continuous, 1G acceleration, just as humans experience on Earth.  This rotating 
spacecraft could take the form of a rotating torus, such as one envisioned by Werner von Braun 
with the crew contained on its outside perimeter (Figure 15A), or the spacecraft could be a 
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rotating truss with the crew habitability module at one extremity (Figure 15B).  Recent studies 
have shown that rotating vehicles like Figure 15B need to only be 130 meters in diameter to 
create 1G while maintaining a tolerable rotation rate (Joosten 2002).  In addition, these designs 
are technically feasible and could be developed for costs comparable to conventional vehicle 
designs; however, this approach has not been popular with program managers.   
  
Figure 15.  Concepts for continuously rotating spacecraft.  A) Werner von Braun’s rotating 
torus, B) Jooston 2007 rotating truss.  
2.2.2 Short-Radius Centrifuge 
AG can also be supplied by a short radius centrifuge, which typically has a radius in the 
range of two or three meters (Figure 16).  This rotating platform would apply artificial gravity 
only intermittently, with astronauts experiencing weightlessness for the remainder of the day.  
Astronauts could be nominally rotated at 1G, or they could be rotated in hypergravity (>1G) to 
try to make up for the lack of gravity in space.   Because the acceleration level is dependent on 
radius in a rotating environment,  
𝐚𝐜 = 𝛚
𝟐𝐫      (1) 





Figure 16.  Example of a short radius centrifuge at the University of Texas Medical Branch 
(NASA) 
AG via SRC was first investigated by White et al. in 1965 (White et al. 1965), and SRC 
research has since continued intermittently in multiple countries around the globe.  To date, only 
one human centrifuge has flown in space on the STS-90 Neurolab mission, although this was an 
off-axis centrifuge and not primarily intended to be used to prevent deconditioning.  In addition, 
some Russian biosatellites (Cosmos series) have flown centrifuges that contained mice; however, 
these centrifuges did not supply AG intermittently, but rather continuously.  Despite this 
research, the questions of „how many Gs?‟, „how long for centrifugation?‟, and „how often to 
apply centrifugation?‟ to prevent human deconditioning still remain due primarily to the overall 
low number of AG studies performed.    
Several SRCs exist throughout the world that are still operational.  On some centrifuges, the 
subject only passively rides, such as the centrifuge at the University of Texas Medical Branch 
(UTMB), while others have the capability for subjects to perform exercise while undergoing 
centrifugation, such as cycling or squats.  One example of this type is the centrifuge at the 
Massachusetts Institute of Technology, Man Vehicle Laboratory.  A list of known short radius 






Despite over four decades of optimization to the „traditional countermeasures‟, a high rate of 
deconditioning is still observed in astronauts returning from ISS Expeditions.  Specifically, a 
study by Trappe et al. has shown that calf muscle maximum voluntary contraction (MVC) and 
muscle volume was significantly decreased after six months aboard the ISS (Trappe et al. 2009).  
Of particular concern, however, is the precipitous loss in bone mineral density (BMD) after six 
month ISS expeditions, with losses of 1.2–1.5%/month (p < 0.0001), 0.4–0.5%/month (p < 0.01), 
and 2.2–2.7%/month (p<0.001) observed in the hip integral, cortical, and trabecular regions, 
respectively (Lang et al. 2004).  Some individuals from this study incurred losses equivalent to 
one-half the BMD loss that they would experience in a lifetime of normal aging.  While these 
rates of deconditioning are deemed acceptable by NASA for low earth orbit and perhaps even 6-
month excursions to the Moon, they will certainly not be acceptable for exploration-class 
missions (e.g. a Mars mission currently has an estimated mission time of three years).  The need 
for improved comprehensive countermeasures from the status quo is clear. 
Space agencies have invested far more resources into studies using traditional 
countermeasures, which have resulted in advanced, although only partially effective, protocols 
that are well past a definition phase.  Before increasing investment in an AG-based 
countermeasure approach, a study is needed to investigate scientific merit of pursuing an AG 
countermeasure instead of only continuing with system specific countermeasures.  The present 
study addresses this problem and is an exploratory analysis on comparing the effectiveness of 
AG-based studies to the effectiveness of traditional countermeasure-based studies.  The 
hypotheses for this analysis is that AG will be as effective as the traditional countermeasures for 
the cardiovascular system, while not enough data exists to make a judgment on the 
musculoskeletal system.  Moreover, AG coupled with exercise is hypothesized to be a greater 
benefit to physiological systems than AG alone. 
2.4 Ground-Based Analogs 
One of the greatest hindrances for evaluating countermeasures during spaceflight is the lack 
of rigorous controls, whereas in the laboratory investigators can control almost all aspects of 
research.  For instance, falling behind the flight plan often led to abbreviating or completely 
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skipping exercise sessions in early spaceflight.  Only since the ISS era has the exercise block 
been completely preserved and only until the installation of ARED and T-2 in 2009 can the 
actual workload and ground reaction forces be recorded and correlated to each astronaut (no 
results yet of this endeavor).  In addition, the lack of a control group in space also serves to 
hinder evaluations of countermeasures as there is no one to which the astronauts can compare, 
save for their own fitness level pre-flight.  Indeed, having a control group in space that did not 
exercise would present a major ethical dilemma, which is most likely the reason it has not been 
executed. 
Because of these difficulties in evaluating countermeasure effectiveness in space (not to 
mention the cost of performing iterative studies), it became necessary to develop methods for 
ground-based studies to represent an analog environment. 
2.4.1 Human Ground-based Deconditioning Paradigms 
Methods to create an analog space environment began almost with the dawn of spaceflight.  
Some method was needed to immobilize the subject as well as reduce the effect of gravity, if 
possible.  A few deconditioning paradigms met these goals. 
2.4.1.1 Wet or Dry Immersion 
Immersion in water seemed like a logical choice as water offloads much of the effect of 
gravity.  The Russians have had vast experience with this method and first utilized wet 
immersion, in which the subject is submerged to the neck, as a deconditioning measure.  
However, subjects cannot stay submerged in water for extended periods of time and this method 
was only used for very short studies on the order of a few days or less.  A suitable modification 
to wet immersion for longer duration studies is dry immersion in which the subject dons a rubber 
suit and thus remains dry throughout the experiment.   
2.4.1.2 Bed Rest 
Another method developed to immobilize subjects is through the bed rest model, in which 
subjects are confined to a bed for the duration of the study.  The only exceptions to bed rest 
would be for countermeasure exercise (ideally it would still be in a recumbent position).  In order 
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to elicit appropriate responses, such as fluid shift, Russian investigators adjusted the paradigm to 
a head down bed rest (HDBR) regime and experimented with angles until 6° head down was 
deemed optimal (Pavy Le Traon et al. 2007).  A 6° HDBR has since become the standard of bed 
rest deconditioning.   
2.4.1.3 Unilateral Lower Limb Suspension 
Another method to immobilize subjects is through unilateral lower limb suspension (ULLS).  
In this paradigm, the subject uses crutches and moves about on only one leg with a shoe that has 
a large sole.  Thus, the other leg does not receive any weight support.  Because this paradigm 
only immobilizes one leg and does not mimic the fluid shift and other deconditioning aspects 
associated with spaceflight, it is not commonly employed. 
2.4.2 Animal Ground-based Deconditioning Paradigm 
Animals are extremely valuable to medical research because they are much cheaper than 
human studies, and animals have the added benefit of enabling the use of invasive or destructive 
techniques.  Large bipedal primates, such as monkeys, can still utilize the HDBR model and 
produce a similar response to humans.  Quadrupeds, such as mice or rats, on the other hand 
cannot use the HDBR model because they would still be standing and not immobilized.  A head-
down, hindlimb unloading model (tail suspension, or SUS) was developed by E. R. Morey in 
1979 to simulate a fluid shift and hindlimb immobilization (Morey-Holton et al. 2005).  In this 
model, the rat, for instance, is suspended from its tail so the hindlimbs are suspended and the 
head is angled sharply downward.  The rat usually retains some mobility with its front limbs; the 
bar to which the tail is attached can swivel 360°.  Since its inception in 1979, the hindlimb 
unloading model has become the standard space analogue for rodents.  One example of the 
model is shown in Figure 17. 
One problem does arise with animal experiments that is not present in human experiments.  
In taking most physiological measurements, animals must be sacrificed because many techniques 
(discussed later in 2.5) require the removal of parts of the anatomy.  Because of this nuance, 
animal experiments require an additional experimental „control‟ group that are killed at the 




Figure 17.  Hindlimb suspension model (Morey-Holton et al. 2005) 
2.4.3 Ground-based Countermeasures 
Countermeasures that have been assessed in human, ground-based studies have tended to 
closely parallel countermeasures used in space.  For example, the cycle ergometer, LBNP, and 
isokinetic exercise of ground studies closely resemble the cycle ergometer, LBNP, and MK-
I/MK-II, respectively, which have been used in space.  Other countermeasures, such as squats 
and calf presses, have been performed on the ground with a flywheel device, such as that shown 
in Figure 18.  In addition, some countermeasures for ground studies have been developed that are 
a combination of these countermeasures.  For instance, an LBNP device with a vertical treadmill 
(Figure 19) has been developed in California.   This device uses LBNP to pull the horizontal 
subject onto the vertical treadmill with the force equivalent to 1G.  Another example is the 
specially designed resistive exercise device for rigorous strength training as shown in Figure 20.  
This device was used only in the Shackelford et al. 2004 study and had the capability to exercise 




Figure 18.  Flywheel exercise device for performing supine squats and calf presses 
 
Figure 19.  LBNP device with a vertical treadmill (Lee et al. 2007) 
 
Figure 20.  Specially designed resistive exercise device for high intensity training for a long-
duration study (Shackelford et al. 2004) 
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As previously mentioned, ground-based studies investigating AG as a countermeasure have 
either had subjects passively ride the centrifuge or have coupled centrifugation with exercises 
such as cycling.  In addition to centrifugation per se, some investigations have used standing or 
walking (in 1G) to simulate the AG countermeasure. 
A variety of countermeasures have also been developed for animals, with many being 
similar to their human counterpart, such as passive centrifugation (in the –Gx direction), standing 
or walking in 1G, or head-up tilt.  On the other hand, some countermeasures to simulate resistive 
exercise differ substantially from their human counterpart, such as dropping the animal from 
58cm (Hauschka et al. 1987), climbing an 85° grid (Herbert et al. 1988), mechanical stimulation 
where the rat‟s leg undergoes external loading (Innman et al. 1999), or electrical stimulation to 
trigger muscle contraction (Haddad et al. 2006).  In addition to these countermeasures, animal 
testing is also very valuable for pharmaceutical countermeasures, where effectiveness and dose 
rates can be investigated before progressing to human trials.  These studies will be detailed in the 
following chapter. 
2.5 Measurement Techniques of Ground Studies 
The measurement techniques used for assessing subjects in ground-based studies are vast.  
Notable diagnostic techniques are discussed in the following sections, which are portioned into 
body systems that the measurements diagnose.  Special attention is given to where and how the 
measurement is performed.  This discussion of techniques will greatly aid in comprehending the 
results of a number of studies. 
2.5.1 Cardiovascular Measurements 
2.5.1.1 Orthostatic Tolerance 
Orthostatic tolerance is measured through a test that stresses the cardiovascular system.  
This test usually takes the form of a head-up tilt to 60°-80° from a supine starting position.  
However, Russian and Japanese investigators have used a +3Gz (measured at the feet) overload 
to provide cardiac stress, while other investigators have used a graded LBNP test as the stressor.  
These tests are terminated when either the subject reaches a preset time limit or the subject 
undergoes presyncope.  Presyncope itself is defined in a variety of manners, though the most 
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common definition is any occurrence of the following: sudden drop in heart rate (>15 beats per 
minute), systolic blood pressure (>25mmHG), or diastolic blood pressure (>15mmHG), 
sweating, nausea, or clammy skin.  Orthostatic tolerance time is the measured by the time 
elapsed in the stress test. 
2.5.1.2 Vital Signs / Cardiac Measurements 
Vital signs that were typically measured in experiments are resting heart rate and blood 
pressure.  If the experiment involved an orthostatic tolerance test or an exercise test, these vital 
signs were typically measured at the termination of the test as well.  Heart rate was measured by 
a standard electrocardiogram (EKG).  Blood pressure was measured either by a 
sphygmomanometer and cuff at the arm, by a photoplethysmographic method (PPG) in the ear 
lobe, or by a finger blood pressure cuff.  The PPG and finger blood pressure cuff could be used 
to obtain continuous blood pressure measurements.  Blood pressure was presented in the 
literature by either systolic/diastolic pressure or by the mean arterial pressure, which is the 
weighted average pressure of an artery over one heart cycle. 
 Cardiac function was measured through an EKG analysis.  Stroke volume was calculated as 
the product of the aorta cross sectional area (CSA) and the integral of the beat-to-beat aortic 
outflow (measured by ultrasound).  Cardiac output was generally calculated as the product of the 
stroke volume and heart rate.  Total peripheral resistance (TPR), which is the sum of resistances 
in the systemic vasculature, was calculated as the mean arterial pressure divided by the cardiac 
output.  The degree of change in TPR with cardiovascular stress is indicative of the baroreflex. 
Blood samples drawn from subjects provided the means to measure hematocrit, which is the 
fraction of packed erythrocyte volume of blood.  Blood assays could also be performed to 
measure catecholamines, such as epinephrine and norepinephrine.  Plasma volume – the liquid 
component of blood – is also measured in a variety of manners.  Older investigations used the 
Evan‟s blue dye dilution method; however, this method has now been banned in many countries 
because it involved the use of a radioisotope.  Plasma volume is also estimated through 
hematocrit measurements, although this method yields only percentage change of plasma 
volume.  A newer method to measuring plasma volume is the carbon monoxide (CO) rebreathing 
method, which has been used extensively in recent studies. 
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2.5.1.3 Aerobic Capacity 
Aerobic capacity was measured by a graded exercise test – either graded cycle ergometer or 
graded treadmill – until the subject underwent volitional fatigue.  Total exercise time, which is a 
measure of endurance, was the total elapsed time of the exercise test.  Gaseous exchange studies 
were performed on these tests and included measurements such as VO2 – the rate of oxygen 
uptake per minute, VE – the volume of air inhaled in one minute (minute ventilation), and 
Respiratory Exchange Ratio (RER) – the ratio between exhaled CO2 and inhaled O2.  Several 
degrees of these measurements are made with the exercise test, including a resting measurement, 
possible submaximal measurements, and maximum measurements (the maximum measurements 
usually occur close to volitional fatigue).  
2.5.1.4 Spectral Power Analysis 
A relatively new technique to measure the autonomic nervous system is through heart rate 
variability.  A frequency analysis of heart rate variability divides the response into low frequency 
(LF) and high frequency (HF).  The high frequency (0.15 – 0.04 Hz) is indicative of 
parasympathetic activity, while the low frequency is affected by both sympathetic and 
parasympathetic activity.  The ratio LF/HF reveals the sympathetic activity alone. 
2.5.1.5 Measurements from Biopsies 
Invasive techniques used for animals have involved the excision of sections of the basilar 
and femoral arteries.  These sections were used to analyze the artery CSA, media (i.e. smooth 
cells and elastin fiber layers) thickness, intraluminal diameter, CSA of smooth cells, and number 
of smooth cells.  In addition, contractile responses of the samples were also obtained with the 
addition of 100 mM potassium chloride (KCl).    
2.5.2 Skeletal Muscle Measurements 
The primary concern with muscle deconditioning lies with the antigravity muscles.  
Therefore, measurements in experiments are almost exclusively performed on the soleus, 
gastrocnemius, and quadriceps.  
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2.5.2.1 Non-invasive Techniques 
Non-invasive techniques for assessing human muscle are widespread.  Magnetic resonance 
imaging (MRI) was used to determine the muscle CSA as well as the whole muscle volume.  A 
dynamometer was used to obtain muscle strength and maximum voluntary contraction (MVC) 
data.  
2.5.2.2 Muscle Fiber 
Muscle biopsies were performed to determine muscle fiber characteristics.  In many studies, 
the biopsy was stained to differentiate between type I, type IIa, and type IIx fibers.  From these 
biopsies, fiber CSA (or diameter) and fiber type ratios could be obtained.  In addition, fiber 
performance characteristics were determined, such as Vo, fiber shortening velocity, and Po, peak 
force.  Finally, a common measurement with animal experiments – since the whole muscle is 
excised – is the wet weight of the muscle. 
2.5.3 Bone Measurements 
2.5.3.1 Direct Bone Measurements 
Dual energy X-ray absorptiometry (DXA) scans have been used extensively throughout 
manned spaceflight for BMD measurements.  Many experiments still utilize this method for the 
ability to compare to historical data.  The major inhibitor to DXA scans, however, is that density 
[g/cm
3
] is not really measured, but rather it is an areal density [g/cm
2
].  Another measurement 
technique that has been used (often in conjunction with DXA) is peripheral quantitative 
computed tomography (pQCT), which can make volumetric measurements and distinguish 
between cortical and trabecular bone.  Measurements are usually performed on the weight 
bearing bones, with special attention given to areas of the hip such as the femoral neck and 
greater trochanter.  Other sights of interest are the calcaneus, lumbar spine, and tibia. 
Because the bone (specifically the femur) is removed in animal experiments, mechanical 
testing can be performed.  Measurements that have been obtained are wet weight, dry weight, 
elastic load, and maximum load.  
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2.5.3.2 Bone Markers 
Bone can also be assessed through an array of bone markers found in blood serum and urine, 
although they tend to be extremely variable depending on the time of day the sample is taken.  
To reduce variability as much as possible, a 24-hour sampling period is performed.  One 
downside of bone marker measurements is that they represent the entire skeletal homeostasis and 
are not capable of translating site-specific information.  Bone markers can represent either 
osteoblast or osteoclast activity; a detailed list is found in Table 1. 
Table 1. Bone markers of the body 
BONE FORMATION 
Acronym Name Location 
25(OH)D 25-Hydroxy vitamin D Serum 
1,25(OH)2D 1,25-dihydroxy vitamin D Serum 
OC Osteocalcin Serum 
BSAP Bone specific alkaline phosphate Serum 
PTH Parathyroid hormone Serum 
BONE RESORPTION 
NTX n-telopeptide cross-link Urinary 
PYD Pyridinoline Urinary 
DPD Deoxypyridinoline Urinary 
  Calcium Urinary 





An exhaustive review of AG literature – published and unpublished studies using either 
human or animal subjects – was performed.  Owing to the absence of long-radius centrifuge 
experiments that investigate countermeasures to deconditioning, this study was limited to 
analyzing results from intermittent AG experiments (via SRC).  Paradigms of standing, walking, 
or head-up tilt were also included as a variant of AG. 
A review of the literature was also performed on traditional countermeasures, which are 
defined as the types of countermeasures, or some variation, currently available on the ISS 
(Section 2.4.3).  It was impossible to perform an exhaustive review of this body of literature, as 
there are a vast number of studies that have been performed.  To bring some order to the 
literature search, a method was adopted to start with the most recent studies and progress 
backwards to older studies.  This method was justified by reasoning that the most recent studies 
will have the most advanced countermeasure protocols, and thus theoretically have the greatest 
salutary effect on the subjects.  
This literature was compiled into a master database that details the experimental methods as 
well as the results of each study.  The following tables are abridged versions of the master 
database and serve to inform the reader of the experiments that were included in this study.  AG 
deconditioning studies that use human subjects are listed in Table 2, while those that use animals 
as subjects are listed in Table 3.  AG training studies (no deconditioning) with humans are found 
in Table 4.  Traditional countermeasure deconditioning studies using human subjects are found 
in Table 5 and that use animals are found in Table 6.  The complete database is shown in 
Appendix B:  Master Database. 
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3.1 Artificial Gravity Studies 
Table 2.  Human AG deconditioning studies 
























et al. 1979  
Moscow 3 Wet Immersion 6M / 5M 1.6   40 3 120 7 AG 
Vil-Viliams et 
al. 1980a 
Moscow 3 Dry Immersion 6M / 5M 1.6   40 3 120 7 AG 
Grigoriev et 
al. 1979 
Moscow 13 Dry Immersion 5M / 5M 
0.6-
2.0 




Iwasaki et al. 
2001  
Nihon 4 HDBR 10M / 10M   2 30 2 60 7 AG 
Sasaki et al. 
1999 
Nihon 4 HDBR 4M / 8M   2 30 2 60 7 AG 
Caiozzo et al. 
2009  
UTMB 21 HDBR 7M / 8M 2.5 1 60 1 60 7 AG 
Smith et al. 
2009  
UTMB 21 HDBR 7M / 8M 2.5 1 60 1 60 7 AG 
Moore et al. 
(Unpublished) 
UTMB 21 HDBR 7M / 8M 2.5 1 60 1 60 7 AG  
Stenger et al. 
(Unpublished)  
UTMB 21 HDBR 7M / 8M 2.5 1 60 1 60 7 AG  
Iwasaki et al. 
2005  
Nagoya 14 HDBR 6M / 6M   1.2 30 1 30 3-4 AG+Cycling 
Iwase 2005  Nagoya 14 HDBR 6M / 6M   1.2 30 1 30 3-4 AG+Cycling 
Katayama et 
al. 2004  
Nagoya 20 HDBR 5M / 5M 1-5 0.3-1.4 40 1 40 3-4 AG+Cycling 
Akima et al. 
2005  
Nagoya 20 HDBR 5M / 5M 1-5 0.3-1.4 40 1 40 3-4 AG+Cycling 
Vil-Viliams et 
al. 1980b  
Moscow 28 Dry Immersion 4M / 4M 
0.8-
1.6 








al. 1996  
Ames 4 HDBR 9M / 9M 1 1 15 8, 16 120, 240 7 Standing 
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al. 1996  
Ames 4 HDBR 9M / 9M 1 1 15 8, 16 120, 240 7 Walking 
Lee et al. 
1997  














Table 3.  Animal AG deconditioning studies 

























28 HDBR 6M 
1.2, 1.4, 
1.6 
30-40 1 30-40 4-5 AG 
1.2 30 1 30 4-5 AG 
Belozerova 
















8F 1.5 60 1 60 7 AG 
8F 1.5 120 1 120 7 AG 
6F 2.6 60 1 60 7 AG 
7F 2.6 120 1 120 7 AG 








9F 1.2 15 4 60 7 AG 







21 SUS 7M 
1.5 60 1 60 7 AG 
2.6 60 1 60 7 AG 
N/A 
120 1 120 7 HUT 
240 1 240 7 HUT 
60 1 60 7 Standing 
120 1 120 7 Standing 
240 1 240 7 Standing 
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28 SUS 7M N/A 
60 1 60 7 Standing 
120 1 120 7 Standing 
240 1 240 7 Standing 
28 SUS 6M 
1.5 60 1 60 7 AG 
2.6 60 1 60 7 AG 
N/A 60 1 60 7 Standing 
28 SUS 10M N/A 
60 1 60 7 Standing 
120 1 120 7 Standing 







28 SUS 8M N/A 60 1 60 7 Standing 






28 SUS 7M N/A 
120 1 120 7 HUT (45°) 
240 1 240 7 HUT (45°) 










60 1 60 7 Standing 
120 1 120 7 Standing 
240 1 240 7 Standing 
120 1 120 7 HUT (45°) 
240 1 240 7 HUT (45°) 
28 6M 240 1 240 7 HUT (45°) 
28 5M 60 1 60 7 Standing 
28 7M 120 1 120 7 Standing 
Thomason 








120 1 120 7 Standing 
SUS 7F 240 1 240 7 Standing 
SUS 8F 90 1 90 7 Walking 
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7 SUS 8M 
 






28 SUS 7F 
 
10 to 90 1 10 to 90 7 Walking 
Hauschka 




7 SUS 12M 
 






7 SUS 12M 
 












Table 4.  Human AG training (no deconditioning) studies 











Iwase et al. 2002 Nagoya 4 sessions 8M / 8M   1-2 N/A 
AG, 
AG+Cycling 
Stenger et al. 2007 Ames 21 
13 / 13 (14 
Male 12 
Female) 
1-2.5   5 
AG, 
AG+Cycling 
Evans et al. 2004 Ames 21 7 / 7 1-2.5   5 
AG, 
AG+Cycling 
Caiozzo et al. 2004 UC - Irvine 4 sessions 
14 (8 Male, 6 
Female) 
1-3   N/A 
AG, 
AG+Cycling 
Iwasaki et al. 1998 Nihon 7 9M   2 7 AG 
Greenleaf et al. 1999 Ames sessions 
4M, 2F Varied   N/A AG+Cycling 
7M 2.2   N/A AG+Cycling 
7M Varied   N/A AG+Cycling 
Yang et al. 2007a UC - Irvine 4 sessions 
14 (8 Male, 6 
Female) 
1.5-3   N/A 
AG+Squats, 
AG+Cycling 
Yang et al. 2007b UC - Irvine N/A 22M, 19F 
1.5, 2.0, 
2.5, 3.0 
  N/A 
AG+Squats, 
AG+Cycling 
Edmonds et al. 2007 MIT N/A 8M, 5F 0.7, 1.0, 1.3   N/A 
AG+Stair 
Stepper 






3.2 Traditional Countermeasure Studies 
Table 5.  Human deconditioning studies using traditional countermeasures 





















Guell et al. 1995 
Series 1 
MEDES 28 HDBR 5M / 5M 20 3-6 120-240 7 LBNP 
Lee et al. 1997 UTMB 5 HDBR 8M / 8M 30 1 30 7 
LBNP w/ 
Treadmill 
Schneider et al. 
2002 




al. 2000  
Ames 15 HDBR 8M / 8M 40 1 40 7 
LBNP w/ 
Treadmill 
Lee et al. 2007  UCSD 30 HDBR 
8M / 8M 
(Twins) 
45 1 45 6 
LBNP w/ 
Treadmill 
Lee et al. 2009  UCSD 30 HDBR 
7F / 7F 
(Twins) 




al. 2007  
UCSD 30 HDBR 
8M, 7F / 
8M, 7F 
(Twins) 
45 1 45 6 
LBNP w/ 
Treadmill 
Smith et al. 2003  UCSD 30 HDBR 
8M / 8M 
(Twins) 
45 1 45 6 
LBNP w/ 
Treadmill  
Zwart et al. 2007  UCSD 30 HDBR 
7F / 7F 
(Twins) 
45 1 45 6 
LBNP w/ 
Treadmill  
Guinet et al. 2009  MEDES 60 HDBR 7F / 6F 50 1 50 6 
LBNP w/ 
Treadmill, Squat 
and Calf Press  
Edgell et al. 2007 MEDES 60 HDBR 7F / 6F 50 1 50 6 
LBNP w/ 
Treadmill, Squat 
and Calf Press  
Schneider et al. 
(Unpublished) 
MEDES 60 HDBR 7F / 6F 50 1 50 6 
LBNP w/ 
Treadmill, Squat 
and Calf Press  
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Trappe et al. 
2007a  
MEDES 60 HDBR 7F / 6F 50 1 50 6 
LBNP w/ 
Treadmill, Squat 
and Calf Press  
Trappe et al. 
2007b  
MEDES 60 HDBR 7F / 6F 50 1 50 6 
LBNP w/ 
Treadmill, Squat 
and Calf Press  
Trappe et al. 
2008  
MEDES 60 HDBR 7F / 6F 50 1 50 6 
LBNP w/ 
Treadmill, Squat 
and Calf Press  
Smith et al. 2008  MEDES 60 HDBR 7F / 6F 50 1 50 6 
LBNP w/ 
Treadmill, Squat 
and Calf Press  
Guell et al. 1995 
Series 2  









Hughson et al. 
1994  







Suzuki et al. 1994  Tokyo 20 
Horizontal Bed 
Rest 
6M / 3M 60 1 60 7 Cycling 
Greenleaf et al. 
1989  
Ames 30 HDBR 5M / 7M 30 2 60 5 Cycling 
Wu et al. 
(Unpublished) 
Beijing 30 HDBR 5M / 5M 30 1 30 6 Cycling 
Shibata et al. 
2010 
Dallas 18 HDBR 
6M, 1F / 
6M, 1F 
30 3 90 7 
Cycling, 
Cycling+Dextran 
Greenleaf et al. 
1989  
Ames 30 HDBR 5M / 7M 30 2 60 5 
Isokinetic 
Exercise 
Bamman et al. 
1998  
UTMB 14 HDBR 8M / 8M 30 1 30 3-4 Squat 
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Chantemele et al. 
2004  
MEDES 90 HDBR 9M / 9M   1   2-3 
Squat and Calf 
Press 
Alkner et al. 2004  MEDES 90 HDBR 9M / 8M 40 1 40 2-3 
Squat and Calf 
Press 
Trappe et al. 
2004  
MEDES 90 HDBR 6M /6M 40 1 40 2-3 
Squat and Calf 
Press 
Wu et al. 
(Unpublished) 
Beijing 30 HDBR 5M / 5M 30 1 30 6 
Squat and Calf 
Press 
Tesch et al. 2004  MEDES 35 ULLS 
7M, 4F / 
7M, 3F 
40 1 40 2-3 
Squat and Calf 
Press 
Koryak et al. 
1997 
Moscow 120 HDBR 4F / 4F 60 1 60 6 
Squat and Arm 
Press 





13M, 5W / 
5M, 4W 












Table 6.  Animal deconditioning studies using traditional countermeasures 
 





















7 SUS 8M 1.5 4 6 7 Climbing 
Hauschka 














6 SUS 7F 27 

































     In order to perform statistical tests across studies, it was imperative to have a single 
parameter that embodied both control group and treatment group data.  This single parameter 
was the so-called treatment effect, which is a difference of differences that was calculated as the 
control group difference minus the treatment group difference.  The control group difference, for 
example, was the difference between post- and pre-bed rest means.  Each study was weighted by 
the inverse variance of its treatment effect, which was determined by first calculating the group 
(e.g. control group) variances with 
 
       
  
2 2
1 1 1 2 2 22
1 2
1 2 1 2
1 1
2
n n s x n n s x
s x x




     (2) 
where the subscripts 1 are post-bed rest values and 2 are the pre-bed rest values.  Then, Eq. (2) 
was used a second time where subscripts 1 were for the treatment group values and subscripts 2 
were for control group values.   
     The treatment effect was calculated for parameters in which there were 1) enough studies 
within a countermeasure group to perform statistical analysis and 2) homogeneity in the 
measurement calculation (e.g. some plasma volume measurements were only presented as 
percentage change from pre-bed rest, so treatment effect could not be calculated).  The treatment 
effect was normalized by dividing by its standard error to find its t-value.  The t
2
 values were 
summed for each countermeasure group and were compared against a Χ2 distribution to test 
whether the countermeasure was effective (i.e. the countermeasure was effective if the treatment 
effect was significantly different from zero).  Then, a least squares linear regression over study 
duration was performed with each countermeasure group to determine if a time effect was 
present in the parameter.  If no significant effect of study duration was observed, the data were 
collapsed into box plots and AG was compared to traditional countermeasures with a two-sample 
t-test.  In all cases, the criterion for statistical significance was set as p < 0.05.  All data are 
reported as mean ± SEM unless otherwise noted. 
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     In cases where treatment effect could not be calculated, data were presented in the form 
of percent change graphs.  Physical measurements were analyzed on a study-by-study basis that 






























4.1 Cardiovascular System 
     Orthostatic tolerance time in the form of a percentage graph is presented in Figure 21A 
for artificial gravity studies and in Figure 21B for traditional countermeasure studies.  AG was 
successful at either preventing the degradation of orthostatic tolerance time or increasing 
tolerance time from baseline in three of the five studies.  No statistical analysis was published 
with the Shulzhenko et al. 1979 study.  Iwase et al. 2005 was the only AG study to stress all 
subjects to presyncope conditions.  In this study, it is curious that the control group increased 
orthostatic tolerance time post-bed rest, since this measurement is well-established to degrade 
with deconditioning.  This phenomenon might have occurred because subjects did not have a 
practice trial with the orthostatic tolerance test (graded +Gz overload) before the study (Iwase, 
personal comm. 2009).  In contrast, the LBNP-based traditional countermeasure studies 
(Watenpaugh et al. 2007, Guinet et al. 2009, and Schneider et al. 2002) along with Shibata et al. 
2010 stressed all subjects to presyncope conditions.  Most of the traditional countermeasure 
studies did not protect orthostatic tolerance; only Wu et al. (unpublished), which had a step 
increase in countermeasure intensity halfway through the protocol, and Shibata et al. 2010, 
which infused Dextran for volume loading after completing a cycling countermeasure protocol,  
prevented a degradation in orthostatic tolerance time.   
     Plasma volume is shown in Figure 22A for the AG studies and in Figure 22B for the 
traditional countermeasure studies.  Only the studies that coupled AG with cycling – Iwasaki et 
al. 2005 and Vernikos et al. 1996 – showed a significant benefit of the treatment group to 
maintain plasma volume.  However, only thirty minutes of upright cycling in Lee et al. 1997 was 
not enough exercise to maintain plasma volume.  In contrast, many traditional countermeasure 
studies maintained plasma volume in the treatment groups.  The 30-day study of Lee et al. 2009 
did not show much of a decrease in the control group because the subjects were women with 
unregulated menstrual cycles.   
Also of interest is that the cycling countermeasure of Greenleaf et al. 1989 prevented a 
decrease in plasma volume while a similar exercise regime of Shibata et al. 2010 did not prevent 
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the decrease.  The treatment group in the Greenleaf study had two bouts of 30 minutes of cycling 
for five days per week at an intensity that varied from 40% to 90% of their pre-bed rest VO2 
max.  On the other hand, the treatment group of the Shibata study had three bouts of 30 minutes 
of cycling seven days per week at a constant intensity of 75% of their pre-bed rest maximum 
heart rate.  Even though the treatment was of longer duration in the Shibata study, the higher 




Figure 21.  Orthostatic tolerance time for AG studies (A) and traditional countermeasures 
(B). * p<0.05 vs. pre-bed rest, $ p<0.05 group effect. 
a
 - 80° tilt for 30 minutes; 
b
 - +3Gz 
overload; 
c
 – graded +Gz overload; 
d
 - graded LBNP; 
e
 - 60° tilt for 60 minutes;
 f
 - 75° tilt 
for 20 minutes;
 g













































































































Figure 22.  Plasma volume for AG studies (A) and for traditional countermeasure studies 
(B). * p<0.05 vs. pre-bed rest, $ p<0.05 group effect 
Hematocrit response is shown in Figure 23.  All of the countermeasure studies except for 
Maillet et al. 1996 (no statistical significance in either group) prevented the increase in 
hematocrit. 
Figure 24A shows stroke volume for AG studies and Figure 24B shows stroke volume for 
traditional countermeasure studies.  Katayama et al. 2004 was the only study to prevent the 
decrease in stroke volume with AG coupled with cycling.  There was no significant decrease in 
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its shorter duration of 14 days versus a duration of 28 days for the Katayama study.  Only two of 
the traditional countermeasure studies prevented the decrease in stroke volume.  The 
countermeasure of cycling 90 minutes per day at 75% of maximum heart rate in Shibata et al. 
2010 prevented stroke volume decrease.  However, this duration and intensity of countermeasure 
was calculated specifically to normalize stroke work for bed rest, so its efficacy at maintaining 
stoke volume was somewhat expected. 
 






















































Figure 24.  Stroke volume for AG studies (A) and for traditional countermeasure studies 
(B). * p<0.05 vs. pre-bed rest, $ p<0.05 group effect 
Cardiac output, which is inherently related to stroke volume and heart rate, is shown in 
Figure 25.  No statistical significance was seen in any AG countermeasure, and indeed, the only 
study to prevent the decrease in cardiac output was Shibata et al. 2010.  The cause of the large 
decrement in the treatment group of Sun et al. 2002 is unknown.  In this study, the LBNP 
countermeasure was only applied at a relatively mild pressure (-30mmHG for one hour/day) 
during the last week of the three week study. 
Spectral analysis data for AG studies are shown as high frequency (HF) heart rate in Figure 























































































performed in any traditional countermeasure study that was reviewed.  For parasympathetic 
activity, or HF heart rate, all three Japanese studies prevented its decrease.  However, the 
increase in sympathetic activity, or HF/LF heart rate was only prevented with AG coupled with 
cycling (Iwasaki et al. 2005). 
 
Figure 25.  Cardiac Output. * p<0.05 vs. pre-bed rest. 
 


























































































Figure 27.  High frequency / low frequency heart rate. * p<0.05 vs. pre-bed rest, $ p<0.05 
group effect 
TPR, which is closely related to cardiac output and mean arterial pressure, is shown in 
Figure 28.  The only study to prevent an increase in TPR is Shibata et al. 2010 with the 
countermeasure of cycling combined with Dextran infusion.  As TPR is calculated from cardiac 
output, the large increase in the treatment group of Sun et al. 2002 is likely a result of the study‟s 
cardiac output data, which is discussed above. 
 
































































































Dissections of arteries were performed in some animal studies.  CSA of the anterior tibial 
artery is shown in Figure 29 and the CSA of anterior tibial artery media thickness is shown in 
Figure 30.  In both measurements the countermeasures of head-up tilt for four hours or standing 
for two hours daily mitigated the decreases in CSA.   
 
Figure 29.  CSA of anterior tibial artery. * p<0.05 vs. control, $ p<0.05 group effect 
 
Figure 30.  CSA of the media thickness of the anterior tibial artery. * p<0.05 vs. control, $ 
p<0.05 group effect 
The treatment effect (see 3.0 Methods) for resting heart rate is shown in Figure 31A for AG 
countermeasures and in Figure 31B for traditional countermeasures.  In general, resting heart rate 
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which results in a negative treatment effect.  Linear regression analyses yielded a non-significant 
slope in both instances. 
The resting heart rate treatment effect is shown as box plots in Figure 32 for the different 
countermeasure groups.  The outlier (denoted by an „*‟) in the traditional countermeasure group 
was the Suzuki et al. 1994 study, which had moderate cycling as the countermeasure.  In the 
LBNP with treadmill group, the Lee et al. 2007 and Lee 2009 studies, which used monozygotic 
twins as subjects, both had a large treatment effect of –19 beats per minute.  All countermeasure 
groups in Figure 32 were effective as countermeasures (p<0.05).  The treatment effect of the AG 
group was not significantly different from the traditional countermeasure group.  Despite 
appearances, the AG group was also not significantly different from the LBNP with treadmill 
group (p=0.142). 
The original heart rate data from the studies is shown as percent change graphs in Figure 










Figure 31.  Resting heart rate treatment effect for AG studies (A) and traditional 
countermeasure studies (B) plotted over time 
 



















































Figure 33.  Resting heart rate for AG studies (A) and traditional countermeasure studies 
(B).  *p<0.05 vs. pre-bed rest, $ p<0.05 group effect 
The VO2 max treatment effect is shown in Figure 34A for AG and in Figure 34B for 
traditional countermeasures.  VO2 max was degraded in the control groups during deconditioning 
while VO2 max was roughly maintained in the treatment groups; this results in mostly positive 
values for the VO2 max treatment effect.  Although treatment effect appears to increase with 
study duration, this trend was not significant by linear regression analyses.   
     A time-independent box plot of the VO2 max treatment effect is shown in Figure 35 for 
the different countermeasure groups. All countermeasure groups were effective, that is, all 





























































































different from either the traditional countermeasures group or the LBNP with treadmill group.  
Note that the outlier in the AG countermeasure group was the Katayama et al. 2004 study, which 
coupled AG with intensive cycling.  In addition, the upper whisker of the traditional 
countermeasures group was from the Greenleaf et al. 1989 study, which used only intensive 
cycling as the countermeasure. 
The original VO2 max data from the studies is shown as percent change graphs in Figure 36. 
 
Figure 34.  VO2 max treatment effect for AG studies (A) and traditional countermeasure 
studies (B) plotted over time 
 


















































Figure 36.  VO2 max for AG studies (A) and traditional countermeasure studies (B). 
*p<0.05 vs. pre-bed rest, $ p<0.05 group effect 
Exercise time to exhaustion is shown in Figure 37 and all of the countermeasures that used 
this measurement completely prevented the exercise time decrement with their respective 
treatment protocols. 
Minute ventilation is shown in Figure 38 and only the AG coupled with cycling (Katayama 
et al. 2004) and the LBNP with vertical treadmill (Lee et al. 2007) prevented the its decrease.  
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found to be significantly different than the control group in Lee et al. 2007, it still decreased 
significantly from pre-bed rest. 
 
Figure 37.  Exercise time to exhaustion. * p<0.05 vs. pre-bed rest, $ p<0.05 group effect 
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Figure 39.  Respiratory exchange ratio. * p<0.05 vs. pre-bed rest, $ p<0.05 group effect 
 
4.2 Muscle Results 
Changes in soleus fiber dimensions are shown in Figure 40.  Fibers in the AG study 
(Caiozzo et al. 2009) were not stained to determine fiber type, thus the percent change represents 
all fiber types.  The resistive exercise study, on the other hand, did stain for fiber types and type I 
fibers are shown in the percent change bars for Trappe et al. 2008.  Further evidence with AG-
like protocols in animals is shown in Figure 41.  Standing for 40 minutes per day in four 
increments (Widrick et al. 1996) or walking 20 meters per minute at 30% grade for ten minutes 
per day and progressively increasing duration to 90 minutes per day (Graham et al. 1989a) were 
successful in lessening type I CSA atrophy; however, the treatment group still deconditioned 
significantly versus control.  Walking for 40 minutes per day at a slower speed (5 meters per 
















































Figure 40.  Soleus fiber cross-sectional area (Caiozzo et al. 2009) and soleus type I fiber 
diameter (Trappe et al. 2008). * p<0.05 vs. pre-bed rest. 
 
Figure 41.  Animal soleus type I fiber cross-sectional area. * p<0.05 vs. pre-bed rest, $ 
p<0.05 group effect 
Figure 42A illustrates the changes in vastus lateralis fiber dimensions.  As in Figure 40, the 
AG study (Caiozzo et al. 2009) represents the average fiber CSA for all fiber types while the 
resistive exercise studies represent only the change in diameter of type IIa fibers.  All resistive 
countermeasures – Trappe et al. 2007 (alternating squats and LBNP w/ treadmill), Bamman et al. 
























































































It is curious to note that Trappe et al. 2004 study did not show significant deconditioning of the 
control group despite its 90-day duration.  No variations in either deconditioning or biopsy 
protocols between studies are noted in the published literature.  Figure 42B shows the change in 
type IIa/IIx fiber CSA of the VL in rhesus monkeys.  Spinning the monkeys at 1.2Gz for 5-20 
minutes per day, five days a week maintained VL type IIa/IIx CSA. 
Knee extensor (the vasti group and rectus femoris) muscle volume is shown in Figure 43.  
No change was seen in the AG study, although all resistive countermeasures successfully 
maintained muscle volume.   
       
Figure 42.  Vastus lateralis fiber CSA or diameter in humans (A) and rhesus monkeys (B). 

































































































Figure 43.  Muscle volume of the knee extensors. * p<0.05 vs. pre-bed rest, $ p<0.05 group 
effect 
Whole muscle volume measurements are rarely performed for the plantar flexors in humans.  
Only one of the analyzed studies (Shackelford et al. 2004) performed a calf muscle volume 
measurement and both treatment and control groups deconditioned significantly versus pre-bed 
rest, although the treatment group was significantly different than the control group (not shown).  
Animal (rat) studies, on the other hand, have largely concentrated on studying the plantar flexors.  
Soleus wet weight is shown in Figure 44A using AG / AG analog countermeasures and is shown 
in Figure 44B using traditional-like countermeasures.  Centrifugation of the rats at 1.5Gx for one 
hour per day maintained soleus wet weight in D‟Aunno et al. 1990, but did not maintain 
treatment groups of the other two AG (1.5Gx) studies.  Rats spun at a higher G-level of 2.6Gx did 
not have increased salutary effects on soleus wet weight.  In fact, 2.6Gx decreased the 
effectiveness of centrifugation in Zhang et al. 2003 Protocol 2.  The source responsible for this 
counter-intuitive phenomenon is not understood (Zhang, personal comm. 2009), although some 
investigators have suggested it might be due to the rats sitting in their cages at higher G-levels 
(Caiozzo, personal comm. 2009).  Unfortunately, visualization of the rats during centrifugation 
was not performed in any study.  Standing for one hour per day was effective at lessening the 
decrement of soleus wet weight in all studies except for the Widrick et al. 1996 study, which had 





















































deconditioning, while walking (on an incline) was effective for two of the studies but not Pierotti 
et al. 1990.  The differences between protocols of Pierotti et al. 1990 (not effective) and 
Hauschka et al. 1988 (effective) are worth noting.  In fact, the only difference (including 
deconditioning paradigm, study duration, and treatment protocol) between these two studies is 
the treatment of walking 12 meters/minute in Pierotti et al. 1990 while only walking at a rate of 5 
meters/minute in Haschka et al. 1988.   The underlying mechanism for why the less strenuous 
protocol is more effective is unknown.  For traditional countermeasure analogues, climbing a 
grid at 85° was an effective countermeasure (Figure 44B, Herbert et al. 1988) while dropping the 
rats from 58 cm was not effective (Hauschka et al. 1987). 
 
 
Figure 44.  Soleus wet weight for AG / AG analog countermeasures (A) and traditional 


















































































































The wet weight of animal gastrocnemius muscle (also a plantar flexor) is shown in Figure 
45.  None of the countermeasures were successful and even centrifugation at 2.6Gx was 
significantly worse than the suspension group, perhaps for same reason as previously discussed. 
 
Figure 45.  Gastrocnemius wet weight for AG / AG analog countermeasures. * p<0.05 vs. 
control, $ p<0.05 group effect 
Knee extensor maximum voluntary contraction of humans is shown in Figure 46.  Protocols 
consisting of squats were successful in maintaining knee extensor MVC, and Wu et al. 
(Unpublished) actually increased MVC compared to pre-bed rest.  The control groups of the 
shorter duration studies of Akima et al. 2005, Suzuki et al. 1994, and Wu et al. (Unpublished) 
(20, 20, and 30 days, respectively) did not significantly change post- versus pre-bed rest whereas 
the control group of the 90-day duration study of Trappe et al. 2004 did decondition 
significantly. 
Peak force, Po, of the soleus muscle was measured in situ in AG analog animal studies 
(Figure 47A) and in humans (Figure 47B).  Alternating days of LBNP with a vertical treadmill 
and squats / calf presses (Trappe et al. 2004) was not an effective countermeasure for soleus Po; 
however, an intensive resistive exercise regiment was effective (Koryak et al. 1997).  Both 





















































Figure 46.  Knee extensor maximum voluntary contraction. * p<0.05 vs. pre-bed rest 
          
Figure 47.  Peak force, Po, of the soleus muscle in animals (A) and humans (B). * p<0.05 vs. 
control, $ p<0.05 group effect 
 
4.3 Bone Results 
The most definitive measurement to gauge bone loss is bone mineral density itself.  BMD 
measurements for various lower limb sights are shown in Figure 48.  Only one human, AG study 
has examined BMD and unfortunately, no significant results were observed.  The 119-day 
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loss in the trochanter and total hip, and increased BMD in the lumbar spine.  These results are 
likely due to the extremely intensive exercise regime that was characteristic of the study.  No 
significant results were observed in arguably the most important weight-bearing region of the 
lower body – the femoral hip. 
        
        
Figure 48.  Bone mineral density in the lumbar spine (A), femoral neck (B), trochanter (C), 
and total hip (D). * p<0.05 vs. pre-bed rest, $ p<0.05 group effect 
Because bone measurements are scarce in humans, data from animals is an important 
supplement.  Rat femur density is shown in Figure 49, while femur maximum load and elastic 
load from mechanical testing is shown in Figure 50A and B, respectively.  Standing or head-up 
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for one hour was also an effective countermeasure though the treatment group still had 
significantly less density than the control group.  Similar to the muscle results of rats, 
centrifugation at 2.6Gx for one hour had worse results than centrifugation at 1.5Gx for the same 
period.  All animal countermeasures had a significant benefit to maximum load except head-up 
tilt, while all countermeasures had a significant benefit to elastic load except standing. 
 




















































Figure 50.  Animal (rat) femur maximum load (A) and elastic load (B). * p<0.05 vs. control, 
$ p<0.05 group effect 
Parathyroid hormone (PTH) is shown in Figure 51 while urinary calcium and serum calcium 
are shown in Figure 52A and B, respectively.  PTH plays an important role in regulating serum 
calcium; thus, with lower serum calcium levels, PTH would be expected to increase.  Also, an 
increased PTH level would be expected to increase calcium absorption in the intestines and 
kidney.  These effects can be seen primarily in the Shackelford et al. 2004 study in Figure 51 and 





























































































Figure 51.  Parathyroid hormone. * p<0.05 vs. pre-bed rest, $ p<0.05 group effect 
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Bone resorption markers are shown in Figure 53.  All markers are increased after bed rest 
and most are increased significantly in every study.  Countermeasures seem to have very little 
impact on any resorption marker; only LBNP with a vertical treadmill was effective at lessening 
the increase in NTX and deoxypyridinoline (Smith et al. 2003).  Interestingly, this same protocol 
was effective for male twins (Smith et al. 2003), but was ineffective for female twins (Zwart et 
al. 2007) in 30 days of bed rest.   
Bone formation markers (Figure 54) – although 25(OH)-Vitamin D and 1,25(OH)-Vitamin 
D are indirect measures of formation as they affect how much dietary calcium is absorbed – are 
much more variable than resorption markers.  The active form of Vitamin D, 1,25(OH)-Vitamin 
D, was generally depressed in all studies (Figure 54B), although it was significantly different 
from the control group in Shackelford et al. 2004.  Subjects in this study took a 400IU 
supplement of Vitamin D, which, when coupled with exercise, could explain this salutary effect.  
This effect could also have ultimately influenced the direct markers of bone formation, 







       
 
Figure 53.  Bone resorption markers.  (A) n-telopeptide crosslink; (B) Pyridinoline 































































































































































         
         
Figure 54.  Bone formation markers.  (A) 25(OH)-Vitamin D; (B) 1,25(OH)-Vitamin D; (C) 
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As with any meta-analyses, vast differences between study protocols exist in the literature.  
An important consideration that must be realized when comparing different countermeasure 
groups is the variation in intent of treatment protocol.  For example, the Shackelford et al. 2004 
study showed salutary effects of a resistive exercise paradigm in almost all bone measurements 
studied in this analysis.  However, the protocol for this study was created specifically to 
counteract bone deconditioning.  In contrast, the AG study (Smith et al. 2009) was a part of a 
larger pilot study at UTMB (Paloski et al. Unpublished), which was the first of its kind to study 
the effects of AG across all physiological systems.  As such, the aim of the protocol was not to 
benefit any specific physiological system, but rather the aim was to have a starting point from 
which to base future protocols.  
     Another important difference between studies that must be noted is the wide range of 
protocol durations.  This tends to not be an issue with the cardiovascular system, which has a 
deconditioning timescale on the order of days (Buckey 2006, Vernikos 1996); however, it could 
be very important in interpreting bone studies, and, to a lesser extent, skeletal muscle studies.  
Recent studies have shown that long-duration deconditioning exposures (i.e. on the order of at 
least eight weeks) are necessary for changes in BMD to become apparent (Pavy Le Traon et al. 
2007, Spector et al. 2009).  This point is illustrated in the Shackelford et al. 2004 study, which 
was 17-weeks in duration.  During this timeframe, the control group exhibited significant 
deconditioning in many bone measurements.  In comparison, the AG study spanned only a 3-
week period, in which the control group showed no significant deviation from pre-bed rest 
means in any bone parameter studied.   
     One limitation of the current meta-analysis lies in the calculation of the variance 
associated with the treatment effect variable, which was performed for VO2 max and resting 
heart rate.  Specifically, Eq. 1, which was used to calculate the post minus pre-bed rest variance, 
is the general equation to find the difference of the variance for two independent samples.  
However, the variance of the post minus pre-bed rest averages is strongly related because they 
are the same people.  As a result, the treatment effect variance is uncertain.  Individual subject 
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data, which is not published, is needed in order to make an accurate calculation.  Although 
attempts have been made by the authors to obtain such data, it has nevertheless been slow to 
come to fruition.  As a result, the statistics associated with the VO2 max and resting heart rate 
parameters are not concrete, but rather a rough estimate. 
Finally, a few AG, bed rest studies exist that were not included in this study because their 
measured physiological parameters were not the same as those currently analyzed.  To the 
author‟s knowledge, the studies White et al. 1965, Shulzhenko et al. 1977, Shulzhenko et al. 
1980, and Symons et al. 2009 combined with Table 2 represent the complete human AG 
deconditioning literature.   
5.1 Cardiovascular Results 
Comparatively, many more studies were found for the cardiovascular system than the 
musculo-skeletal system, which is perhaps due to muscle and bone only recently emerging into 
the countermeasure spotlight.  One of the most persistently measured parameters to gauge 
cardiovascular deconditioning and the efficacy of countermeasures is orthostatic tolerance time 
under cardiac stress, which is an integrated performance measure that depends on hydration 
status, vascular status, and the integrity of the sympathetic nervous system.  Although this is a 
gross measurement, it is useful because it serves to elucidate the overall cardiovascular state.  
The results of this study have shown that an AG-based countermeasure is effective at 
maintaining orthostatic tolerance, whereas traditional countermeasures have had limited 
effectiveness.  One confounding variable in this measurement, however, is the fact that some 
investigations have a preset time limit for the cardiovascular test, while other investigations will 
continue the stress until presyncope occurs.  For instance, consider a stress test (e.g. head-up tilt 
to 80°) with a time limit of 10 minutes.  A subject in the treatment group might pass the test in 
both pre- and post-bed rest; however, had the test continued to presyncope, true tolerance time 
might be 17 minutes pre-bed rest and 12 minutes post-bed rest.  This true decrement in tolerance 
might be significant and is not observed in the time-limited tests.  However, this nuance does not 
completely negate results from studies that performed time-limited tolerance tests.  If the control 
group shows a significant decrement in tolerance time from pre- to post-bed rest whereas the 
85 
 
countermeasure group does not, a salutary effect of the countermeasure is seen; however, the 
entire story is not quite told.   
Other measurements have been taken and have been presented that characterize the 
cardiovascular system to a finer detail than orthostatic tolerance time.  Plasma volume is an 
important parameter to orthostatic tolerance that strongly affects stroke volume and cardiac 
output.  However, it has been shown that merely supplanting the loss of plasma volume does not 
counteract orthostatic tolerance.  Thus, plasma volume is not a direct indicator of orthostatic 
intolerance, though it might serve as a triggering mechanism for further dysfunction (Platts et al. 
2009).  Plasma volume seems to be maintained with an exercising countermeasure; AG alone 
was not effective at counteracting its loss.  However, AG coupled with cycling as well as several 
traditional countermeasures were effective in maintaining plasma volume.   
Vascular status is a slightly more difficult parameter to measure and in humans, it is 
primarily measured as total peripheral resistance.  As expected, TPR increases after 
deconditioning due to increased vasoconstriction because the heart tries to maintain systemic 
blood pressure with lower plasma volume.  None of the countermeasure groups were effective at 
maintaining TPR except the Shibata et al. 2010 study where the cycling plus Dextran group 
maintained TPR whereas pure cycling significantly increased from pre-bed rest.  Dextran was 
administered only at the end of the bed-rest as a fluid loading measure.  Its effect on TPR is 
expected as restoring plasma volume would cause a measure of vasodilation and thus reduce 
TPR.  Vascular status can also be assessed by arterial dissection in animals.  The AG analog of 
standing for two hours was an effective countermeasure in preserving CSA of the anterior tibial 
artery and CSA of its media thickness.   
Finally, spectral analysis of the heart is beneficial to assess sympathetic and parasympathetic 
levels.  Unfortunately, these measurements have been confined to AG studies and have yet to be 
used in traditional countermeasure studies.  While both pure AG and AG coupled with cycling 
maintained parasympathetic activity from a depressed level, only AG coupled with cycling 
successfully maintained sympathetic activity.  Autonomic responses of the heart are important in 
understanding its capability, although other factors such as its atrophy and distensibility play an 
important role in its function and ultimately have some impact on orthostatic tolerance.  The 
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latter two measurements are not routinely performed in deconditioning studies.  A crucial 
sympathetic response – the baroreflex – is also not traditionally measured in deconditioning 
studies although its integrity is indirectly measured with orthostatic tolerance time.  Only an AG-
based countermeasure or LBNP are capable of stimulating the baroreflex in deconditioning and 
thus maintaining its effectiveness. 
Exercise capacity is the second facet of the cardiovascular system that must be maintained.  
This analysis has shown that an AG-based countermeasure is as effective as traditional 
countermeasures in measurements of VO2 max, minute ventilation, and exercise time to 
exhaustion.  Specifically, both pure AG and AG coupled with cycling were effective at 
maintaining the former two measurements, while only AG coupled with cycling studies have 
measured exercise time to exhaustion and have consequently maintained this parameter.  
5.2 Muscle Results 
Only two bed rest studies exist that have examined AG as a countermeasure to human 
skeletal muscle deconditioning.  AG alone (Caiozzo et al. 2009) significantly attenuated the 
decrease in soleus CSA, possibly because of ad lib calf presses that subjects were instructed to 
perform to maintain the muscle pump during centrifugation.  No similar benefit was observed for 
any AG study for all other muscle measurements as the control groups did not degrade 
significantly from pre-deconditioning.  It is important to note that most of the traditional 
countermeasure studies that examine muscle are of a longer duration (35-119 days) than the AG 
studies (20 and 21 days) (Table 2 and Table 5).  Owing to slow adaptation time constants, 
evaluation of the skeletal muscle effects may require longer duration AG studies, especially with 
regards to knee extensor muscle volume and MVC. 
Animal studies are useful in this instance because of the lack of data in human studies.  
Standing or walking of rats significantly lessened the soleus type I fiber CSA and soleus peak 
force.  In addition, pure AG or standing maintained the soleus wet weight; however, none of the 
countermeasures maintained the gastrocnemius wet weight.  Most of the rat studies have 
concentrated on the soleus muscle.  While this is advantageous because human studies have 
mostly analyzed the quadriceps, which results in little overlap, rat studies should also examine 
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effects of countermeasures on the quadriceps so common measures between animal and human 
can be compared.   
Primates, such as Rhesus monkeys, are especially useful because their bipedal nature closely 
links their physiology with homo sapiens.  Belozerova et al. 2000 found that pure AG maintained 
fast-twitch vastus lateralis CSA.  In another AG study analyzing Rhesus monkeys, Korolkov et 
al. 2001 found that extracellular fluid, interstitial fluid, and blood flow to the medial 
gastocnemius was maintained with centrifugation.   
Finally, no human, bed rest, AG study has examined the quality of muscle fibers after 
deconditioning (i.e. CSA and distribution by fiber type), while this has been performed in many 
of the traditional countermeasure studies.  These measurements can be used to assess the degree 
of slow-to-fast fiber transition as well as peak force and shortening velocity of the fiber.  Future 
AG studies should analyze global muscle parameters (e.g. muscle volume, MVC, endurance, 
etc.) as well as individual muscle fibers by fiber type in order to better understand any salutary 
effects of centrifugation on skeletal muscle.  In sum, AG has shown some salutary effects on 
muscle as seen in human and animal studies; however, additional AG bed rest studies are much 
needed in order to have a consensus on the efficacy of AG in preventing skeletal muscle 
deconditioning.   
5.3 Bone Results 
Like the skeletal muscle studies, AG bed rest studies that analyze bone are very few in 
number; the Smith et al. 2009 study is the only comprehensive AG bone study.  Like previously 
mentioned, study duration is important to note in analyzing the results.  The AG study was only 
21 days whereas the traditional countermeasure studies were of much longer duration [30 days 
(Zwart et al. 2007) to 117 days (Shackelford et al. 2004)].  As a result, no significant BMD 
results were seen in the AG study and only few were present in the traditional countermeasure 
studies.  
Again, animal studies are very beneficial in supplementing human bone data.  Generally, 
AG was effective at maintaining animal density and strength of the femur, although relatively 
few intermittent AG studies have been performed on animals.  Because of the close 
88 
 
physiological ties primates have to humans, primates such as the Rhesus monkey should be 
utilized in future AG studies. 
Urinary and serum calcium are two markers of calcium balance that are commonly studied.  
For these parameters, dietary calcium plays an important role and can bias results if calcium 
intake is different between studies.  However, for all studies analyzed, calcium intake was 1±0.1 
g/day.  For urinary calcium, only the Smith et al. 2003 and Shackelford et al. 2004 studies show 
a benefit with traditional countermeasures.  The Shackelford et al. 2004 and Smith et al. 2008 
studies both significantly reduced the increase in serum calcium.  No conclusions can be made 
for any other study.  It is interesting to note that as part of the Shackelford et al. 2004 study 
protocol, all subjects were required to take a daily vitamin pill, which contained a 400IU vitamin 
D dose.  This vitamin D supplement may have had additional salutary effects on urinary and 
serum calcium levels when coupled with exercise. 
Daily activities in 1Gz result in high loading of the lower skeleton, especially the hip and 
lumbar spine.  Resistive exercise countermeasures have incorporated high loading of the lower 
skeleton through the use of supine squats.  However, no comparable loads were attained in the 
AG protocols discussed thus far (pure AG and AG coupled with cycling).  Proof-of-concept 
studies without human deconditioning have been performed that compare squats during 
centrifugation to upright squats and have found that squats during centrifugation can provide 
high foot forces that are analogous to squats in 1G (Yang et al. 2007a).  In addition to providing 
high loading for bone, AG squats might also be beneficial for the skeletal muscle as previously 
discussed.    
A countermeasure for bone deconditioning remains elusive.  Unfortunately, due to the 
shortage of AG bed rest studies that have examined bone and due to the relatively short duration 
of those AG studies, few conclusions can be made regarding its efficacy as a countermeasure for 
bone deconditioning.  Future AG studies should be designed specifically to evaluate its potential 





5.4 Vestibular Motivations for Artificial Gravity 
Maintaining any dysfunction that might be associated with the vestibular system or 
measuring any deleterious effects AG might have on the vestibular system has not been the focus 
of AG studies.  The comprehensive AG study performed at UTMB was the first ground-based 
study to analyze neurovestibular effects of AG.  This study found that AG did not impact balance 
control or ocular counter-rolling, which affects posture, compared to the control group (Paloski 
et al. Unpublished).  In the same study, error in subjective visual vertical was significantly 
different from zero in the treatment group and not different in the control group; however, this 
effect was short-lived. 
Another important function of the vestibular system that has only recently emerged into the 
forefront of vestibular research is the vestibulosympathetic reflex (VSR), which is enacted by 
otolith stimulation (Yates and Miller 1994).  VSR in humans has been found to be a mediator of 
cardiovascular stress (Dyckman et al. 2007, Saunder et al. 2008) and to even have shorter 
response latency than the baroreflex (Kaufman et al. 2002 and Voustianiouk et al. 2006).  The 
latter finding indicates that the VSR could be the first line-of-defense to cardiovascular stress and 
thus could play a vital role in maintaining astronaut orthostatic tolerance.  Little is known about 
the sympathetic response to spaceflight, especially with regard to the VSR, though any 
deconditioning of the VSR might act an instigator to additional reflexes responsible for 
orthostatic tolerance.  AG may be a suitable countermeasure to protect the integrity of the VSR.  
Anecdotal evidence of the efficacy of AG is given in a study that analyzed the hemodynamic 
responses from the four centrifuged astronauts against the two non-rotated astronauts of the 
Neurolab mission (Moore et al. 2005).  This study found that one of the non-rotated astronauts 
exhibited signs that were indicative of orthostatic intolerance (although none of the astronauts 
became presyncopal during the tilt test), which suggests that AG stimulation of the VSR and 
baroreflex was a successful countermeasure.  Although this evidence is extremely circumstantial, 
it nevertheless represents the only space-based evidence that AG assisted in mitigating 
orthostatic intolerance.  As research continues on the VSR, its role in triggering the first 
sympathetic response to cardiovascular stress is paramount; if there continues a drive to address 
orthostatic intolerance post-spaceflight, it must also address the VSR and any associated 
deconditioning.  Artificial gravity is the only space-tested countermeasure that can not only 
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stimulate the vestibular apparatus, but can also stimulate the otoliths in the appropriate manner to 
elicit a vestibulosympathetic reflex. 
5.5 Nutritional Aspects 
Some studies have been performed that have examined nutrition as a countermeasure (e.g. 
the WISE-2005 campaign as noted in Guinet et al. 2009, Trappe et al. 2007a, 2007b, 2008, and 
Smith et al. 2008).  Based on the WISE-2005 study, a nutritional countermeasure alone was not 
effective in protecting most of the physiological measurements of the cardiovascular or musculo-
skeletal systems.  However, ensuring nutritional parameters are maintained in daily diet is 
critical for countermeasure effectiveness.  For example, daily intake of calcium must be 
maintained at 1.0 g/day to help prevent exaggerated bone loss.  Also, a 400 IU Vitamin D 
supplement seems to exhibit salutary effects when combined with intensive resistive exercise.  
While nutrition alone appears to not be an effective countermeasure, providing adequate 
nutrition will create a strong foundation that with a concomitant countermeasure may have 
increased salutary effects than with a countermeasure alone. 
5.6 Implementation of Artificial Gravity in Space 
While this study has analyzed the scientific motivations for continuing AG research, there 
exist several issues with its implementation in exploration-class spaceflight that warrant separate 
trade-based studies.  Despite implementation issues being a rather large topic, a few of these 
issues are highlighted here for reference.  One issue that arises with an AG-based 
countermeasure is vibration; however, this can be solved by a vibration isolation system similar 
to that found on the current ISS countermeasure devices.  Other, perhaps more challenging, 
factors for AG in exploration-class spaceflight is the extremely limited mass and power, if any, 
that will be available to support a centrifuge.  A space centrifuge will have to be designed with 
little mass, which can possibly be accomplished by using only a lightweight frame for the 
centrifuge.  Power can be minimized by having a centrifuge that is powered by human cycling.  
This type of centrifuge (a „Space Cycle‟) has been developed and tested at the University of 




5.7 A Comprehensive Artificial Gravity Protocol 
While the questions of „how much?‟, „how long?‟, and „how often?‟ still persist with regards 
to a comprehensive AG protocol, an attempt is made to address these questions through the 
present analysis.  Table 7 lists all of the measurements that were analyzed in this study.  The 
columns represent different AG modalities: pure AG, AG coupled with cycling, standing, and 
running upright.  Only the protocols that were effective for each measurement are listed.  Red 
cells indicates the protocol was ineffective, blue cells indicate that no significance was associated 
with either control or treatment group (i.e. the protocol might be effective, but is unclear as 
control did not significantly change), and grey cells indicate that the measurement has not been 
performed with the protocol.  If more than one study was effective for a given protocol type (e.g. 
two pure AG studies were effective at a measurement), the table was populated with the protocol 














Table 7.  Comprehensive results of AG studies for the different physiological systems.  Red 
cells – ineffective protocol, blue – effectiveness could not be determined, grey – protocol not 
attempted.
 
As seen in the table and discussed previously, AG coupled with cycling is effective for 
many of the cardiovascular parameters, including orthostatic tolerance time and VO2 max.  The 
minimum duration and minimum intensity protocol that works is specifically two 20 minute 
sessions of: 1) centrifugation at 0.8-1.4 Gz at the heart (2.9-5.0 Gz at the feet), which is based on 

















Orthostatic Tolerance Time 2.5 60 every Iwasaki 30 60W alt.
Plasma Volume Iwasaki 30 60W alt. 240 240 3mph




Stroke Volume 1 to 5 40
60W for 20 minutes 




High Freqency Heart Rate Iwasaki 60 every Iwasaki 30 60W alt.
High Frequency / Low Frequency 
Heart Rate
Iwasaki 30 60W alt.
Total Peripheral Resistance
Resting Heart Rate Iwasaki 60 every Iwasaki 30 60W alt.
Maximum Rate of Oxygen Uptake 2.5 60 every 1 to 5 40
60W for 20 minutes 
/ 40-80% VO2max 
for 20 minutes
alt. 240 120 3mph
Exercise Time to Exhaustion 1 to 5 40
60W for 20 minutes 






Minute Ventilation 1 to 5 40
60W for 20 minutes 




CSA of anterior tibial artery 120
CSA of media thickness of anterior 
tibial artery
120
Soleus Fiber CSA 2.5 60 every
Vastus Lateralis Fiber CSA
Muscle Volume of Knee Extensors
Knee Extensor MVC
Monkey Vastus Lateralis Fiber CSA 1.2 5 to 20 every
Soleus Type I Fiber CSA 40 10 to 90 0.75 mph
Soleus Wet Weight 1.5 60 every 60 40 0.2 mph
Gastrocnemius Wet Weight















Femur Density 1.5 60 every 60
Femur Maximum Load 1.5 60 every 60



































centrifugation at 0.3 Gz at the heart (1.0 Gz at the feet) coupled with cycling at variable levels 
based on pre-bed rest VO2max (2 min. at 40% VO2max, 3 min. at 60%, 2 min. at 40%, 3 min. at 
70%, 2 min. at 40%, 3 min. at 80%, 2 min. at 40%, and 3 min. at 80%).  This protocol was 
effective with alternating days of treatment. 
As mentioned earlier, little musculo-skeletal data exists for AG.  Soleus fiber CSA was 
preserved with 60 minutes of 2.5 Gz and calf presses.  If animal data can be interpreted 
synonymously with human data, 60 minutes of standing or centrifugation at 1.5 Gz protects 
soleus muscle characteristics, vastus lateralis fiber CSA, and femur density and strength.  
Moreover, squats and calf presses have been the primary effectors at preserving leg muscle 
characteristics in traditional countermeasure studies and to some extent bone.  Squats have been 
successfully performed in AG training studies without adverse effects from coriolis forces or 
motion sickness (Duda 2007, Yang et al. 2007b).  In addition, high intensity squats have been 
performed in a training study and have shown similar foot forces and EMG activity with squats 
during centrifugation versus standing upright (Yang et al. 2007a).  For these reasons, a 
comprehensive AG protocol should consist of squats and calf presses to maintain the musculo-
skeletal system.  Adopting the protocol used by many traditional countermeasure studies seems 
to be a logical starting choice.  Specifically, squats and calf presses are performed every other 
day and consist of four sets of seven maximal repetition squats followed by four sets of 14 
maximal repetition calf presses.  By combining the AG squat and cycling protocol, a two day 
















Subject #1 Subject #2 
Day 1 
20 2.9-5.0 Cycling at 60W 4x14 calf presses 
20 2.5 Cycling at 40W Passive 
20 1.0 
Graded Cycling based 
on VO2 max 
4x7 squats 
Day 2 
20 2.9-5.0 4x14 calf presses Cycling at 60W 
20 2.5 Passive Cycling at 40W 
20 1.0 4x7 squats 
Graded Cycling 
based on VO2 
max 
 
This protocol could easily be accommodated by a human-powered, two arm centrifuge.  The 
subject performing aerobic exercise would supply power to the centrifuge, while the other 
subject would perform resistive exercise.  In the event that squats in 1 Gz do not supply the 
correct intensity, cables could be added to the centrifuge to increase resistance (Duda 2007).  
This protocol could be the starting point in the continuing search for a comprehensive protocol.  
In addition, before reambulation, subjects should perform fluid loading to augment the salutary 
effects of this countermeasure regime. 
5.8 Future Work on Artificial Gravity 
Several avenues exist for future research of artificial gravity as a spaceflight 
countermeasure.  As Table 7 shows, the paucity of data found with the musculo-skeletal system 
reflects the amount of AG research still to be performed.  Ground-based studies must be 
performed to address these gaps in the musculo-skeletal system.  Moreover, parametric studies 
should be performed to systematically address those persisting questions of „how much?‟, „how 
long?‟, and „how often?‟.  However, such studies must not lose sight of the multi-system benefits 
of AG by examining only one system at a time.  Instead, such studies should investigate 
comprehensive protocols with experts from all the target systems playing roles in the study.  
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Such a multi-system, multi-investigator approach is the only manner in which to gauge the true 
effectiveness of an AG protocol.   
As mentioned in the beginning of the discussion section, many confounding variables arose 
from the varying protocols of deconditioning itself.  Differences were observed in all aspects of 
the deconditioning protocol, including deconditioning paradigm, daily nutritional content and 
supplements (if any) used, fluid intake, etc.  Standardizing the deconditioning protocols should 
be the first step in future research – either AG or traditional countermeasures – as it will allow 
for a more compatible assessment across various studies.    
Admittedly, deconditioning studies are extremely expensive, especially given that studies 
needed for AG should be of a very long duration (eight weeks) to observe musculo-skeletal 
changes.  However, a pilot study for bone could be performed for very low cost.  Bone is chosen 
because it is the system that arguably lacks the most useful AG data and it is the constraint for 
having a long duration deconditioning study.  To demonstrate the salutary effect of AG on bone, 
a training study could be devised where ambulatory subjects are rotated three times per week.  
Because squats have proven to be beneficial for bone maintenance, AG could be coupled with 
squats, and the intensity of the squat exercise would be determined in the same manner as the 
comprehensive AG protocol in 5.7.  BMD measurements of the lower limbs and biological bone 
markers would be taken before and after six months of training.  Calcium supplements could be 
administered as needed by monitoring nutritional intake.  If AG coupled with squats increases 
BMD after six months of training, this relatively inexpensive study might perhaps provide the 
motivation for a larger deconditioning study.   
Although ground-based studies will ultimately be the medium for determining a 
comprehensive AG protocol, a centrifuge in space might provide the impetus for further ground-
based research.  At present, there exist two possibilities for introducing a centrifuge to the ISS.  
EADS-Astrium in Europe is working on a centrifuge design for an eventual proposal to the 
European Space Agency (ESA). This centrifuge could be placed in either the Multi-Purpose 
Logistics Module (MPLM) or the Automated Transfer Vehicle (ATV).  The other possibility is a 
proposal to the Japanese Aerospace Exploration Agency (JAXA) for a low up-mass centrifuge to 
be placed in the ISS (Iwase, personal comm. 2009).  If either of these two efforts succeeds, it will 
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mark the first time a human centrifuge will be in space and will have been built specifically to 
counteract cardiovascular and musculo-skeletal deconditioning.  Any positive results from this 
space centrifuge would surely spur subsequent ground-based research. 
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6.0 Conclusion  
In the state of global waning of funding for artificial gravity research, this analysis has 
attempted to quantify the scientific evidence for an AG countermeasure to spaceflight 
deconditioning by examining its effectiveness in ground-based studies to the effectiveness of 
more traditional countermeasures.  In reviewing both human and animal literature, AG, 
especially AG coupled with cycling, was determined to be as effective as traditional 
countermeasures for the cardiovascular system.  AG and AG analogue studies (e.g. standing) 
with animals provided some measure of protection against deconditioning of the musculo-
skeletal system; however, this phenomenon was not present in human studies due to their paucity 
as well as their short-duration.  Based on the AG literature, motivations for an AG 
countermeasure in spaceflight were discussed and a hypothetical comprehensive AG protocol 
was derived. 
While it may ultimately be a large-radius, continually-rotating centrifuge that will become 
spacecraft architecture, its manifestation might not be realized until far into the future based on 
current NASA ideology and technical direction.  As exploration-class missions will be planned 
and developed in the interim, an improvement must be made upon the current countermeasures 
in order to prevent deleterious deconditioning of humans.  Artificial gravity could be such an 
improvement as it is the countermeasure that addresses the root cause of the deconditioning 
phenomenon instead of treating its end-effects system-by-system as do the current 
countermeasures.  As this analysis has shown, there exists substantial rationale to continue 
research on an AG-based countermeasure to prevent spaceflight deconditioning of all 
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Appendix A:  World Centrifuges 
The tables below list the known human (Table A1) and animal (Table A2) centrifuges located around the world.  The human 
centrifuges are limited to those that supply a Gz acceleration and that are short-radius since those were the focus of the present study.  
Only animal centrifuges that have been used in deconditioning studies are shown.  Operational details – to the extent that they are 
known – are presented.    











Short-Arm Centrifuge UTMB, Galveston, USA 3 2 Bed   3.5 




Human Powered Centrifuge NASA Ames, USA 2 2 Bed Cycling 5 
Space Cycle 
University of California, Irvine, 
USA 






Artificial Gravity Simulator 
Baylor College of Medicine, 
Houston, USA  
2 4 Bed   3 
Self-Powered Short-Arm 
Human Centrifuge 
Fourth Military Medical 
University, Xi' An, China 
2 2 Bed Cycling 4 
Short-Radius Human 
Centrifuge 
Aichi Medical University (was 
Nagoya University), Aichi 
Prefecture, Japan 
2 1 Bed Cycling 5 
Short-Arm Human Centrifuge 
Nihon University, Nishi-
Funibashi, Japan 
1.8 1 Gondola   3 
Short-Radius Centrifuge IBMP, Moscow, Russia 2   Bed Cycling 2 
Human Centrifuge "ASEA" IBMP, Moscow, Russia 7.25 1 Bed   12 
ESA Short-Arm Centrifuge MEDES, Toulouse, France 2.9 4 bed/chair   3.5 
Short-Arm Centrifuge DLR, Cologne, Germany 2.9 4 bed/chair   3.5 
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Xi' An, China 










1.34 1 Gondola 2 Rats 
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Appendix B:  Master Database  
This appendix includes the master spreadsheet that was populated in compiling countermeasure data.  In the master spreadsheet, a 
few parameters, such as treatment applied, deconditioning paradigm, species, and protocol specifics are coded.  Table B1 below shows 
the key for species, while Table B2 shows the key for deconditioning paradigm, and Table B3 is the key for treatment (or 
countermeasure) applied.  If two treatments are applied, their treatments codes are summed and entered into the master database.  For 
instance, the LBNP with a vertical treadmill countermeasure will have the code 260 (LBNP: 256 plus treadmill: 4).  Table B4 shows 
the master database itself. 







1 Rhesus Monkeys 
 
1 5 Head Down Bed Rest 
2 Sprague-Dawley Rats 
 
2 6 Head Down Bed Rest 
3 Wistar Rats 
 
3 10 Head Down Bed Rest 
4 Fisher 334 Rats 
 
4 0 Head Down Bed Rest 
   
5 Dry Immersion 
   
6 Wet Immersion 
   
7 
Unilateral Lower Limb 
Suspension 
   
8 Tail Suspension 











 1 Artificial Gravity 
       2 Cycle Ergometer 
       4 Treadmill 
       8 Standing Upright 
       16 Walking Upright 
       32 Water / Salt Supplement 
       64 Squat 
       128 Heel Raises / Calf Press 
       256 Lower Body Negative Pressure 
       512 Head-Up Tilt 
       1024 Isokinetic Exercise 
       2048 Nutrition 
       4096 Pamidronate 
       8192 Combined resistive exercise 
       16384 Isometric 
       32768 Arm Press 
       65536 Dropped 
       131072 Stair Stepper 
       262144 Parathyroid Harmone 
       524288 Climbing 
       1048576 Beta-Blockers 
       2097152 Leptin 
       4194304 1,25-D 
       8388608 EB1089 
       16777216 Testosterone 
       33554432 Nandrolone Decanoate 
       
115 
 
Table B4.  Master database for countermeasure studies 
 

























1 Caiozzo 2009 0 21 2 0 CON 0 7 Muscle Strength Knee Flexors -3
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Muscle Strength Knee Flexors -6
1 Caiozzo 2009 0 21 2 0 CON 0 7 Muscle Strength Plantar Flexor -7
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Muscle Strength Plantar Flexor 7
1 Caiozzo 2009 0 21 2 0 CON 0 7 Myofiber Cross Sectional Area Vastus Lateralis -11.5
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Myofiber Cross Sectional Area Vastus Lateralis 0
1 Caiozzo 2009 0 21 2 0 CON 0 7 Myofiber Cross Sectional Area Soleus -26.8 1
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Myofiber Cross Sectional Area Soleus 5.5
1 Caiozzo 2009 0 21 2 0 CON 0 7 Total RNA Concentration Vastus Lateralis 5.9
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Total RNA Concentration Vastus Lateralis -5.2
1 Caiozzo 2009 0 21 2 0 CON 0 7 Total RNA Concentration Soleus -5
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Total RNA Concentration Soleus 5.8
1 Caiozzo 2009 0 21 2 0 CON 0 7 Total MHC mRNA levels Vastus Lateralis -27 1
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Total MHC mRNA levels Vastus Lateralis -33 1
1 Caiozzo 2009 0 21 2 0 CON 0 7 Total MHC mRNA levels Soleus -40 1
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Total MHC mRNA levels Soleus -16.7
1 Caiozzo 2009 0 21 2 0 CON 0 7 Actin Levels Vastus Lateralis -33 1
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Actin Levels Vastus Lateralis -22.4
1 Caiozzo 2009 0 21 2 0 CON 0 7 Actin Levels Soleus -15.6
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Actin Levels Soleus -6.2
1 Caiozzo 2009 0 21 2 0 CON 0 7 Myostatin Levels Vastus Lateralis 14.3
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Myostatin Levels Vastus Lateralis -9.7
1 Caiozzo 2009 0 21 2 0 CON 0 7 Myostatin Levels Soleus 56.1
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Myostatin Levels Soleus 17.1
1 Caiozzo 2009 0 21 2 0 CON 0 7 Atrogin Levels Vastus Lateralis 42.7
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Atrogin Levels Vastus Lateralis 11.1
1 Caiozzo 2009 0 21 2 0 CON 0 7 Atrogin Levels Soleus 13.6
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Atrogin Levels Soleus -31.3
1 Caiozzo 2009 0 21 2 0 CON 0 7 Type I MHC mRNA Levels Vastus Lateralis -25
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Type I MHC mRNA Levels Vastus Lateralis -5
1 Caiozzo 2009 0 21 2 0 CON 0 7 Type I MHC mRNA Levels Soleus -43 1
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Type I MHC mRNA Levels Soleus -23
1 Caiozzo 2009 0 21 2 0 CON 0 7 Type IIa MHC mRNA Levels Vastus Lateralis -7.1
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Type IIa MHC mRNA Levels Vastus Lateralis -22.7
1 Caiozzo 2009 0 21 2 0 CON 0 7 Type IIa MHC mRNA Levels Soleus -21.1
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Type IIa MHC mRNA Levels Soleus -26.8
1 Caiozzo 2009 0 21 2 0 CON 0 7 Type IIxMHC mRNA Levels Vastus Lateralis 29
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Type IIxMHC mRNA Levels Vastus Lateralis 68.6 1
1 Caiozzo 2009 0 21 2 0 CON 0 7 Type IIxMHC mRNA Levels Soleus 236 1
1 Caiozzo 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Type IIxMHC mRNA Levels Soleus 246 1
2 Symons 2009 0 21 2 0 CON 0 7 Fractional Synthesis Rate Vastus Lateralis -48.5 1
2 Symons 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Fractional Synthesis Rate Vastus Lateralis -14
2 Symons 2009 0 21 2 0 CON 0 7 Fractional Synthesis Rate Soleus -22
2 Symons 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Fractional Synthesis Rate Soleus -9
2 Symons 2009 0 21 2 0 CON 0 7 Fractional Breakdown Rate Vastus Lateralis -17
2 Symons 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Fractional Breakdown Rate Vastus Lateralis -10
2 Symons 2009 0 21 2 0 CON 0 7 Fractional Breakdown Rate Soleus 1
2 Symons 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Fractional Breakdown Rate Soleus -23
3 Akima 2005 0 20 2 0 CON 0 5 Muscle Volume Knee Extensor -9.4






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Muscle Volume Knee Extensor 0.9
3 Akima 2005 0 20 2 0 CON 0 5 Muscle Volume Rectus Femoris -11.8






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Muscle Volume Rectus Femoris 8.1
3 Akima 2005 0 20 2 0 CON 0 5 Muscle Volume Vastus Lateralis -8.1 1






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Muscle Volume Vastus Lateralis 4.3










cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Muscle Volume Vastus Intermedius -0.6
3 Akima 2005 0 20 2 0 CON 0 5 Muscle Volume Vastus Medialis -7.8 1






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Muscle Volume Vastus Medialis -3.7
3 Akima 2005 0 20 2 0 CON 0 5 Muscle Volume Knee Flexors -7.5






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Muscle Volume Knee Flexors -6.4
3 Akima 2005 0 20 2 0 CON 0 5 Muscle Volume Adductors -7.0






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Muscle Volume Adductors 1.4
3 Akima 2005 0 20 2 0 CON 0 5 Muscle Volume Total -8.5 1






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Muscle Volume Total -0.7
















3 Akima 2005 0 20 2 0 CON 0 5 MVC / Muscle Volume Knee Extensor -16.7






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 MVC / Muscle Volume Knee Extensor -8.3
3 Akima 2005 0 20 2 0 CON 0 5 EMG activity Knee Extensor -14.4






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 EMG activity Knee Extensor -12.9 1
3 Akima 2005 0 20 2 0 CON 0 5
mfMRI (T2) (% change pre- and 
post- exercise
Knee Extensor 1.0






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5

















































































































0 21 2 0 CON 0 7






0 21 2 1 3 2.5 1 60 Daily AG 0 8






0 21 2 0 CON 0 7






0 21 2 1 3 2.5 1 60 Daily AG 0 8






















































0 21 2 0 CON 0 7






0 21 2 1 3 2.5 1 60 Daily AG 0 8






0 21 2 0 CON 0 7






0 21 2 1 3 2.5 1 60 Daily AG 0 8






0 21 2 0 CON 0 7






0 21 2 1 3 2.5 1 60 Daily AG 0 8






0 21 2 0 CON 0 7






0 21 2 1 3 2.5 1 60 Daily AG 0 8






















0 21 2 0 CON 0 7
Delta Total peripheral 
resistance




0 21 2 1 3 2.5 1 60 Daily AG 0 8
Delta Total peripheral 
resistance































































0 21 2 0 CON 0 7
Delta HF parasympathetic 
activity




0 21 2 1 3 2.5 1 60 Daily AG 0 8
Delta HF parasympathetic 
activity












0 21 2 0 CON 0 7






0 21 2 1 3 2.5 1 60 Daily AG 0 8






0 21 2 0 CON 0 7






0 21 2 1 3 2.5 1 60 Daily AG 0 8














0 21 2 0 CON 0 7






0 21 2 1 3 2.5 1 60 Daily AG 0 8


















0 21 2 1 3 2.5 1 60 Daily AG 0 8 Mitral E to A wave ratio -7.04
6 Katayama 2004 0 20 2 0 CON 0 5 VO2 (L/min) Resting 0






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 VO2 (L/min) Resting 3.7037037
6 Katayama 2004 0 20 2 0 CON 0 5 VCO2 Resting 0






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 VCO2 Resting 4.34782609
6 Katayama 2004 0 20 2 0 CON 0 5 Ve (L/min) Resting 12.6315789






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Ve (L/min) Resting 9.09090909
6 Katayama 2004 0 20 2 0 CON 0 5 Respiratory Exchange Ratio Resting 0






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Respiratory Exchange Ratio Resting 1.17647059
6 Katayama 2004 0 20 2 0 CON 0 5 Heart Rate (beats/min) Resting 15.2905199






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Heart Rate (beats/min) Resting 4.31654676
6 Katayama 2004 0 20 2 0 CON 0 5
Systolic Blood Pressure 
(mmHg)
Resting -1.8612521






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5
Systolic Blood Pressure 
(mmHg)
Resting 2.02286719
6 Katayama 2004 0 20 2 0 CON 0 5
Diastolic Blood Pressure 
(mmHg)
Resting 1.13798009






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5






6 Katayama 2004 0 20 2 0 CON 0 5 Stroke Volume (mL) Resting -27.628032 1






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Stroke Volume (mL) Resting -4.4534413 1
6 Katayama 2004 0 20 2 0 CON 0 5 Cardiac Output Resting -14.893617






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Cardiac Output Resting -5.5555556
6 Katayama 2004 0 20 2 0 CON 0 5 VO2 (L/min) Submaximal Exercise -5






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 VO2 (L/min) Submaximal Exercise -2.5
6 Katayama 2004 0 20 2 0 CON 0 5 VCO2 Submaximal Exercise 6






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 VCO2 Submaximal Exercise -5
6 Katayama 2004 0 20 2 0 CON 0 5 Ve (L/min) Submaximal Exercise 15 1






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Ve (L/min) Submaximal Exercise -5
6 Katayama 2004 0 20 2 0 CON 0 5 Respiratory Exchange Ratio Submaximal Exercise 20 1






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Respiratory Exchange Ratio Submaximal Exercise -3
6 Katayama 2004 0 20 2 0 CON 0 5 Heart Rate (beats/min) Submaximal Exercise 20 1






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Heart Rate (beats/min) Submaximal Exercise 5
6 Katayama 2004 0 20 2 0 CON 0 5
Systolic Blood Pressure 
(mmHg)
Submaximal Exercise 7






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5
Systolic Blood Pressure 
(mmHg)
Submaximal Exercise -5
6 Katayama 2004 0 20 2 0 CON 0 5
Diastolic Blood Pressure 
(mmHg)
Submaximal Exercise 3






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5
Diastolic Blood Pressure 
(mmHg)
Submaximal Exercise 0
6 Katayama 2004 0 20 2 0 CON 0 5 Stroke Volume (mL) Submaximal Exercise -15 1






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Stroke Volume (mL) Submaximal Exercise -3
6 Katayama 2004 0 20 2 0 CON 0 5 Cardiac Output Submaximal Exercise 9






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Cardiac Output Submaximal Exercise 0
6 Katayama 2004 0 20 2 0 CON 0 5 VO2 (L/min) Max -26.923077 1






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 VO2 (L/min) Max -8.7719298
6 Katayama 2004 0 20 2 0 CON 0 5 VO2 (L/min) Max -25.957447 1






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 VO2 (L/min) Max -7.966457
6 Katayama 2004 0 20 2 0 CON 0 5 VCO2 Max -24.668435 1






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 VCO2 Max -6.3953488 1
6 Katayama 2004 0 20 2 0 CON 0 5 Ve (L/min) Max -15.47619






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Ve (L/min) Max -6.0921248 1
6 Katayama 2004 0 20 2 0 CON 0 5 Respiratory Exchange Ratio Max 3.30578512






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Respiratory Exchange Ratio Max 2.47933884
6 Katayama 2004 0 20 2 0 CON 0 5 Heart Rate (beats/min) Max 1.16525424






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Heart Rate (beats/min) Max 1.42566191
6 Katayama 2004 0 20 2 0 CON 0 5 Exercise Time Max -20.27027 1






cycle@60W for 20min, then profile based on 
VO2max
AG 0 5 Exercise Time Max -2.962963 1
7 Iwasaki 2005 0 14 2 0 CON 0 6 Heart Rate (beats/min) Resting 14.7540984 1
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Heart Rate (beats/min) Resting 8.47457627
7 Iwasaki 2005 0 14 2 0 CON 0 6 R-R Interval Resting -13.875124 1
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 R-R Interval Resting -8.097561
7 Iwasaki 2005 0 14 2 0 CON 0 6
Systolic Blood Pressure 
(mmHg)
Resting 0.80645161
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6
Systolic Blood Pressure 
(mmHg)
Resting 0
7 Iwasaki 2005 0 14 2 0 CON 0 6
Diastolic Blood Pressure 
(mmHg)
Resting 4.28571429
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6
Diastolic Blood Pressure 
(mmHg)
Resting -2.8571429
7 Iwasaki 2005 0 14 2 0 CON 0 6 Respiratory Rate Resting 0
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Respiratory Rate Resting 6.25




7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 End Tidal CO2 Resting 0
7 Iwasaki 2005 0 14 2 0 CON 0 6
Low Frequency (LF) Heart 
Rate
Resting -43.823147
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6
Low Frequency (LF) Heart 
Rate
Resting -37.751561
7 Iwasaki 2005 0 14 2 0 CON 0 6
High Frequency (HF) Heart 
Rate
Resting -64.980159 1
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6
High Frequency (HF) Heart 
Rate
Resting -33.217391
7 Iwasaki 2005 0 14 2 0 CON 0 6
HF sympathetic activity (SNS) 
(LF/HF)
Resting 47.7272727 1
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6
HF sympathetic activity (SNS) 
(LF/HF)
Resting 7.1942446 1
7 Iwasaki 2005 0 14 2 0 CON 0 6 Low Frequency (LF) BP Resting -27.419355
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Low Frequency (LF) BP Resting -24.528302
7 Iwasaki 2005 0 14 2 0 CON 0 6 High Frequency (HF) BP Resting -14.285714
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 High Frequency (HF) BP Resting -8.3333333
7 Iwasaki 2005 0 14 2 0 CON 0 6 Coherence-LF (unit) Resting 1.72413793
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Coherence-LF (unit) Resting -14.285714
7 Iwasaki 2005 0 14 2 0 CON 0 6 Coherence-HF (unit) Resting -8.0645161
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Coherence-HF (unit) Resting -8.0645161
7 Iwasaki 2005 0 14 2 0 CON 0 6 Phase-LF (radian) Resting 11.1111111
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Phase-LF (radian) Resting 1.00719424
7 Iwasaki 2005 0 14 2 0 CON 0 6 Phase-HF (radian) Resting 0
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Phase-HF (radian) Resting -3.7383178
7 Iwasaki 2005 0 14 2 0 CON 0 6 Gain-LF (ms/mmHg) Resting -14.83871
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Gain-LF (ms/mmHg) Resting -9.0322581
7 Iwasaki 2005 0 14 2 0 CON 0 6 Gain-HF (ms/mmHg) Resting -33.789954 1
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Gain-HF (ms/mmHg) Resting -13.488372
7 Iwasaki 2005 0 14 2 0 CON 0 6
Baroflex gain by sequence 
analysis (m/mmHg)
Resting -37.5 1
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6
Baroflex gain by sequence 
analysis (m/mmHg)
Resting -24.623116
7 Iwasaki 2005 0 14 2 0 CON 0 6 Plasme Volume (mL) Resting -16.2
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Plasme Volume (mL) Resting -6.8 1
7 Iwasaki 2005 0 14 2 0 CON 0 6 Deoxypyridinoline Resting 72
7 Iwasaki 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Deoxypyridinoline Resting 22.9
8 Iwase 2005 0 14 2 0 CON 0 6 Plasme Volume (mL) Resting -16.4
8 Iwase 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Plasme Volume (mL) Resting -5 1
8 Iwase 2005 0 14 2 0 CON 0 6 Anti-G Score Resting 11.9521912
8 Iwase 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Anti-G Score Resting 34.4295992 1
8 Iwase 2005 0 14 2 0 CON 0 6 Tolerance Time 10.3
8 Iwase 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Tolerance Time 26.3 1
8 Iwase 2005 0 14 2 0 CON 0 6 Heart Rate (beats/min) Resting 14.1065831
8 Iwase 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Heart Rate (beats/min) Resting 9.3442623 1
8 Iwase 2005 0 14 2 0 CON 0 6
Systolic Blood Pressure 
(mmHg)
Resting 3.05676856
8 Iwase 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6
Systolic Blood Pressure 
(mmHg)
Resting 3.80779692
8 Iwase 2005 0 14 2 0 CON 0 6
Diastolic Blood Pressure 
(mmHg)
Resting 1.2145749
8 Iwase 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6
Diastolic Blood Pressure 
(mmHg)
Resting 2.65363128
8 Iwase 2005 0 14 2 0 CON 0 6 Stroke Volume (mL) Resting -8.0357143
8 Iwase 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Stroke Volume (mL) Resting -10.485934
8 Iwase 2005 0 14 2 0 CON 0 6 Plasma Angiotensin II Resting 143.333333 1
8 Iwase 2005 0 14 2 3 2 1.2 30
~Every 
other day




8 Iwase 2005 0 14 2 0 CON 0 6 MSNA Burst Rate Resting 21.4285714
8 Iwase 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 MSNA Burst Rate Resting -11.764706
8 Iwase 2005 0 14 2 0 CON 0 6 Delta MSNA 30 Head-Up Tilt -43.986448
8 Iwase 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Delta MSNA 30 Head-Up Tilt -59.455916
8 Iwase 2005 0 14 2 0 CON 0 6 Delta Heart rate 30 Head-Up Tilt 18.4210526
8 Iwase 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Delta Heart rate 30 Head-Up Tilt -10.377358 1
8 Iwase 2005 0 14 2 0 CON 0 6 Delta Angiotensin II 30 Head-Up Tilt
8 Iwase 2005 0 14 2 3 2 1.2 30
~Every 
other day
Cycle at constant intensity of 60W, (n=4)           AG 0 6 Delta Angiotensin II 30 Head-Up Tilt
9 Iwasaki 2001 0 4 2 0 CON 0 10 Heart Rate (beats/min) Resting 8.8 1
9 Iwasaki 2001 0 4 2 1 2 30 Twice / AG 0 10 Heart Rate (beats/min) Resting -3.4
9 Iwasaki 2001 0 4 2 0 CON 0 10
High Frequency (HF) Heart 
Rate
-50 1




High Frequency (HF) Heart 
Rate
13.6
9 Iwasaki 2001 0 4 2 0 CON 0 10
HF sympathetic activity (SNS) 
(LF/HF)
Resting 16.7




HF sympathetic activity (SNS) 
(LF/HF)
Resting 4
9 Iwasaki 2001 0 4 2 0 CON 0 10 Low Frequency (LF) BP Resting -60 1
9 Iwasaki 2001 0 4 2 1 2 30 Twice / AG 0 10 Low Frequency (LF) BP Resting 52.8 1
9 Iwasaki 2001 0 4 2 0 CON 0 10 Hematocrit 11.6 1
9 Iwasaki 2001 0 4 2 1 2 30 Twice / AG 0 10 Hematocrit 4.4
9 Iwasaki 2001 0 4 2 0 CON 0 10 VO2 (L/min) Max -10 1
9 Iwasaki 2001 0 4 2 1 2 30 Twice / AG 0 10 VO2 (L/min) Max -10 1
10 Vernikos 1996 0 4 2 0 CON 0 9 Tolerance Time 60 Head-Up Tilt -50 1
10 Vernikos 1996 0 4 2 8 15
8 times / 
day
STD2 0 9 Tolerance Time 60 Head-Up Tilt -25
10 Vernikos 1996 0 4 2 8 15
16 times / 
day
STD4 0 9 Tolerance Time 60 Head-Up Tilt -11.1
10 Vernikos 1996 0 4 2 16 15
8 times / 
day
3mph WLK2 0 9 Tolerance Time 60 Head-Up Tilt -17.333333 1
10 Vernikos 1996 0 4 2 16 15
16 times / 
day
3mph WLK4 0 9 Tolerance Time 60 Head-Up Tilt -28.534704 1
10 Vernikos 1996 0 4 2 0 CON 0 9 Delta Heart rate 60 Head-Up Tilt 125 1
10 Vernikos 1996 0 4 2 8 15
8 times / 
day
STD2 0 9 Delta Heart rate 60 Head-Up Tilt 62.5 1
10 Vernikos 1996 0 4 2 8 15
16 times / 
day
STD4 0 9 Delta Heart rate 60 Head-Up Tilt 56.2 1
10 Vernikos 1996 0 4 2 16 15
8 times / 
day
3mph WLK2 0 9 Delta Heart rate 60 Head-Up Tilt 62.5 1
10 Vernikos 1996 0 4 2 16 15
16 times / 
day
3mph WLK4 0 9 Delta Heart rate 60 Head-Up Tilt 56.2 1
10 Vernikos 1996 0 4 2 0 CON 0 9 Delta Mean Arterial Pressure 60 Head-Up Tilt 0
10 Vernikos 1996 0 4 2 8 15
8 times / 
day
STD2 0 9 Delta Mean Arterial Pressure 60 Head-Up Tilt 0
10 Vernikos 1996 0 4 2 8 15
16 times / 
day
STD4 0 9 Delta Mean Arterial Pressure 60 Head-Up Tilt 0
10 Vernikos 1996 0 4 2 16 15
8 times / 
day
3mph WLK2 0 9 Delta Mean Arterial Pressure 60 Head-Up Tilt 0
10 Vernikos 1996 0 4 2 16 15
16 times / 
day
3mph WLK4 0 9 Delta Mean Arterial Pressure 60 Head-Up Tilt 0
10 Vernikos 1996 0 4 2 0 CON 0 9 VO2 (L/min) Max -16.9
10 Vernikos 1996 0 4 2 8 15
8 times / 
day
STD2 0 9 VO2 (L/min) Max -14
10 Vernikos 1996 0 4 2 8 15
16 times / 
day
STD4 0 9 VO2 (L/min) Max -11.5 1
10 Vernikos 1996 0 4 2 16 15
8 times / 
day
3mph WLK2 0 9 VO2 (L/min) Max -9 1
10 Vernikos 1996 0 4 2 16 15
16 times / 
day
3mph WLK4 0 9 VO2 (L/min) Max -9.3 1
10 Vernikos 1996 0 4 2 0 CON 0 9 Plasme Volume (mL) Resting -10.5
10 Vernikos 1996 0 4 2 8 15
8 times / 
day
STD2 0 9 Plasme Volume (mL) Resting -11.8
10 Vernikos 1996 0 4 2 8 15
16 times / 
day
STD4 0 9 Plasme Volume (mL) Resting -5.2 1
10 Vernikos 1996 0 4 2 16 15
8 times / 
day
3mph WLK2 0 9 Plasme Volume (mL) Resting -11
10 Vernikos 1996 0 4 2 16 15
16 times / 
day
3mph WLK4 0 9 Plasme Volume (mL) Resting -3.7 1




10 Vernikos 1996 0 4 2 8 15
8 times / 
day
STD2 0 9 Calcium Urinary 30
10 Vernikos 1996 0 4 2 8 15
16 times / 
day
STD4 0 9 Calcium Urinary 35
10 Vernikos 1996 0 4 2 16 15
8 times / 
day
3mph WLK2 0 9 Calcium Urinary 5
10 Vernikos 1996 0 4 2 16 15
16 times / 
day
3mph WLK4 0 9 Calcium Urinary 3






































































11 Vil-Viliams 1980 0 3 5 0 CON 0 6 Anti-G Score





0 5 Anti-G Score






























































































































































12 Shulzhenko 1977 0 56 6 1 0.6-0.9 90
Daily for 7 
days
Protocol: Day 1-7 Centrifugation; 8-21 Immersion 
only; 22-28 Centrifuge + water/salt; 29-35 Immersion 
only; 36-40 Exercise (bungee cords 2340kg total on 
legs, ab, arms); 41-47 Immersion only; 48-52 
Centrifugation +Exercise; 53-54 Immersion only; 55-
56 All three 
AG 0 2 Heart Rate (beats/min) Resting 44.5
12 Shulzhenko 1977 0 56 6 64
Daily for 5 
days
Protocol: Day 1-7 Centrifugation; 8-21 Immersion 
only; 22-28 Centrifuge + water/salt; 29-35 Immersion 
only; 36-40 Exercise (bungee cords 2340kg total on 
legs, ab, arms); 41-47 Immersion only; 48-52 
Centrifugation +Exercise; 53-54 Immersion only; 55-
56 All three 
BRE 0 2 Heart Rate (beats/min) Resting 15.5




Daily for 5 
days
Protocol: Day 1-7 Centrifugation; 8-21 Immersion 
only; 22-28 Centrifuge + water/salt; 29-35 Immersion 
only; 36-40 Exercise (bungee cords 2340kg total on 
legs, ab, arms); 41-47 Immersion only; 48-52 
Centrifugation +Exercise; 53-54 Immersion only; 55-
56 All three 
AG+BR
E
0 2 Heart Rate (beats/min) Resting 82
12 Shulzhenko 1977 0 56 6 0
Protocol: Day 1-7 Centrifugation; 8-21 Immersion 
only; 22-28 Centrifuge + water/salt; 29-35 Immersion 
only; 36-40 Exercise (bungee cords 2340kg total on 
legs, ab, arms); 41-47 Immersion only; 48-52 
Centrifugation +Exercise; 53-54 Immersion only; 55-
56 All three 
CON 0 2 Total Renal Excretion 11.1
12 Shulzhenko 1977 0 56 6 1 0.6-0.9 90
Daily for 7 
days
Protocol: Day 1-7 Centrifugation; 8-21 Immersion 
only; 22-28 Centrifuge + water/salt; 29-35 Immersion 
only; 36-40 Exercise (bungee cords 2340kg total on 
legs, ab, arms); 41-47 Immersion only; 48-52 
Centrifugation +Exercise; 53-54 Immersion only; 55-
56 All three 
AG 0 2 Total Renal Excretion -25.2




Daily for 5 
days
Protocol: Day 1-7 Centrifugation; 8-21 Immersion 
only; 22-28 Centrifuge + water/salt; 29-35 Immersion 
only; 36-40 Exercise (bungee cords 2340kg total on 
legs, ab, arms); 41-47 Immersion only; 48-52 
Centrifugation +Exercise; 53-54 Immersion only; 55-
56 All three 
AGNaCl 0 2 Total Renal Excretion -74.1
12 Shulzhenko 1977 0 56 6 1 0.6-0.9 90
Daily for 7 
days
Protocol: Day 1-7 Centrifugation; 8-21 Immersion 
only; 22-28 Centrifuge + water/salt; 29-35 Immersion 
only; 36-40 Exercise (bungee cords 2340kg total on 
legs, ab, arms); 41-47 Immersion only; 48-52 
Centrifugation +Exercise; 53-54 Immersion only; 55-
56 All three 
AG 0 2
Total Renal Excretion of 
Creatinine
-9
12 Shulzhenko 1977 0 56 6 1 0.6-0.9 90
Daily for 7 
days
Protocol: Day 1-7 Centrifugation; 8-21 Immersion 
only; 22-28 Centrifuge + water/salt; 29-35 Immersion 
only; 36-40 Exercise (bungee cords 2340kg total on 
legs, ab, arms); 41-47 Immersion only; 48-52 
Centrifugation +Exercise; 53-54 Immersion only; 55-
56 All three 
AG 0 2
Total Renal Excretion of 
Sodium
-25.5
12 Shulzhenko 1977 0 56 6 1 0.6-0.9 90
Daily for 7 
days
Protocol: Day 1-7 Centrifugation; 8-21 Immersion 
only; 22-28 Centrifuge + water/salt; 29-35 Immersion 
only; 36-40 Exercise (bungee cords 2340kg total on 
legs, ab, arms); 41-47 Immersion only; 48-52 
Centrifugation +Exercise; 53-54 Immersion only; 55-
56 All three 
AG 0 2
Total Renal Excretion of 
Potassium
-20
12 Shulzhenko 1977 0 56 6 1 0.6-0.9 90
Daily for 7 
days
Protocol: Day 1-7 Centrifugation; 8-21 Immersion 
only; 22-28 Centrifuge + water/salt; 29-35 Immersion 
only; 36-40 Exercise (bungee cords 2340kg total on 
legs, ab, arms); 41-47 Immersion only; 48-52 
Centrifugation +Exercise; 53-54 Immersion only; 55-
56 All three 
AG 0 2











13 Shulzhenko 1979 0 3 6 1 2 0.8 40
3 times / 
day





13 Shulzhenko 1979 0 3 6 1 2 1.2 40
3 times / 
day





13 Shulzhenko 1979 0 3 6 1 2 1.6 40
3 times / 
day





13 Shulzhenko 1979 0 3 6 0 CON 0 6 Plasme Volume (mL) -20
13 Shulzhenko 1979 0 3 6 1 2 0.8 40
3 times / 
day
0.8AG 0 6 Plasme Volume (mL) -17.9
13 Shulzhenko 1979 0 3 6 1 2 1.2 40
3 times / 
day
1.2AG 0 5 Plasme Volume (mL) -14.4
13 Shulzhenko 1979 0 3 6 1 2 1.6 40
3 times / 
day
1.6AG 0 5 Plasme Volume (mL) -14.9
13 Shulzhenko 1979 0 3 6 0 CON 0 6 Fluid Balance
13 Shulzhenko 1979 0 3 6 1 2 0.8 40
3 times / 
day
0.8AG 0 6 Fluid Balance -23.5
13 Shulzhenko 1979 0 3 6 1 2 1.2 40
3 times / 
day
1.2AG 0 5 Fluid Balance -59.5
13 Shulzhenko 1979 0 3 6 1 2 1.6 40
3 times / 
day
1.6AG 0 5 Fluid Balance -52
14 Grigoriev 1979 0 13 5 0 CON 0 5
Sodium Concentration in 
Serum
2.8




Sodium Concentration in 
Serum
0
14 Grigoriev 1979 0 13 5 0 CON 0 5
Potassium Concentration in 
Serum
-15.2 1




Potassium Concentration in 
Serum
-4.4
14 Grigoriev 1979 0 13 5 0 CON 0 5
Calcium Concentration in 
Serum
16.6




Calcium Concentration in 
Serum
10.4
14 Grigoriev 1979 0 13 5 0 CON 0 5
Magnesium Concentration in 
Serum
19.2




Magnesium Concentration in 
Serum
13.5
14 Grigoriev 1979 0 13 5 0 CON 0 5 Osmolarity 1.7
14 Grigoriev 1979 0 13 5 1 7.25 0.6-2 60-90
Daily after 
day 8
AG 0 5 Osmolarity -0.6
14 Grigoriev 1979 0 13 5 0 CON 0 5 Total Renal Excretion 36 1
14 Grigoriev 1979 0 13 5 1 7.25 0.6-2 60-90
Daily after 
day 8
AG 0 5 Total Renal Excretion 14.2
14 Grigoriev 1979 0 13 5 0 CON 0 5












14 Grigoriev 1979 0 13 5 0 CON 0 5
Total Renal Excretion of 
Sodium
31.4 1




Total Renal Excretion of 
Sodium
0
14 Grigoriev 1979 0 13 5 0 CON 0 5
Total Renal Excretion of 
Potassium
69.5 1




Total Renal Excretion of 
Potassium
44.6
14 Grigoriev 1979 0 13 5 0 CON 0 5
Total Renal Excretion of 
Calcium
37.2 1




Total Renal Excretion of 
Calcium
29.2
14 Grigoriev 1979 0 13 5 0 CON 0 5
Total Renal Excretion of 
Magnesium
38.9 1




Total Renal Excretion of 
Magnesium
13.2
15 Shulzhenko 1980 0 3 5 0 CON 0 10 Total Renal Excretion 39.4 1
15 Shulzhenko 1980 0 3 5 1 2 1.2,1.6 30 Twice / 15 min @ 1.2, 15 min @ 1.6 AG 0 10 Total Renal Excretion 22.8 1 1
15 Shulzhenko 1980 0 3 5 0 CON 0 10






15 Shulzhenko 1980 0 3 5 1 2 1.2,1.6 30
Twice / 
day
15 min @ 1.2, 15 min @ 1.6 AG 0 10
Total Renal Excretion of 
Sodium
-0.2
15 Shulzhenko 1980 0 3 5 0 CON 0 10
Total Renal Excretion of 
Potassium
14.1
15 Shulzhenko 1980 0 3 5 1 2 1.2,1.6 30
Twice / 
day
15 min @ 1.2, 15 min @ 1.6 AG 0 10
Total Renal Excretion of 
Potassium
0
15 Shulzhenko 1980 0 3 5 0 CON 0 10 Sodium / Potassium 6.9 1
15 Shulzhenko 1980 0 3 5 1 2 1.2,1.6 30 Twice / 15 min @ 1.2, 15 min @ 1.6 AG 0 10 Sodium / Potassium 2.3











Day 1-8, 15, 22 - immersion, Day 9-14 - SAC, Day 16-
21 cycling @600kgf/min 10 min then 10 rest for 60 
min twice/day, Day 23-28 SACwith cycling
AG+CY
C





16 Vil-Viliams 1980 0 28 5 0 CON 0 4 Anti-G Score






Day 1-8, 15, 22 - immersion, Day 9-14 - SAC, Day 16-
21 cycling @600kgf/min 10 min then 10 rest for 60 
min twice/day, Day 23-28 SACwith cycling
AG+CY
C
0 4 Anti-G Score
17 Sasaki 1999 0 4 2 0 BR 0 4 R-R Interval Resting -5.96 1
17 Sasaki 1999 0 4 2 1 1.8 2 30 Twice / AG 0 8 R-R Interval Resting 2.22 1
17 Sasaki 1999 0 4 2 0 BR 0 4
High Frequency (HF) Heart 
Rate
Resting -46.3 1




High Frequency (HF) Heart 
Rate
Resting 5.08 1
17 Sasaki 1999 0 4 2 0 BR 0 4
HF sympathetic activity (SNS) 
(LF/HF)
Resting 18.5




HF sympathetic activity (SNS) 
(LF/HF)
Resting 5.17
17 Sasaki 1999 0 4 2 0 BR 0 4
Baroflex gain by sequence 
analysis (m/mmHg)
Resting -30.9 1




Baroflex gain by sequence 
analysis (m/mmHg)
Resting 10.6 1
19 Smith 2009 0 21 2 0 CON 0 7 25(OH)-vitamin D Serum 1.8
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 25(OH)-vitamin D Serum 3.2
19 Smith 2009 0 21 2 0 CON 0 7 1,25(OH)-vitamin D Serum -2.4
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 1,25(OH)-vitamin D Serum -21.4
19 Smith 2009 0 21 2 0 CON 0 7
Parathyroid Hormone (intact 
molecule)
Serum -22 1
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8
Parathyroid Hormone (intact 
molecule)
Serum -18 1
19 Smith 2009 0 21 2 0 CON 0 7 Ionized Calcium Serum 0.8
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Ionized Calcium Serum 0
19 Smith 2009 0 21 2 0 CON 0 7 Calcium Serum -1
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Calcium Serum 0.5
19 Smith 2009 0 21 2 0 CON 0 7 Calcium Urinary 9.2
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Calcium Urinary 12.7
19 Smith 2009 0 21 2 0 CON 0 7 n-telopeptide Urinary 44.4 1
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 n-telopeptide Urinary 19.1 1
19 Smith 2009 0 21 2 0 CON 0 7 c-telopeptide Serum 33.3 1
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 c-telopeptide Serum 22.2 1
19 Smith 2009 0 21 2 0 CON 0 7 Helical Peptide Urinary 54.5 1
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Helical Peptide Urinary 42.4 1
19 Smith 2009 0 21 2 0 CON 0 7 Deoxypyridinoline Urinary 55 1
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Deoxypyridinoline Urinary 44.4 1
19 Smith 2009 0 21 2 0 CON 0 7 Pyridinium cosslink Urinary 43
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Pyridinium cosslink Urinary 23.9
19 Smith 2009 0 21 2 0 CON 0 7
Bone specific alkaline 
phosphate
Serum 3.2
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8
Bone specific alkaline 
phosphate
Serum -13.3
19 Smith 2009 0 21 2 0 CON 0 7 Total Alkaline Phosphatase Serum 9.8
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Total Alkaline Phosphatase Serum -3.3
19 Smith 2009 0 21 2 0 CON 0 7
Procollagen type 1 N 
propeptide
Serum -3.4
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8
Procollagen type 1 N 
propeptide
Serum -11.8
19 Smith 2009 0 21 2 0 CON 0 7 Osteocalcin Serum -4.3 1
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Osteocalcin Serum -11.5 1
19 Smith 2009 0 21 2 0 CON 0 7 Osteoprotegerin Serum 0
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Osteoprotegerin Serum 2.3











19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Content Whole Body -1.1
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Content Whole Body -0.7
19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Density Whole Body -0.3
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Density Whole Body 0
19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Density Pelvis -1.1
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Density Pelvis -0.6
19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Density Calcaneus 0.6
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Density Calcaneus -0.1
19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Density Spine -0.6
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Density Spine -0.2
19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Density Trochanter -0.9
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Density Trochanter -0.7
19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Density Femoral Neck -0.1
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Density Femoral Neck 0.2
19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Density Total Hip -0.8
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Density Total Hip -0.5
19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Density
Tibia Epiphysis (5% 
from ankle)
0.8
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Density
Tibia Epiphysis (5% 
from ankle)
0
19 Smith 2009 0 21 2 0 CON 0 7 Cortical Density
Tibia Epiphysis (5% 
from ankle)
1.2
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Cortical Density
Tibia Epiphysis (5% 
from ankle)
0
19 Smith 2009 0 21 2 0 CON 0 7 Trabecular Density
Tibia Epiphysis (5% 
from ankle)
-0.4
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Trabecular Density
Tibia Epiphysis (5% 
from ankle)
-0.4
19 Smith 2009 0 21 2 0 CON 0 7 Polar Strength-strain Index
Tibia Epiphysis (5% 
from ankle)
1.6
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Polar Strength-strain Index
Tibia Epiphysis (5% 
from ankle)
0.1
19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Density
Tibia Shaft (50% from 
ankle)
-0.3
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Density
Tibia Shaft (50% from 
ankle)
0
19 Smith 2009 0 21 2 0 CON 0 7 Cortical Density
Tibia Shaft (50% from 
ankle)
-0.6
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Cortical Density
Tibia Shaft (50% from 
ankle)
0.3
19 Smith 2009 0 21 2 0 CON 0 7 Trabecular Density
Tibia Shaft (50% from 
ankle)
0.8
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Trabecular Density
Tibia Shaft (50% from 
ankle)
-0.4
19 Smith 2009 0 21 2 0 CON 0 7 Polar Strength-strain Index
Tibia Shaft (50% from 
ankle)
0.3
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Polar Strength-strain Index
Tibia Shaft (50% from 
ankle)
-0.2
19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Density
Tibia Proximal #1 
(insertion of patellar)
0.3
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Density
Tibia Proximal #1 
(insertion of patellar)
0
19 Smith 2009 0 21 2 0 CON 0 7 Cortical Density
Tibia Proximal #1 
(insertion of patellar)
-0.2
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Cortical Density
Tibia Proximal #1 
(insertion of patellar)
0.4
19 Smith 2009 0 21 2 0 CON 0 7 Trabecular Density
Tibia Proximal #1 
(insertion of patellar)
1.2
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Trabecular Density
Tibia Proximal #1 
(insertion of patellar)
-1.2
19 Smith 2009 0 21 2 0 CON 0 7 Polar Strength-strain Index
Tibia Proximal #1 
(insertion of patellar)
-1
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Polar Strength-strain Index
Tibia Proximal #1 
(insertion of patellar)
1.5
19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Density
Tibia Proximal #2 
(insertion of patellar)
0
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Density
Tibia Proximal #2 
(insertion of patellar)
0.3
19 Smith 2009 0 21 2 0 CON 0 7 Cortical Density
Tibia Proximal #2 
(insertion of patellar)
-0.2
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Cortical Density
Tibia Proximal #2 
(insertion of patellar)
0.2
19 Smith 2009 0 21 2 0 CON 0 7 Trabecular Density






19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Trabecular Density
Tibia Proximal #2 
(insertion of patellar)
0
19 Smith 2009 0 21 2 0 CON 0 7 Polar Strength-strain Index
Tibia Proximal #2 
(insertion of patellar)
-1.4
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Polar Strength-strain Index
Tibia Proximal #2 
(insertion of patellar)
0.2
19 Smith 2009 0 21 2 0 CON 0 7 Bone Mineral Density
Tibia Proximal #3 
(insertion of patellar)
0.7
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Bone Mineral Density
Tibia Proximal #3 
(insertion of patellar)
0
19 Smith 2009 0 21 2 0 CON 0 7 Cortical Density
Tibia Proximal #3 
(insertion of patellar)
0.8
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Cortical Density
Tibia Proximal #3 
(insertion of patellar)
0
19 Smith 2009 0 21 2 0 CON 0 7 Trabecular Density
Tibia Proximal #3 
(insertion of patellar)
0
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Trabecular Density
Tibia Proximal #3 
(insertion of patellar)
0
19 Smith 2009 0 21 2 0 CON 0 7 Polar Strength-strain Index
Tibia Proximal #3 
(insertion of patellar)
0.3
19 Smith 2009 0 21 2 1 3 2.5 1 60 Daily AG 0 8 Polar Strength-strain Index
Tibia Proximal #3 
(insertion of patellar)
1.9
20 Greenleaf 1989 0 30 2 0 CON 0 5 Tolerance Time 60 Head-Up Tilt -34.7 1
20 Greenleaf 1989 0 30 2 2 30
Twice daily 
/ 5 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
CYC 0 7 Tolerance Time 60 Head-Up Tilt -19 1
20 Greenleaf 1989 0 30 2 1024 30
Twice daily 
/ 5 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
ISK 0 7 Tolerance Time 60 Head-Up Tilt -43.3 1
20 Greenleaf 1989 0 30 2 0 CON 0 5 Anti-G Score
20 Greenleaf 1989 0 30 2 2 30
Twice daily 
/ 5 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
CYC 0 7 Anti-G Score
20 Greenleaf 1989 0 30 2 1024 30
Twice daily 
/ 5 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
ISK 0 7 Anti-G Score
20 Greenleaf 1989 0 30 2 0 CON 0 5 Delta Heart rate 60 Head-Up Tilt 156.2 1
20 Greenleaf 1989 0 30 2 2 30
Twice daily 
/ 5 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
CYC 0 7 Delta Heart rate 60 Head-Up Tilt 150 1
20 Greenleaf 1989 0 30 2 1024 30
Twice daily 
/ 5 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
ISK 0 7 Delta Heart rate 60 Head-Up Tilt 142.1 1
20 Greenleaf 1989 0 30 2 0 CON 0 5 Delta SBP 60 Head-Up Tilt #DIV/0!
20 Greenleaf 1989 0 30 2 2 30
Twice daily 
/ 5 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
CYC 0 7 Delta SBP 60 Head-Up Tilt 0
20 Greenleaf 1989 0 30 2 1024 30
Twice daily 
/ 5 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
ISK 0 7 Delta SBP 60 Head-Up Tilt 125
20 Greenleaf 1989 0 30 2 0 CON 0 5 Delta DBP 60 Head-Up Tilt 122.2
20 Greenleaf 1989 0 30 2 2 30
Twice daily 
/ 5 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
CYC 0 7 Delta DBP 60 Head-Up Tilt 125
20 Greenleaf 1989 0 30 2 1024 30
Twice daily 
/ 5 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
ISK 0 7 Delta DBP 60 Head-Up Tilt -16.6
20 Greenleaf 1989 0 30 2 0 CON 0 5 Plasme Volume (mL) -17.3 1
20 Greenleaf 1989 0 30 2 2 30
Twice daily 
/ 5 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
CYC 0 7 Plasme Volume (mL) -4.4
20 Greenleaf 1989 0 30 2 1024 30
Twice daily 
/ 5 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
ISK 0 7 Plasme Volume (mL) -18.4 1
20 Greenleaf 1989 0 30 2 0 CON 0 5 VO2 (L/min) Max -20.4 1
20 Greenleaf 1989 0 30 2 2 30
Twice daily 
/ 5 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
CYC 0 7 VO2 (L/min) Max 0.3
20 Greenleaf 1989 0 30 2 1024 30
Twice daily 
/ 5 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
ISK 0 7 VO2 (L/min) Max -10.4 1
20 Greenleaf 1989 0 30 2 0 CON 0 5 Red Blood Cell Volume -11.1 1
20 Greenleaf 1989 0 30 2 2 30
Twice daily 
/ 5 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)




20 Greenleaf 1989 0 30 2 1024 30
Twice daily 
/ 5 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
ISK 0 7 Red Blood Cell Volume -17.2 1
20 Greenleaf 1989 0 30 2 0 CON 0 5 Total Blood Volume -12.6
20 Greenleaf 1989 0 30 2 2 30
Twice daily 
/ 5 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
CYC 0 7 Total Blood Volume -3
20 Greenleaf 1989 0 30 2 1024 30
Twice daily 
/ 5 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
ISK 0 7 Total Blood Volume -17.7 1
20 Greenleaf 1989 0 30 2 0 CON 0 5 Heart Rate (beats/min) Resting 19.6
20 Greenleaf 1989 0 30 2 2 30
Twice daily 
/ 5 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
CYC 0 7 Heart Rate (beats/min) Resting 8.1
20 Greenleaf 1989 0 30 2 1024 30
Twice daily 
/ 5 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
ISK 0 7 Heart Rate (beats/min) Resting 13.2
21 Lee 2009 0 30 2 0 CON 7 0 Exercise Time Max -20.9 1 1
21 Lee 2009 0 30 2 260 45
Daily / 6 
days per 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 0 Exercise Time Max -3.7
21 Lee 2009 0 30 2 0 CON 7 0 Peak Treadmill Grade -100 1 1
21 Lee 2009 0 30 2 260 45
Daily / 6 
days per 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 0 Peak Treadmill Grade -6.6
21 Lee 2009 0 30 2 0 CON 7 0 VO2 (L/min) Max -16.3 1 1
21 Lee 2009 0 30 2 260 45
Daily / 6 
days per 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 0 VO2 (L/min) Max -6.3
21 Lee 2009 0 30 2 0 CON 7 0 Sprint Time 35 1 1
21 Lee 2009 0 30 2 260 45
Daily / 6 
days per 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 0 Sprint Time 9
21 Lee 2009 0 30 2 0 CON 7 0 Sprint Speed -24 1 1
21 Lee 2009 0 30 2 260 45
Daily / 6 
days per 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 0 Sprint Speed -8
21 Lee 2009 0 30 2 0 CON 7 0 Plasme Volume (mL) -3.1
21 Lee 2009 0 30 2 260 45
Daily / 6 
days per 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 0 Plasme Volume (mL) -2.6
21 Lee 2009 0 30 2 0 CON 7 0 Body Mass -0.6 1
21 Lee 2009 0 30 2 260 45
Daily / 6 
days per 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 0 Body Mass 1
21 Lee 2009 0 30 2 0 CON 7 0 Lean Tissue -0.7 1
21 Lee 2009 0 30 2 260 45
Daily / 6 
days per 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 0 Lean Tissue 1.8 1
21 Lee 2009 0 30 2 0 CON 7 0 Fat Mass 7.9 1 1
21 Lee 2009 0 30 2 260 45
Daily / 6 
days per 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 0 Fat Mass 4.6




21 Lee 2009 0 30 2 260 45
Daily / 6 
days per 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 0 Body Fat 3.7
21 Lee 2009 0 30 2 0 CON 7 0 Heart Rate (beats/min) Resting 24.3 1
21 Lee 2009 0 30 2 260 45
Daily / 6 
days per 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 0 Heart Rate (beats/min) Resting 0
22 Watenpaugh 2000 0 15 2 0 CON 0 8 Exercise Time Max -9.9 1
22 Watenpaugh 2000 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
@ 80%, 2 @ 50%, 3 @70%, 2 @ 40%, 3 @60%, 5 
@ 40%
LBNP 0 8 Exercise Time Max -0.5
22 Watenpaugh 2000 0 15 2 0 CON 0 8 VO2 (L/min) Max -13.5 1
22 Watenpaugh 2000 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
LBNP 0 8 VO2 (L/min) Max -5.2
22 Watenpaugh 2000 0 15 2 0 CON 0 8 Sprint Time
22 Watenpaugh 2000 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
@ 80%, 2 @ 50%, 3 @70%, 2 @ 40%, 3 @60%, 5 
@ 40%
LBNP 0 8 Sprint Time
22 Watenpaugh 2000 0 15 2 0 CON 0 8 Sprint Speed -16.3 1
22 Watenpaugh 2000 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
@ 80%, 2 @ 50%, 3 @70%, 2 @ 40%, 3 @60%, 5 
@ 40%
LBNP 0 8 Sprint Speed -4.5
22 Watenpaugh 2000 0 15 2 0 CON 0 8 Muscle Strength Plantar Flexor -7
22 Watenpaugh 2000 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
LBNP 0 8 Muscle Strength Plantar Flexor 2.1
22 Watenpaugh 2000 0 15 2 0 CON 0 8 Hematocrit 6.5 1
22 Watenpaugh 2000 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
LBNP 0 8 Hematocrit 0.5
22 Watenpaugh 2000 0 15 2 0 CON 0 8 Plasme Volume (mL) -13.7
22 Watenpaugh 2000 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
LBNP 0 8 Plasme Volume (mL) -5.6
22 Watenpaugh 2000 0 15 2 0 CON 0 8 Total Blood Volume -10.5
22 Watenpaugh 2000 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
LBNP 0 8 Total Blood Volume -4.4
22 Watenpaugh 2000 0 15 2 0 CON 0 8 Erythrocyte Volume -4.4
22 Watenpaugh 2000 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
LBNP 0 8 Erythrocyte Volume -1.9
23 Lee 1997 0 5 2 0
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
CON 0 8 VO2 (L/min) Max -7.2
23 Lee 1997 0 5 2 16 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%




23 Lee 1997 0 5 2 260 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
LBNP 0 8 VO2 (L/min) Max -7.1
23 Lee 1997 0 5 2 0
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
CON 0 8 Heart Rate (beats/min) Max 0
23 Lee 1997 0 5 2 16 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
Upex 0 8 Heart Rate (beats/min) Max 0
23 Lee 1997 0 5 2 260 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
LBNP 0 8 Heart Rate (beats/min) Max 1
23 Lee 1997 0 5 2 0
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
CON 0 8 Respiratory Exchange Ratio Max -0.8
23 Lee 1997 0 5 2 16 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
Upex 0 8 Respiratory Exchange Ratio Max 0
23 Lee 1997 0 5 2 260 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
LBNP 0 8 Respiratory Exchange Ratio Max 0
23 Lee 1997 0 5 2 0
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
CON 0 8 Ve (L/min) Max -3.7
23 Lee 1997 0 5 2 16 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
Upex 0 8 Ve (L/min) Max -3.6
23 Lee 1997 0 5 2 260 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
LBNP 0 8 Ve (L/min) Max 1.4
23 Lee 1997 0 5 2 0
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
CON 0 8 Exercise Time Max -9 1
23 Lee 1997 0 5 2 16 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
Upex 0 8 Exercise Time Max -1.7
23 Lee 1997 0 5 2 260 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
LBNP 0 8 Exercise Time Max -1.6
23 Lee 1997 0 5 2 0
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
CON 0 8 Plasme Volume (mL) -16.2 1
23 Lee 1997 0 5 2 16 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
Upex 0 8 Plasme Volume (mL) -9.5 1
23 Lee 1997 0 5 2 260 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
LBNP 0 8 Plasme Volume (mL) -3.6
23 Lee 1997 0 5 2 0
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
CON 0 8 Hemoglobin 11.4 1
23 Lee 1997 0 5 2 16 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
Upex 0 8 Hemoglobin 6.6
23 Lee 1997 0 5 2 260 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
LBNP 0 8 Hemoglobin 2.1
23 Lee 1997 0 5 2 0
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
CON 0 8 Hematocrit 11.3 1
23 Lee 1997 0 5 2 16 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
Upex 0 8 Hematocrit 5.9
23 Lee 1997 0 5 2 260 30 Daily
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40%, 5 min @40%
LBNP 0 8 Hematocrit 5.7
24 Watenpaugh 2007 0 30 2 0 CON 7 8 Tolerance Time
60 Head-Up Tilt with 
graded LBNP
-34 1
24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Tolerance Time
60 Head-Up Tilt with 
graded LBNP
-13 1 1




24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Anti-G Score
24 Watenpaugh 2007 0 30 2 0 CON 7 8 Stroke Volume (mL) Resting -13 1
24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Stroke Volume (mL) Resting 7.3
24 Watenpaugh 2007 0 30 2 0 CON 7 8 Stroke Volume (mL) 60 Head-Up Tilt -28 1
24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Stroke Volume (mL) 60 Head-Up Tilt
24 Watenpaugh 2007 0 30 2 0 CON 7 8 Heart Rate (beats/min) Resting 20 1
24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Heart Rate (beats/min) Resting -3 1
24 Watenpaugh 2007 0 30 2 0 CON 7 8 Heart Rate (beats/min) Max 1
24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Heart Rate (beats/min) Max 1
24 Watenpaugh 2007 0 30 2 0 CON 7 8 Cardiac Output Resting 0
24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Cardiac Output Resting 3.9
24 Watenpaugh 2007 0 30 2 0 CON 7 8 Cardiac Output 60 Head-Up Tilt
24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Cardiac Output 60 Head-Up Tilt
24 Watenpaugh 2007 0 30 2 0 CON 7 8 Total Peripheral Resistance Resting 12.8
24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Total Peripheral Resistance Resting -6.3
24 Watenpaugh 2007 0 30 2 0 CON 7 8 Total Peripheral Resistance 60 Head-Up Tilt
24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Total Peripheral Resistance 60 Head-Up Tilt
24 Watenpaugh 2007 0 30 2 0 CON 7 8 Mean Arterial Pressure Resting
24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Mean Arterial Pressure Resting
24 Watenpaugh 2007 0 30 2 0 CON 7 8 Mean Arterial Pressure 60 Head-Up Tilt
24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Mean Arterial Pressure 60 Head-Up Tilt
24 Watenpaugh 2007 0 30 2 0 CON 7 8 Cerebral Vascular Resistance Resting
24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Cerebral Vascular Resistance Resting




24 Watenpaugh 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 7 8 Cerebral Vascular Resistance 60 Head-Up Tilt
25 Suzuki 1994 0 20 4 0 CON 0 6 VO2 (L/min) Max -11
25 Suzuki 1994 0 20 4 2 60 Daily 50W (~40%VO2max) CYC 0 3 VO2 (L/min) Max -11.3 1








25 Suzuki 1994 0 20 4 0 CON 0 6 Heart Rate (beats/min) Resting 25.2
25 Suzuki 1994 0 20 4 2 60 Daily 50W (~40%VO2max) CYC 0 3 Heart Rate (beats/min) Resting 9.3
25 Suzuki 1994 0 20 4 0 CON 0 6
Systolic Blood Pressure 
(mmHg)
Resting -11.3
25 Suzuki 1994 0 20 4 2 60 Daily 50W (~40%VO2max) CYC 0 3
Systolic Blood Pressure 
(mmHg)
Resting -16.8
25 Suzuki 1994 0 20 4 0 CON 0 6
Diastolic Blood Pressure 
(mmHg)
Resting -16
25 Suzuki 1994 0 20 4 2 60 Daily 50W (~40%VO2max) CYC 0 3
Diastolic Blood Pressure 
(mmHg)
Resting -23.7
25 Suzuki 1994 0 20 4 0 CON 0 6 Stroke Volume (mL) Resting -27.7
25 Suzuki 1994 0 20 4 2 60 Daily 50W (~40%VO2max) CYC 0 3 Stroke Volume (mL) Resting -20.2
25 Suzuki 1994 0 20 4 0 CON 0 6 Cardiac Output Resting -9.4
25 Suzuki 1994 0 20 4 2 60 Daily 50W (~40%VO2max) CYC 0 3 Cardiac Output Resting -15.1
26 Smith 2003 0 30 2 0 CON 0 8 Calcium Serum 1.7 1
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 0 8 Calcium Serum 1.2 1
26 Smith 2003 0 30 2 0 CON 0 8 25(OH)-vitamin D Serum -1.5
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 0 8 25(OH)-vitamin D Serum -3
26 Smith 2003 0 30 2 0 CON 0 8 1,25(OH)-vitamin D Serum -21.3 1
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 0 8 1,25(OH)-vitamin D Serum -31.2 1
26 Smith 2003 0 30 2 0 CON 0 8
Parathyroid Hormone (intact 
molecule)
Serum -36.5 1
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 0 8
Parathyroid Hormone (intact 
molecule)
Serum -32.9 1
26 Smith 2003 0 30 2 0 CON 0 8
Bone specific alkaline 
phosphate
Serum -0.4
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 0 8
Bone specific alkaline 
phosphate
Serum 13.3
26 Smith 2003 0 30 2 0 CON 0 8 Alkaline Phosphate Serum 5.1
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 0 8 Alkaline Phosphate Serum 5.3
26 Smith 2003 0 30 2 0 CON 0 8 Osteocalcin Serum 2.2
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 0 8 Osteocalcin Serum -5.3
26 Smith 2003 0 30 2 0 CON 0 8 Calcium Urinary 31.9 1
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%




26 Smith 2003 0 30 2 0 CON 0 8 n-telopeptide Urinary 59.3 1
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 0 8 n-telopeptide Urinary 31.6 1 1
26 Smith 2003 0 30 2 0 CON 0 8 Pyridinium cosslink Urinary 71.1
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 0 8 Pyridinium cosslink Urinary 34
26 Smith 2003 0 30 2 0 CON 0 8 Deoxypyridinoline Urinary 64.3 1
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 0 8 Deoxypyridinoline Urinary 36.9 1 1
26 Smith 2003 0 30 2 0 CON 0 8 Creatinine Urinary 13.6
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 0 8 Creatinine Urinary 9
26 Smith 2003 0 30 2 0 CON 0 8 Urinary Volume Urinary 5.7
26 Smith 2003 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
LBNP 0 8 Urinary Volume Urinary -6.2
28 Rittweger 2005 0 90 2 0 CON 0 9 Muscle Cross Section Area Calf -25.6
28 Rittweger 2005 0 90 2 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device




28 Rittweger 2005 0 90 2 4096 Once
On C-14, infused 60mg dose of drug dissolved in 
500mL 0.9% saline over 3hr
PMD 0 7 Muscle Cross Section Area Calf -25.6
28 Rittweger 2005 0 90 2 0 CON 0 9 Muscle Cross Section Area Forearm -6.4
28 Rittweger 2005 0 90 2 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 9 Muscle Cross Section Area Forearm -7.6
28 Rittweger 2005 0 90 2 4096 Once
On C-14, infused 60mg dose of drug dissolved in 
500mL 0.9% saline over 3hr
PMD 0 7 Muscle Cross Section Area Forearm -7.7
28 Rittweger 2005 0 90 2 0 CON 0 9 Bone Mineral Content
Tibia Epiphysis (4% 
from ankle)
-6
28 Rittweger 2005 0 90 2 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 9 Bone Mineral Content
Tibia Epiphysis (4% 
from ankle)
-2.8
28 Rittweger 2005 0 90 2 4096 Once
On C-14, infused 60mg dose of drug dissolved in 
500mL 0.9% saline over 3hr
PMD 0 7 Bone Mineral Content
Tibia Epiphysis (4% 
from ankle)
-3.6
28 Rittweger 2005 0 90 2 0 CON 0 9 Bone Mineral Content
Tibia Metaphysis (14% 
from ankle)
-1
28 Rittweger 2005 0 90 2 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 9 Bone Mineral Content
Tibia Metaphysis (14% 
from ankle)
-0.9
28 Rittweger 2005 0 90 2 4096 Once
On C-14, infused 60mg dose of drug dissolved in 
500mL 0.9% saline over 3hr
PMD 0 7 Bone Mineral Content
Tibia Metaphysis (14% 
from ankle)
-0.7
28 Rittweger 2005 0 90 2 0 CON 0 9 Bone Mineral Content






28 Rittweger 2005 0 90 2 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 9 Bone Mineral Content
Tibia Shaft (33% from 
ankle)
-0.7
28 Rittweger 2005 0 90 2 4096 Once
On C-14, infused 60mg dose of drug dissolved in 
500mL 0.9% saline over 3hr
PMD 0 7 Bone Mineral Content
Tibia Shaft (33% from 
ankle)
-0.5
28 Rittweger 2005 0 90 2 0 CON 0 9 Bone Mineral Content






28 Rittweger 2005 0 90 2 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 9 Bone Mineral Content
Tibia Shaft (66% from 
ankle)
-0.9
28 Rittweger 2005 0 90 2 4096 Once
On C-14, infused 60mg dose of drug dissolved in 
500mL 0.9% saline over 3hr
PMD 0 7 Bone Mineral Content
Tibia Shaft (66% from 
ankle)
-0.5
28 Rittweger 2005 0 90 2 0 CON 0 9 Bone Mineral Content Distal Radius -0.6
28 Rittweger 2005 0 90 2 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device




28 Rittweger 2005 0 90 2 4096 Once
On C-14, infused 60mg dose of drug dissolved in 
500mL 0.9% saline over 3hr
PMD 0 7 Bone Mineral Content Distal Radius -0.3
28 Rittweger 2005 0 90 2 0 CON 0 9 Bone Mineral Content
Radius Shaft (60% from 
wrist)
-0.4
28 Rittweger 2005 0 90 2 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 9 Bone Mineral Content
Radius Shaft (60% from 
wrist)
-0.4
28 Rittweger 2005 0 90 2 4096 Once
On C-14, infused 60mg dose of drug dissolved in 
500mL 0.9% saline over 3hr
PMD 0 7 Bone Mineral Content
Radius Shaft (60% from 
wrist)
-0.2
29 Zwart 2007 0 30 2 0 CON 7 0 Calcium Urinary 68.1 1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Calcium Urinary 40 1
29 Zwart 2007 0 30 2 0 CON 7 0 n-telopeptide Urinary 64.4 1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 n-telopeptide Urinary 47.8 1
29 Zwart 2007 0 30 2 0 CON 7 0 Pyridinium cosslink Urinary 83.8 1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Pyridinium cosslink Urinary 50.8 1
29 Zwart 2007 0 30 2 0 CON 7 0 Deoxypyridinoline Urinary 94 1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Deoxypyridinoline Urinary 64 1
29 Zwart 2007 0 30 2 0 CON 7 0 Helical Peptide Urinary 81.3 1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Helical Peptide Urinary 9.3 1 1
29 Zwart 2007 0 30 2 0 CON 7 0 Creatinine Urinary 19 1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Creatinine Urinary 26.1 1
29 Zwart 2007 0 30 2 0 CON 7 0 Phosphorous Urinary 69 1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Phosphorous Urinary 65.8 1
29 Zwart 2007 0 30 2 0 CON 7 0 Calcium Serum 2.6
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Calcium Serum 0.9
29 Zwart 2007 0 30 2 0 CON 7 0 25(OH)-vitamin D Serum -10.3
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 25(OH)-vitamin D Serum 10.5
29 Zwart 2007 0 30 2 0 CON 7 0 1,25(OH)-vitamin D Serum -15.1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 1,25(OH)-vitamin D Serum -10.9
29 Zwart 2007 0 30 2 0 CON 7 0






29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0
Parathyroid Hormone (intact 
molecule)
Serum -6.8
29 Zwart 2007 0 30 2 0 CON 7 0
Bone specific alkaline 
phosphate
Serum 1.1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0
Bone specific alkaline 
phosphate
Serum -10.1
29 Zwart 2007 0 30 2 0 CON 7 0 Alkaline Phosphate Serum 0
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Alkaline Phosphate Serum -8.5
29 Zwart 2007 0 30 2 0 CON 7 0 Osteocalcin Serum 12.1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Osteocalcin Serum 19.4
29 Zwart 2007 0 30 2 0 CON 7 0 Bone Mineral Density Whole Body 0.3
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Bone Mineral Density Whole Body -0.1
29 Zwart 2007 0 30 2 0 CON 7 0 Bone Mineral Density Legs -0.4
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Bone Mineral Density Legs -0.5
29 Zwart 2007 0 30 2 0 CON 7 0 Bone Mineral Density Femoral Neck -0.1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Bone Mineral Density Femoral Neck 2
29 Zwart 2007 0 30 2 0 CON 7 0 Bone Mineral Density Femoral Shaft -2 1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Bone Mineral Density Femoral Shaft 0.5
29 Zwart 2007 0 30 2 0 CON 7 0 Bone Mineral Density Total Hip -1.6 1
29 Zwart 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 7 0 Bone Mineral Density Total Hip 0.3
30 Shackelford 2004 0 119 4 0 CON 5 13 Bone Mineral Density Spine -1.3 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Bone Mineral Density Spine 3.4 1 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Bone Mineral Density Femoral Neck -1.5
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Bone Mineral Density Femoral Neck 0.1
30 Shackelford 2004 0 119 4 0 CON 5 13 Bone Mineral Density Trochanter -3.6 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Bone Mineral Density Trochanter -2.3
30 Shackelford 2004 0 119 4 0 CON 5 13 Bone Mineral Density Total Hip -3.4 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Bone Mineral Density Total Hip -0.9 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Bone Mineral Density Calcaneus -9.2 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Bone Mineral Density Calcaneus 1.2 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Bone Mineral Density Distal Radius 0
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Bone Mineral Density Distal Radius -1
30 Shackelford 2004 0 119 4 0 CON 5 13 Bone Mineral Density Proximal Radius -0.2
30 Shackelford 2004 0 119 4 8192
6 days/ 
week




30 Shackelford 2004 0 119 4 0 CON 5 13 Bone Mineral Density Whole Body -0.7 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Bone Mineral Density Whole Body 0.1 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Bone Mineral Density Pelvis -3.3 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Bone Mineral Density Pelvis -0.5 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Bone Mineral Density Legs -1.8 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Bone Mineral Density Legs -0.8
30 Shackelford 2004 0 119 4 0 CON 5 13 Bone Mineral Density Arms -0.6
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Bone Mineral Density Arms -0.5
30 Shackelford 2004 0 119 4 0 CON 5 13 Calcium Urinary 38.6 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Calcium Urinary -7.4
30 Shackelford 2004 0 119 4 0 CON 5 13 n-telopeptide Urinary 48.5 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 n-telopeptide Urinary 31.6 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Pyridinium cosslink Urinary 46.5 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Pyridinium cosslink Urinary 25.8 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Deoxypyridinoline Urinary 34.9 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Deoxypyridinoline Urinary 23.5 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Alkaline Phosphate Serum 4.9
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Alkaline Phosphate Serum 31.4 1 1
30 Shackelford 2004 0 119 4 0 CON 5 13
Bone specific alkaline 
phosphate
Serum -0.1




Bone specific alkaline 
phosphate
Serum 63.6 1 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Osteocalcin Serum 10.5
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Osteocalcin Serum 42.7 1 1
30 Shackelford 2004 0 119 4 0 CON 5 13 1,25(OH)-vitamin D Serum -14.7 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 1,25(OH)-vitamin D Serum 12.1 1
30 Shackelford 2004 0 119 4 0 CON 5 13 25(OH)-vitamin D Serum 10.9
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 25(OH)-vitamin D Serum 6











30 Shackelford 2004 0 119 4 0 CON 5 13
Parathyroid Hormone (intact 
molecule)
Serum -25.1 1




Parathyroid Hormone (intact 
molecule)
Serum 17.9 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Calcium Serum 0.9
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Calcium Serum -1.3 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Ionized Calcium Serum 1.1 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Ionized Calcium Serum -0.8 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Calcium Fecal 19.5 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Calcium Fecal 0.8
30 Shackelford 2004 0 119 4 0 CON 5 13 Muscle Volume Posterior Back -5.6
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Muscle Volume Posterior Back 1.6
30 Shackelford 2004 0 119 4 0 CON 5 13 Muscle Volume Psoas Back 7.2 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Muscle Volume Psoas Back 16.4 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Muscle Volume Soleus -29.3 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Muscle Volume Soleus -9.7 1 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Muscle Volume Gastrocnemius -28.1 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Muscle Volume Gastrocnemius -6.6 1 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Muscle Volume Calf -22.9 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Muscle Volume Calf -7.3 1 1




30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Muscle Volume Sartorius 3.1 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Muscle Volume Knee Extensor -15.8 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Muscle Volume Knee Extensor 2 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Muscle Volume Hamstrings -13.2 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Muscle Volume Hamstrings -8.3 1
30 Shackelford 2004 0 119 4 0 CON 5 13 Muscle Volume Adductors -8.6 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Muscle Volume Adductors -3.1
30 Shackelford 2004 0 119 4 0 CON 5 13 Muscle Volume Thigh -13.2 1
30 Shackelford 2004 0 119 4 8192
6 days/ 
week
BRE 4 5 Muscle Volume Thigh -2.1 1
31 Lee 2007 0 30 2 0 CON 0 8 VO2 (L/min) Max -18.9 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 VO2 (L/min) Max -3.2 1
31 Lee 2007 0 30 2 0 CON 0 8 Heart Rate (beats/min) Max
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Heart Rate (beats/min) Max 1
31 Lee 2007 0 30 2 0 CON 0 8 Respiratory Exchange Ratio Max -8.3 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Respiratory Exchange Ratio Max -2.5 1 1
31 Lee 2007 0 30 2 0 CON 0 8 Ve (L/min) Max -11.1 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Ve (L/min) Max -0.8
31 Lee 2007 0 30 2 0 CON 0 8 Exercise Time Max -22.3 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Exercise Time Max -3 1
31 Lee 2007 0 30 2 0 CON 0 8 VO2 (L/min) Submaximal Exercise
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 VO2 (L/min) Submaximal Exercise
31 Lee 2007 0 30 2 0 CON 0 8 Heart Rate (beats/min) Submaximal Exercise 20 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Heart Rate (beats/min) Submaximal Exercise 1
31 Lee 2007 0 30 2 0 CON 0 8 Respiratory Exchange Ratio Submaximal Exercise
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Respiratory Exchange Ratio Submaximal Exercise
31 Lee 2007 0 30 2 0 CON 0 8 Ve (L/min) Submaximal Exercise
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Ve (L/min) Submaximal Exercise
31 Lee 2007 0 30 2 0 CON 0 8 VO2 (L/min) Submaximal Exercise
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%




31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Heart Rate (beats/min) Submaximal Exercise 1
31 Lee 2007 0 30 2 0 CON 0 8 Respiratory Exchange Ratio Submaximal Exercise
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Respiratory Exchange Ratio Submaximal Exercise 1
31 Lee 2007 0 30 2 0 CON 0 8 Ve (L/min) Submaximal Exercise 18 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Ve (L/min) Submaximal Exercise 1
31 Lee 2007 0 30 2 0 CON 0 8 VO2 (L/min) Submaximal Exercise
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 VO2 (L/min) Submaximal Exercise
31 Lee 2007 0 30 2 0 CON 0 8 Heart Rate (beats/min) Submaximal Exercise 9 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Heart Rate (beats/min) Submaximal Exercise 1
31 Lee 2007 0 30 2 0 CON 0 8 Respiratory Exchange Ratio Submaximal Exercise 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Respiratory Exchange Ratio Submaximal Exercise 1
31 Lee 2007 0 30 2 0 CON 0 8 Ve (L/min) Submaximal Exercise 23 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Ve (L/min) Submaximal Exercise 1
31 Lee 2007 0 30 2 0 CON 0 8 Sprint Time Max 24 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Sprint Time Max 8
31 Lee 2007 0 30 2 0 CON 0 8 Heart Rate (beats/min) Resting 20.5 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Heart Rate (beats/min) Resting -5.6 1
31 Lee 2007 0 30 2 0 CON 0 8 Heart Rate (beats/min) Resting 43.4 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Heart Rate (beats/min) Resting 7.1 1
31 Lee 2007 0 30 2 0 CON 0 8 Plasme Volume (mL) -13.3 1
31 Lee 2007 0 30 2 260 45
6 days/ 
week
LBNP at 1 body weight.  40 min exercisewith LBNP, 
then 5 min resting LBNP.  7min @ 40% Pre-BR 
VO2max, 3 @ 60%, 2 @ 40%, 3 @ 70%, 2 @ 50%, 
3 @ 80%, 2 @60%, 3 @ 80%, 2 @ 50%, 3 @70%, 2 
@ 40%, 3 @60%, 5 @ 40%
BRE 0 8 Plasme Volume (mL) -4
32 Maillet 1996 0 28 2 0 CON 0 6 Tolerance Time 60 Head-Up Tilt -14.2
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Tolerance Time 60 Head-Up Tilt 15.8




32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Anti-G Score
32 Maillet 1996 0 28 2 0 CON 0 6 Hematocrit Serum 1.6
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Hematocrit Serum 1.6
32 Maillet 1996 0 28 2 0 CON 0 6
Sodium Concentration in 
Serum
Serum 1.4
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6
Sodium Concentration in 
Serum
Serum -0.7
32 Maillet 1996 0 28 2 0 CON 0 6 Creatinine Serum 4.3
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Creatinine Serum 1
32 Maillet 1996 0 28 2 0 CON 0 6 Protein Serum 2.3
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Protein Serum -1.2
32 Maillet 1996 0 28 2 0 CON 0 6 Plasme Volume (mL) Serum -11.2 1
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Plasme Volume (mL) Serum -2.2
32 Maillet 1996 0 28 2 0 CON 0 6 VO2 (L/min) Max -13.3 1
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 VO2 (L/min) Max -5.6
32 Maillet 1996 0 28 2 0 CON 0 6 Heart Rate (beats/min) Resting 18.2
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Heart Rate (beats/min) Resting 17.7
32 Maillet 1996 0 28 2 0 CON 0 6
Diastolic Blood Pressure 
(mmHg)
Resting 8.6 1
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6
Diastolic Blood Pressure 
(mmHg)
Resting 14.8 1
32 Maillet 1996 0 28 2 0 CON 0 6 Atrial Natriuretic Peptide Serum
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Atrial Natriuretic Peptide Serum
32 Maillet 1996 0 28 2 0 CON 0 6 Plasma Renin Peptide Serum 258.4 1
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Plasma Renin Peptide Serum 166.3 1
32 Maillet 1996 0 28 2 0 CON 0 6 Aldosterone Serum 148.5 1
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Aldosterone Serum 98.7 1




32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Norepinephrine Serum
32 Maillet 1996 0 28 2 0 CON 0 6 Epinephrine Serum
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Epinephrine Serum
32 Maillet 1996 0 28 2 0 CON 0 6
Total Renal Excretion of 
Sodium
Urinary -30.3 1
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6
Total Renal Excretion of 
Sodium
Urinary -28.8
32 Maillet 1996 0 28 2 0 CON 0 6
Total Renal Excretion of 
Potassium
Urinary
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6
Total Renal Excretion of 
Potassium
Urinary
32 Maillet 1996 0 28 2 0 CON 0 6
Total Renal Excretion of 
Creatinine
Urinary
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6
Total Renal Excretion of 
Creatinine
Urinary
32 Maillet 1996 0 28 2 0 CON 0 6 Atrial Natriuretic Peptide Urinary
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Atrial Natriuretic Peptide Urinary
32 Maillet 1996 0 28 2 0 CON 0 6 ADH Urinary
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 ADH Urinary
32 Maillet 1996 0 28 2 0 CON 0 6 c GMP Urinary
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 c GMP Urinary
32 Maillet 1996 0 28 2 0 CON 0 6 Metanephrine Urinary
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Metanephrine Urinary
32 Maillet 1996 0 28 2 0 CON 0 6 Nometanephrine Urinary
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 Nometanephrine Urinary
32 Maillet 1996 0 28 2 0 CON 0 6 MHPG Glucuronides Urinary
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 MHPG Glucuronides Urinary
32 Maillet 1996 0 28 2 0 CON 0 6 MPHG Sulfates Urinary
32 Maillet 1996 0 28 2 1280 20
6 days/ 
week
LBNP - 15min @ 30mmHg daily on BR16,18,20,22-
28; RE - knee extension - 4s3r @ 50% max torque, 
3s2r @ 80-90% max torque, 1s1r @ max torque; 
isometric exerc - (3-5s) @ 90, 120, 150 knee joint 
angle
BRE 0 6 MPHG Sulfates Urinary




33 Greenleaf 1992 0 30 2 2 30
Twice daily 
/ 6 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
ITE 0 7 Plasme Volume (mL) Serum -1.5
33 Greenleaf 1992 0 30 2 1024 30
Twice daily 
/ 6 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
IKE 0 7 Plasme Volume (mL) Serum -16.8 1
33 Greenleaf 1992 0 30 2 0 CON 0 5 Erythrocyte Volume Serum -10.3 1
33 Greenleaf 1992 0 30 2 2 30
Twice daily 
/ 6 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
ITE 0 7 Erythrocyte Volume Serum
33 Greenleaf 1992 0 30 2 1024 30
Twice daily 
/ 6 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
IKE 0 7 Erythrocyte Volume Serum -17.2 1
33 Greenleaf 1992 0 30 2 0 CON 0 5 Fluid Balance 72.5 1
33 Greenleaf 1992 0 30 2 2 30
Twice daily 
/ 6 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
ITE 0 7 Fluid Balance 344.7 1
33 Greenleaf 1992 0 30 2 1024 30
Twice daily 
/ 6 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
IKE 0 7 Fluid Balance -170.7 1
33 Greenleaf 1992 0 30 2 0 CON 0 5 Protein Serum
33 Greenleaf 1992 0 30 2 2 30
Twice daily 
/ 6 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
ITE 0 7 Protein Serum
33 Greenleaf 1992 0 30 2 1024 30
Twice daily 
/ 6 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
IKE 0 7 Protein Serum
33 Greenleaf 1992 0 30 2 0 CON 0 5 Osmolarity Serum
33 Greenleaf 1992 0 30 2 2 30
Twice daily 
/ 6 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
ITE 0 7 Osmolarity Serum
33 Greenleaf 1992 0 30 2 1024 30
Twice daily 
/ 6 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
IKE 0 7 Osmolarity Serum
33 Greenleaf 1992 0 30 2 0 CON 0 5 VO2 (L/min) Max -18.2 1
33 Greenleaf 1992 0 30 2 2 30
Twice daily 
/ 6 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
ITE 0 7 VO2 (L/min) Max 2.6
33 Greenleaf 1992 0 30 2 1024 30
Twice daily 
/ 6 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
IKE 0 7 VO2 (L/min) Max -9.1 1
33 Greenleaf 1992 0 30 2 0 CON 0 5 Energy Cost of Regime
33 Greenleaf 1992 0 30 2 2 30
Twice daily 
/ 6 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
ITE 0 7 Energy Cost of Regime
33 Greenleaf 1992 0 30 2 1024 30
Twice daily 
/ 6 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
IKE 0 7 Energy Cost of Regime
34 Greenleaf 1983 0 14 2 0 CON 0 7 Muscle Strength Handgrip 0
34 Greenleaf 1983 0 14 2 2 30
Twice daily 
/ everyday
60rpm @68% VO2max ITE 0 7 Muscle Strength Handgrip -1
34 Greenleaf 1983 0 14 2 16384 30
Twice daily 
/ everyday
21% maximal leg extension force for 1min then 1min 
relax
IME 0 7 Muscle Strength Handgrip 1
34 Greenleaf 1983 0 14 2 0 CON 0 7 Muscle Endurance Handgrip -19.6 1
34 Greenleaf 1983 0 14 2 2 30
Twice daily 
/ everyday
60rpm @68% VO2max ITE 0 7 Muscle Endurance Handgrip -7.5
34 Greenleaf 1983 0 14 2 16384 30
Twice daily 
/ everyday
21% maximal leg extension force for 1min then 1min 
relax
IME 0 7 Muscle Endurance Handgrip 3.6
34 Greenleaf 1983 0 14 2 0 CON 0 7
Systolic Blood Pressure 
(mmHg)
Max -4.5
34 Greenleaf 1983 0 14 2 2 30
Twice daily 
/ everyday
60rpm @68% VO2max ITE 0 7
Systolic Blood Pressure 
(mmHg)
Max 0.6
34 Greenleaf 1983 0 14 2 16384 30
Twice daily 
/ everyday
21% maximal leg extension force for 1min then 1min 
relax
IME 0 7
Systolic Blood Pressure 
(mmHg)
Max 0
34 Greenleaf 1983 0 14 2 0 CON 0 7
Diastolic Blood Pressure 
(mmHg)
Max 0.8
34 Greenleaf 1983 0 14 2 2 30
Twice daily 
/ everyday
60rpm @68% VO2max ITE 0 7
Diastolic Blood Pressure 
(mmHg)
Max 16.4
34 Greenleaf 1983 0 14 2 16384 30
Twice daily 
/ everyday
21% maximal leg extension force for 1min then 1min 
relax
IME 0 7
Diastolic Blood Pressure 
(mmHg)
Max 9.1
36 Alkner 2004 0 90 2 0 CON 0 9 Muscle Volume Knee Extensor -18 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 8 Muscle Volume Knee Extensor -1








4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 8 Muscle Volume Vastii Group 0
36 Alkner 2004 0 90 2 0 CON 0 9 Muscle Volume Rectus Femoris -9 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 8 Muscle Volume Rectus Femoris 0
36 Alkner 2004 0 90 2 0 CON 0 9 Muscle Volume Plantar Flexor -29 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 8 Muscle Volume Plantar Flexor -15 1 1
38 Tesch 2004 0 35 7 0 CON 4 7 Muscle Volume Knee Extensor -8.8 1
38 Tesch 2004 0 35 7 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
ULLSE 3 7 Muscle Volume Knee Extensor 7.7 1
38 Tesch 2004 0 35 7 0 CON 4 7 Muscle Volume Plantar Flexor -10.5 1
38 Tesch 2004 0 35 7 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
ULLSE 3 7 Muscle Volume Plantar Flexor -11.1 1
38 Tesch 2004 0 35 7 0 CON 4 7 Muscle Volume Vastus Lateralis -9.3 1
38 Tesch 2004 0 35 7 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
ULLSE 3 7 Muscle Volume Vastus Lateralis 6.2 1
38 Tesch 2004 0 35 7 0 CON 4 7 Muscle Volume Vastus Intermedius -8.8 1
38 Tesch 2004 0 35 7 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
ULLSE 3 7 Muscle Volume Vastus Intermedius 5.3 1
38 Tesch 2004 0 35 7 0 CON 4 7 Muscle Volume Vastus Medialis -12.1 1
38 Tesch 2004 0 35 7 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
ULLSE 3 7 Muscle Volume Vastus Medialis 9.3 1
38 Tesch 2004 0 35 7 0 CON 4 7 Muscle Volume Rectus Femoris 0
38 Tesch 2004 0 35 7 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
ULLSE 3 7 Muscle Volume Rectus Femoris 16.7 1
38 Tesch 2004 0 35 7 0 CON 4 7
Maximum Voluntary 
Contraction (MVC)
90 degrees knee -24 1
38 Tesch 2004 0 35 7 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 




90 degrees knee -7
38 Tesch 2004 0 35 7 0 CON 4 7
Maximum Voluntary 
Contraction (MVC)
120 degrees knee -26 1
38 Tesch 2004 0 35 7 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 




120 degrees knee -8
38 Tesch 2004 0 35 7 0 CON 4 7
Maximum Voluntary 
Contraction (MVC)
90 degrees calf -32 1
38 Tesch 2004 0 35 7 192
Every third 
day
4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 




90 degrees calf -12 1 1
39 Trappe 2008 0 60 2 0 CON 7 0 Diameter MHC l Soleus -14.4 1
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Diameter MHC l Soleus -13 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Diameter MHC l Soleus -9.7 1
39 Trappe 2008 0 60 2 0 CON 7 0 Myofiber Cross Sectional Area Total Soleus -24.7
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Myofiber Cross Sectional Area Total Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Myofiber Cross Sectional Area Total Soleus -8.5




39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po, Peak force MHC l Soleus -28.3 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po, Peak force MHC l Soleus -23.2 1 1
39 Trappe 2008 0 60 2 0 CON 7 0 Po/CSA MHC l Soleus -14.8 1
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po/CSA MHC l Soleus -2.2





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po/CSA MHC l Soleus -10
39 Trappe 2008 0 60 2 0 CON 7 0 Vo, shortening velocity MHC l Soleus -7.2
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vo, shortening velocity MHC l Soleus 2.7





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vo, shortening velocity MHC l Soleus 6.4
39 Trappe 2008 0 60 2 0 CON 7 0 Vmax MHC l Soleus 4.3
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vmax MHC l Soleus 3.3 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vmax MHC l Soleus 26.1 1
39 Trappe 2008 0 60 2 0 CON 7 0 Absolute Power MHC l Soleus -39.1
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Absolute Power MHC l Soleus -29.8 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)








39 Trappe 2008 0 60 2 0 CON 7 0 Normalized Power MHC l Soleus -16
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Normalized Power MHC l Soleus -3.6





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Normalized Power MHC l Soleus 11.1
39 Trappe 2008 0 60 2 0 CON 7 0 Diameter MHC I / Ila Soleus -10.5
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day









RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Diameter MHC I / Ila Soleus -2.1
39 Trappe 2008 0 60 2 0 CON 7 0 Po, Peak force MHC I / Ila Soleus -44.9
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po, Peak force MHC I / Ila Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po, Peak force MHC I / Ila Soleus -23.3
39 Trappe 2008 0 60 2 0 CON 7 0 Po/CSA MHC I / Ila Soleus -30.8
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po/CSA MHC I / Ila Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po/CSA MHC I / Ila Soleus -21.7
39 Trappe 2008 0 60 2 0 CON 7 0 Vo, shortening velocity MHC I / Ila Soleus -4
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vo, shortening velocity MHC I / Ila Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vo, shortening velocity MHC I / Ila Soleus 41.6
39 Trappe 2008 0 60 2 0 CON 7 0 Vmax MHC I / Ila Soleus -30.2
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vmax MHC I / Ila Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vmax MHC I / Ila Soleus 53.2
39 Trappe 2008 0 60 2 0 CON 7 0 Absolute Power MHC I / Ila Soleus -69.5
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Absolute Power MHC I / Ila Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Absolute Power MHC I / Ila Soleus -5.1
39 Trappe 2008 0 60 2 0 CON 7 0 Normalized Power MHC I / Ila Soleus -62.9
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Normalized Power MHC I / Ila Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Normalized Power MHC I / Ila Soleus -2.4




39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Diameter MHC IIa Soleus -12





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Diameter MHC IIa Soleus 1.1
39 Trappe 2008 0 60 2 0 CON 7 0 Po, Peak force MHC IIa Soleus -21.5
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po, Peak force MHC IIa Soleus -31.4





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po, Peak force MHC IIa Soleus 8
39 Trappe 2008 0 60 2 0 CON 7 0 Po/CSA MHC IIa Soleus -1.6
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po/CSA MHC IIa Soleus -7.2





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po/CSA MHC IIa Soleus 4.8
39 Trappe 2008 0 60 2 0 CON 7 0 Vo, shortening velocity MHC IIa Soleus -8.5
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vo, shortening velocity MHC IIa Soleus 2.1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vo, shortening velocity MHC IIa Soleus 12.2
39 Trappe 2008 0 60 2 0 CON 7 0 Vmax MHC IIa Soleus 1.8
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vmax MHC IIa Soleus 15.3





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vmax MHC IIa Soleus 18.9
39 Trappe 2008 0 60 2 0 CON 7 0 Absolute Power MHC IIa Soleus -7.8
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Absolute Power MHC IIa Soleus -28.5





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Absolute Power MHC IIa Soleus 13.5
39 Trappe 2008 0 60 2 0 CON 7 0 Normalized Power MHC IIa Soleus 11.4
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Normalized Power MHC IIa Soleus -11.6





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)




39 Trappe 2008 0 60 2 0 CON 7 0 Diameter MHC IIa / IIx Soleus -6
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Diameter MHC IIa / IIx Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Diameter MHC IIa / IIx Soleus 14.1
39 Trappe 2008 0 60 2 0 CON 7 0 Po, Peak force MHC IIa / IIx Soleus -18.1
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po, Peak force MHC IIa / IIx Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po, Peak force MHC IIa / IIx Soleus 15.8
39 Trappe 2008 0 60 2 0 CON 7 0 Po/CSA MHC IIa / IIx Soleus -11.3
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po/CSA MHC IIa / IIx Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po/CSA MHC IIa / IIx Soleus -9.2
39 Trappe 2008 0 60 2 0 CON 7 0 Vo, shortening velocity MHC IIa / IIx Soleus 14.6
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vo, shortening velocity MHC IIa / IIx Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vo, shortening velocity MHC IIa / IIx Soleus 1.5
39 Trappe 2008 0 60 2 0 CON 7 0 Vmax MHC IIa / IIx Soleus 69.2
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vmax MHC IIa / IIx Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vmax MHC IIa / IIx Soleus -11.8
39 Trappe 2008 0 60 2 0 CON 7 0 Absolute Power MHC IIa / IIx Soleus 13.9
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Absolute Power MHC IIa / IIx Soleus





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Absolute Power MHC IIa / IIx Soleus -19.6
39 Trappe 2008 0 60 2 0 CON 7 0 Normalized Power MHC IIa / IIx Soleus 29.4
39 Trappe 2008 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day









RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Normalized Power MHC IIa / IIx Soleus -36.6
40 Trappe 2007 0 60 2 0 CON 7 0 Diameter MHC l Vastus Lateralis -13.5 1
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Diameter MHC l Vastus Lateralis -18.2 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Diameter MHC l Vastus Lateralis -1.2 1
40 Trappe 2007 0 60 2 0 CON 7 0 Po, Peak force MHC l Vastus Lateralis -35.7 1
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po, Peak force MHC l Vastus Lateralis -39.7 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po, Peak force MHC l Vastus Lateralis -9.8 1
40 Trappe 2007 0 60 2 0 CON 7 0 Po/CSA MHC l Vastus Lateralis -16.2 1
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po/CSA MHC l Vastus Lateralis -6.9





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po/CSA MHC l Vastus Lateralis -8.6 1
40 Trappe 2007 0 60 2 0 CON 7 0 Vo, shortening velocity MHC l Vastus Lateralis -12.2
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vo, shortening velocity MHC l Vastus Lateralis -4.8





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vo, shortening velocity MHC l Vastus Lateralis 1
40 Trappe 2007 0 60 2 0 CON 7 0 Vmax MHC l Vastus Lateralis -9.5
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vmax MHC l Vastus Lateralis 2.4





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vmax MHC l Vastus Lateralis 14.9
40 Trappe 2007 0 60 2 0 CON 7 0 Absolute Power MHC l Vastus Lateralis -41.2 1
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Absolute Power MHC l Vastus Lateralis -43.3 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Absolute Power MHC l Vastus Lateralis -2.1 1




40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Normalized Power MHC l Vastus Lateralis -13.8





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Normalized Power MHC l Vastus Lateralis -3.7
40 Trappe 2007 0 60 2 0 CON 7 0 Diameter MHC I / Ila Vastus Lateralis -5.6
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Diameter MHC I / Ila Vastus Lateralis -12





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Diameter MHC I / Ila Vastus Lateralis -17.5
40 Trappe 2007 0 60 2 0 CON 7 0 Po, Peak force MHC I / Ila Vastus Lateralis -51.7
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po, Peak force MHC I / Ila Vastus Lateralis -25





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po, Peak force MHC I / Ila Vastus Lateralis -35.2
40 Trappe 2007 0 60 2 0 CON 7 0 Po/CSA MHC I / Ila Vastus Lateralis -44.2
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po/CSA MHC I / Ila Vastus Lateralis 1.9





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po/CSA MHC I / Ila Vastus Lateralis -5.1
40 Trappe 2007 0 60 2 0 CON 7 0 Vo, shortening velocity MHC I / Ila Vastus Lateralis -23.8
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vo, shortening velocity MHC I / Ila Vastus Lateralis -18.8





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vo, shortening velocity MHC I / Ila Vastus Lateralis -22.3
40 Trappe 2007 0 60 2 0 CON 7 0 Vmax MHC I / Ila Vastus Lateralis -15.1
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vmax MHC I / Ila Vastus Lateralis -12.4





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vmax MHC I / Ila Vastus Lateralis 1.2
40 Trappe 2007 0 60 2 0 CON 7 0 Absolute Power MHC I / Ila Vastus Lateralis -78.9
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Absolute Power MHC I / Ila Vastus Lateralis -53.8





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)




40 Trappe 2007 0 60 2 0 CON 7 0 Normalized Power MHC I / Ila Vastus Lateralis -74.6
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Normalized Power MHC I / Ila Vastus Lateralis -27.6





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Normalized Power MHC I / Ila Vastus Lateralis -23.5
40 Trappe 2007 0 60 2 0 CON 7 0 Diameter MHC IIa Vastus Lateralis -15.8 1
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Diameter MHC IIa Vastus Lateralis -20.5 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Diameter MHC IIa Vastus Lateralis 1.3 1
40 Trappe 2007 0 60 2 0 CON 7 0 Myofiber Cross Sectional Area Total Vastus Lateralis -31.6
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Myofiber Cross Sectional Area Total Vastus Lateralis





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Myofiber Cross Sectional Area Total Vastus Lateralis -0.9
40 Trappe 2007 0 60 2 0 CON 7 0 Po, Peak force MHC IIa Vastus Lateralis -30.6
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po, Peak force MHC IIa Vastus Lateralis -30





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po, Peak force MHC IIa Vastus Lateralis 4.3
40 Trappe 2007 0 60 2 0 CON 7 0 Po/CSA MHC IIa Vastus Lateralis -6.6
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po/CSA MHC IIa Vastus Lateralis 5.4





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po/CSA MHC IIa Vastus Lateralis -2.5
40 Trappe 2007 0 60 2 0 CON 7 0 Vo, shortening velocity MHC IIa Vastus Lateralis -8.8
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vo, shortening velocity MHC IIa Vastus Lateralis 5





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vo, shortening velocity MHC IIa Vastus Lateralis 1.2
40 Trappe 2007 0 60 2 0 CON 7 0 Vmax MHC IIa Vastus Lateralis 0
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day









RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vmax MHC IIa Vastus Lateralis 9.1
40 Trappe 2007 0 60 2 0 CON 7 0 Absolute Power MHC IIa Vastus Lateralis -27.8
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Absolute Power MHC IIa Vastus Lateralis -24.1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Absolute Power MHC IIa Vastus Lateralis 8.4
40 Trappe 2007 0 60 2 0 CON 7 0 Normalized Power MHC IIa Vastus Lateralis -3.1
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Normalized Power MHC IIa Vastus Lateralis 16.9





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Normalized Power MHC IIa Vastus Lateralis -0.6
40 Trappe 2007 0 60 2 0 CON 7 0 Diameter MHC IIa / IIx Vastus Lateralis -9.1
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Diameter MHC IIa / IIx Vastus Lateralis 6.8





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Diameter MHC IIa / IIx Vastus Lateralis 4.6
40 Trappe 2007 0 60 2 0 CON 7 0 Po, Peak force MHC IIa / IIx Vastus Lateralis -25.5
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po, Peak force MHC IIa / IIx Vastus Lateralis 12.2





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po, Peak force MHC IIa / IIx Vastus Lateralis 1.7
40 Trappe 2007 0 60 2 0 CON 7 0 Po/CSA MHC IIa / IIx Vastus Lateralis -8.9
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Po/CSA MHC IIa / IIx Vastus Lateralis 1.4





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Po/CSA MHC IIa / IIx Vastus Lateralis -1.8
40 Trappe 2007 0 60 2 0 CON 7 0 Vo, shortening velocity MHC IIa / IIx Vastus Lateralis -6.7
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vo, shortening velocity MHC IIa / IIx Vastus Lateralis -13.8





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vo, shortening velocity MHC IIa / IIx Vastus Lateralis -6.7




40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Vmax MHC IIa / IIx Vastus Lateralis -22.9





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Vmax MHC IIa / IIx Vastus Lateralis -7.1
40 Trappe 2007 0 60 2 0 CON 7 0 Absolute Power MHC IIa / IIx Vastus Lateralis -39.9
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Absolute Power MHC IIa / IIx Vastus Lateralis -14.5





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Absolute Power MHC IIa / IIx Vastus Lateralis -14.6
40 Trappe 2007 0 60 2 0 CON 7 0 Normalized Power MHC IIa / IIx Vastus Lateralis -22.9
40 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Normalized Power MHC IIa / IIx Vastus Lateralis -18.5





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Normalized Power MHC IIa / IIx Vastus Lateralis -16.3
41 Trappe 2007 0 60 2 0 CON 7 0 Muscle Volume Knee Extensor Vastus Lateralis -21.2 1
41 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Muscle Volume Knee Extensor Vastus Lateralis -24.1 1 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Muscle Volume Knee Extensor Vastus Lateralis -2.8 1
41 Trappe 2007 0 60 2 0 CON 7 0 Muscle Volume Plantar Flexor Vastus Lateralis -28.8 1
41 Trappe 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Muscle Volume Plantar Flexor Vastus Lateralis -27.3 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 6 0 Muscle Volume Plantar Flexor Vastus Lateralis -7.3 1 1
42 Trappe 2004 0 90 2 0 CON 0 6 Muscle Volume Knee Extensor Vastus Lateralis -17 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Muscle Volume Knee Extensor Vastus Lateralis -0.5
42 Trappe 2004 0 90 2 0 CON 0 6
Maximum Voluntary 
Contraction (MVC)
Knee Extensor Vastus Lateralis -44 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 




Knee Extensor Vastus Lateralis -12.4
42 Trappe 2004 0 90 2 0 CON 0 6 Concentric Peak Force Knee Extensor Vastus Lateralis -40.5 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Concentric Peak Force Knee Extensor Vastus Lateralis 1.1
42 Trappe 2004 0 90 2 0 CON 0 6 Eccentric Peak Force Knee Extensor Vastus Lateralis -36.2 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Eccentric Peak Force Knee Extensor Vastus Lateralis -9.4
42 Trappe 2004 0 90 2 0 CON 0 6 Absolute Power Knee Extensor Vastus Lateralis -48.2 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device




42 Trappe 2004 0 90 2 0 CON 0 6 Diameter MHC l Vastus Lateralis -15.4 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Diameter MHC l Vastus Lateralis 4.6
42 Trappe 2004 0 90 2 0 CON 0 6 Po, Peak force MHC l Vastus Lateralis -47.7 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Po, Peak force MHC l Vastus Lateralis -19
42 Trappe 2004 0 90 2 0 CON 0 6 Po/CSA MHC l Vastus Lateralis -27.7 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Po/CSA MHC l Vastus Lateralis -20.2
42 Trappe 2004 0 90 2 0 CON 0 6 Vo, shortening velocity MHC l Vastus Lateralis -21.2 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Vo, shortening velocity MHC l Vastus Lateralis -0.8
42 Trappe 2004 0 90 2 0 CON 0 6 Vmax MHC l Vastus Lateralis -22.2 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Vmax MHC l Vastus Lateralis 6
42 Trappe 2004 0 90 2 0 CON 0 6 Absolute Power MHC l Vastus Lateralis -55.2 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Absolute Power MHC l Vastus Lateralis -28.9 1
42 Trappe 2004 0 90 2 0 CON 0 6 Normalized Power MHC l Vastus Lateralis -40.7 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Normalized Power MHC l Vastus Lateralis -31.3 1
42 Trappe 2004 0 90 2 0 CON 0 6 Diameter MHC I / Ila Vastus Lateralis -14




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Diameter MHC I / Ila Vastus Lateralis -14.7
42 Trappe 2004 0 90 2 0 CON 0 6 Po, Peak force MHC I / Ila Vastus Lateralis -39.1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Po, Peak force MHC I / Ila Vastus Lateralis -30.8
42 Trappe 2004 0 90 2 0 CON 0 6 Po/CSA MHC I / Ila Vastus Lateralis -17.5




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Po/CSA MHC I / Ila Vastus Lateralis -8.6
42 Trappe 2004 0 90 2 0 CON 0 6 Vo, shortening velocity MHC I / Ila Vastus Lateralis -23.5




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Vo, shortening velocity MHC I / Ila Vastus Lateralis -19.1
42 Trappe 2004 0 90 2 0 CON 0 6 Vmax MHC I / Ila Vastus Lateralis -53.1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Vmax MHC I / Ila Vastus Lateralis -15.1
42 Trappe 2004 0 90 2 0 CON 0 6 Absolute Power MHC I / Ila Vastus Lateralis -59.1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Absolute Power MHC I / Ila Vastus Lateralis -53.4
42 Trappe 2004 0 90 2 0 CON 0 6 Normalized Power MHC I / Ila Vastus Lateralis -37.2




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Normalized Power MHC I / Ila Vastus Lateralis -41.8
42 Trappe 2004 0 90 2 0 CON 0 6 Diameter MHC IIa Vastus Lateralis -8.4




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Diameter MHC IIa Vastus Lateralis 8.2 1
42 Trappe 2004 0 90 2 0 CON 0 6 Myofiber Cross Sectional Area Total Vastus Lateralis -23.2




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Myofiber Cross Sectional Area Total Vastus Lateralis 13.7
42 Trappe 2004 0 90 2 0 CON 0 6 Po, Peak force MHC IIa Vastus Lateralis -25 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Po, Peak force MHC IIa Vastus Lateralis 4.3
42 Trappe 2004 0 90 2 0 CON 0 6 Po/CSA MHC IIa Vastus Lateralis -12.9




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Po/CSA MHC IIa Vastus Lateralis -9.3








4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Vo, shortening velocity MHC IIa Vastus Lateralis 12.8
42 Trappe 2004 0 90 2 0 CON 0 6 Vmax MHC IIa Vastus Lateralis -32.6




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Vmax MHC IIa Vastus Lateralis 7.2
42 Trappe 2004 0 90 2 0 CON 0 6 Absolute Power MHC IIa Vastus Lateralis -24.5




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Absolute Power MHC IIa Vastus Lateralis 1
42 Trappe 2004 0 90 2 0 CON 0 6 Normalized Power MHC IIa Vastus Lateralis -13.5




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Normalized Power MHC IIa Vastus Lateralis -13.6
42 Trappe 2004 0 90 2 0 CON 0 6 Diameter MHC IIa / IIx Vastus Lateralis 0




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Diameter MHC IIa / IIx Vastus Lateralis 22.7
42 Trappe 2004 0 90 2 0 CON 0 6 Po, Peak force MHC IIa / IIx Vastus Lateralis -20.8




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Po, Peak force MHC IIa / IIx Vastus Lateralis -1.2
42 Trappe 2004 0 90 2 0 CON 0 6 Po/CSA MHC IIa / IIx Vastus Lateralis -33.5




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Po/CSA MHC IIa / IIx Vastus Lateralis -36.2
42 Trappe 2004 0 90 2 0 CON 0 6 Vo, shortening velocity MHC IIa / IIx Vastus Lateralis -10




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Vo, shortening velocity MHC IIa / IIx Vastus Lateralis -8.4
42 Trappe 2004 0 90 2 0 CON 0 6 Vmax MHC IIa / IIx Vastus Lateralis -15.6




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Vmax MHC IIa / IIx Vastus Lateralis -8.1
42 Trappe 2004 0 90 2 0 CON 0 6 Absolute Power MHC IIa / IIx Vastus Lateralis -45.1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Absolute Power MHC IIa / IIx Vastus Lateralis 2.9
42 Trappe 2004 0 90 2 0 CON 0 6 Normalized Power MHC IIa / IIx Vastus Lateralis -53




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Normalized Power MHC IIa / IIx Vastus Lateralis -34.9
42 Trappe 2004 0 90 2 0 CON 0 6 Diameter MHC I / Ila / Ilx Vastus Lateralis




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Diameter MHC I / Ila / Ilx Vastus Lateralis
42 Trappe 2004 0 90 2 0 CON 0 6 Po, Peak force MHC I / Ila / Ilx Vastus Lateralis




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Po, Peak force MHC I / Ila / Ilx Vastus Lateralis
42 Trappe 2004 0 90 2 0 CON 0 6 Po/CSA MHC I / Ila / Ilx Vastus Lateralis




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Po/CSA MHC I / Ila / Ilx Vastus Lateralis
42 Trappe 2004 0 90 2 0 CON 0 6 Vo, shortening velocity MHC I / Ila / Ilx Vastus Lateralis




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Vo, shortening velocity MHC I / Ila / Ilx Vastus Lateralis
42 Trappe 2004 0 90 2 0 CON 0 6 Vmax MHC I / Ila / Ilx Vastus Lateralis




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Vmax MHC I / Ila / Ilx Vastus Lateralis
42 Trappe 2004 0 90 2 0 CON 0 6 Absolute Power MHC I / Ila / Ilx Vastus Lateralis




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Absolute Power MHC I / Ila / Ilx Vastus Lateralis
42 Trappe 2004 0 90 2 0 CON 0 6 Normalized Power MHC I / Ila / Ilx Vastus Lateralis




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Normalized Power MHC I / Ila / Ilx Vastus Lateralis
42 Trappe 2004 0 90 2 0 CON 0 6 Diameter
Single muscle fiber V.L. 
composition data
Vastus Lateralis -9.9 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Diameter






42 Trappe 2004 0 90 2 0 CON 0 6 Po, Peak force
Single muscle fiber V.L. 
composition data
Vastus Lateralis -36.6 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Po, Peak force
Single muscle fiber V.L. 
composition data
Vastus Lateralis 4.3
42 Trappe 2004 0 90 2 0 CON 0 6 Po/CSA
Single muscle fiber V.L. 
composition data
Vastus Lateralis -21.1 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Po/CSA
Single muscle fiber V.L. 
composition data
Vastus Lateralis -14.7 1
42 Trappe 2004 0 90 2 0 CON 0 6 Vo, shortening velocity
Single muscle fiber V.L. 
composition data
Vastus Lateralis 11.4




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Vo, shortening velocity
Single muscle fiber V.L. 
composition data
Vastus Lateralis 11.6
42 Trappe 2004 0 90 2 0 CON 0 6 Absolute Power
Single muscle fiber V.L. 
composition data
Vastus Lateralis -22.9 1




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Absolute Power
Single muscle fiber V.L. 
composition data
Vastus Lateralis 0.5
42 Trappe 2004 0 90 2 0 CON 0 6 Normalized Power
Single muscle fiber V.L. 
composition data
Vastus Lateralis -11.4




4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 6 Normalized Power
Single muscle fiber V.L. 
composition data
Vastus Lateralis -13.6
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Rectus Femoris -4.8 1
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Rectus Femoris -2.2
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Vastus Lateralis -5.1 1
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Vastus Lateralis 6.6 1
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Vastus Intermedius -9.8 1
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Vastus Intermedius 11.6 1 1
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Vastus Medialis -8.9
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Vastus Medialis 4.1 1
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Knee Extensor -7.1 1
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Knee Extensor 6 1 1
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area
Biceps Femoris Short 
Head
-2.9
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area
Biceps Femoris Short 
Head
-4.6
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area
Biceps Femoris Long 
Head
-7.5 1
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area
Biceps Femoris Long 
Head
1.4 1
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Semitendinosus -6.6
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Semitendinosus -5.9
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Semimembranosus -12.1 1
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Semimembranosus -5.9 1




44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Sartorius -3.4
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Gracilis -2.9
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Gracilis 3.4
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Hamstrings -8.8 1
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Hamstrings -3 1
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Gastrocnemius -12.5 1
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Gastrocnemius -12.3 1
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Gastrocnemius -12.2
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Gastrocnemius -16.8 1
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Soleus -12.2 1
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Soleus -9.8 1
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Plantar Flexor -12.4 1
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Plantar Flexor -12.2 1
44 Akima 2001 0 20 2 0 CON 0 10 Muscle Cross Section Area Tibialis Anterior -0.8 1
44 Akima 2001 0 20 2 64
Twice / 
day
Morning - 3 sets of 10 reps leg press @ 90% 
maximal load.  1 min between sets.  Afternoon - 
isotonic leg press @ 40% max load until volitional 
exhaustion
BRE 0 5 Muscle Cross Section Area Tibialis Anterior -9.4
45 Bamman 1998 0 14 2 0 CON 0 8 Myofiber Cross Sectional Area MHC l Vastus Lateralis -14.6 1
45 Bamman 1998 0 14 2 64
Every other 
day
Warmup - 10-12 repititions @ ~67% previous 
repitition maximum (RM).  5 sets  of 8 reps @ 80-
85% of 1 RM
BRE 0 8 Myofiber Cross Sectional Area MHC l Vastus Lateralis -2.2
45 Bamman 1998 0 14 2 0 CON 0 8 Myofiber distribution % MHC l Vastus Lateralis 7.6
45 Bamman 1998 0 14 2 64
Every other 
day
Warmup - 10-12 repititions @ ~67% previous 
repitition maximum (RM).  5 sets  of 8 reps @ 80-
85% of 1 RM
BRE 0 8 Myofiber distribution % MHC l Vastus Lateralis 8.9
45 Bamman 1998 0 14 2 0 CON 0 8 MHC distribution % MHC l Vastus Lateralis -2.5
45 Bamman 1998 0 14 2 64
Every other 
day
Warmup - 10-12 repititions @ ~67% previous 
repitition maximum (RM).  5 sets  of 8 reps @ 80-
85% of 1 RM
BRE 0 8 MHC distribution % MHC l Vastus Lateralis 8.6
45 Bamman 1998 0 14 2 0 CON 0 8 Myofiber Cross Sectional Area MHC IIa Vastus Lateralis -17.3 1
45 Bamman 1998 0 14 2 64
Every other 
day
Warmup - 10-12 repititions @ ~67% previous 
repitition maximum (RM).  5 sets  of 8 reps @ 80-
85% of 1 RM
BRE 0 8 Myofiber Cross Sectional Area MHC IIa Vastus Lateralis 8.1
45 Bamman 1998 0 14 2 0 CON 0 8 Myofiber distribution % MHC IIa Vastus Lateralis -6.2
45 Bamman 1998 0 14 2 64
Every other 
day
Warmup - 10-12 repititions @ ~67% previous 
repitition maximum (RM).  5 sets  of 8 reps @ 80-
85% of 1 RM
BRE 0 8 Myofiber distribution % MHC IIa Vastus Lateralis 8.1
45 Bamman 1998 0 14 2 0 CON 0 8 MHC distribution % MHC IIa Vastus Lateralis -12.8
45 Bamman 1998 0 14 2 64
Every other 
day
Warmup - 10-12 repititions @ ~67% previous 
repitition maximum (RM).  5 sets  of 8 reps @ 80-
85% of 1 RM
BRE 0 8 MHC distribution % MHC IIa Vastus Lateralis -4.6
45 Bamman 1998 0 14 2 0 CON 0 8 Myofiber distribution % MHC Ilx Vastus Lateralis 21.4
45 Bamman 1998 0 14 2 64
Every other 
day
Warmup - 10-12 repititions @ ~67% previous 
repitition maximum (RM).  5 sets  of 8 reps @ 80-
85% of 1 RM
BRE 0 8 Myofiber distribution % MHC Ilx Vastus Lateralis -83.6 1
45 Bamman 1998 0 14 2 0 CON 0 8 MHC distribution % MHC Ilx Vastus Lateralis 36.5
45 Bamman 1998 0 14 2 64
Every other 
day
Warmup - 10-12 repititions @ ~67% previous 
repitition maximum (RM).  5 sets  of 8 reps @ 80-
85% of 1 RM
BRE 0 8 MHC distribution % MHC Ilx Vastus Lateralis -5.7




45 Bamman 1998 0 14 2 64
Every other 
day
Warmup - 10-12 repititions @ ~67% previous 
repitition maximum (RM).  5 sets  of 8 reps @ 80-
85% of 1 RM
BRE 0 8 Myofiber Cross Sectional Area Total 4.7
46 Koryak 1997 0 120 2 0 CON 4 0 Pt, Isometric max twitch force Plantar Flexor -18.7 1
46 Koryak 1997 0 120 2 32832
4 day 
cycle
First day - force-velocity regime (70% force-velocity 
exercise, 15% velocity and force requiring exercise). 
Second day - velocity regime (70% velocity requiring 
exercise, 15% force and force-velocity exercise). 
Third day - force regime (70% force exercise, 15% 
velocit and force-velocity requiring exercise).  Fourth 
day rest.  Repeat
BRE 4 0 Pt, Isometric max twitch force Plantar Flexor -13.5 1
46 Koryak 1997 0 120 2 0 CON 4 0
Maximum Voluntary 
Contraction (MVC)
Plantar Flexor -36.1 1
46 Koryak 1997 0 120 2 32832
4 day 
cycle
First day - force-velocity regime (70% force-velocity 
exercise, 15% velocity and force requiring exercise). 
Second day - velocity regime (70% velocity requiring 
exercise, 15% force and force-velocity exercise). 
Third day - force regime (70% force exercise, 15% 
velocit and force-velocity requiring exercise).  Fourth 





46 Koryak 1997 0 120 2 0 CON 4 0 Po, Peak force Plantar Flexor -24.3 1
46 Koryak 1997 0 120 2 32832
4 day 
cycle
First day - force-velocity regime (70% force-velocity 
exercise, 15% velocity and force requiring exercise). 
Second day - velocity regime (70% velocity requiring 
exercise, 15% force and force-velocity exercise). 
Third day - force regime (70% force exercise, 15% 
velocit and force-velocity requiring exercise).  Fourth 
day rest.  Repeat
BRE 4 0 Po, Peak force Plantar Flexor -9.4
46 Koryak 1997 0 120 2 0 CON 4 0
Force deficiency (difference b/t 
Po and MVC)
Plantar Flexor 29.7 1
46 Koryak 1997 0 120 2 32832
4 day 
cycle
First day - force-velocity regime (70% force-velocity 
exercise, 15% velocity and force requiring exercise). 
Second day - velocity regime (70% velocity requiring 
exercise, 15% force and force-velocity exercise). 
Third day - force regime (70% force exercise, 15% 
velocit and force-velocity requiring exercise).  Fourth 
day rest.  Repeat
BRE 4 0
Force deficiency (difference b/t 
Po and MVC)
Plantar Flexor -9.9 1
46 Koryak 1997 0 120 2 0 CON 4 0 Time to peak tension Plantar Flexor 13.5
46 Koryak 1997 0 120 2 32832
4 day 
cycle
First day - force-velocity regime (70% force-velocity 
exercise, 15% velocity and force requiring exercise). 
Second day - velocity regime (70% velocity requiring 
exercise, 15% force and force-velocity exercise). 
Third day - force regime (70% force exercise, 15% 
velocit and force-velocity requiring exercise).  Fourth 
day rest.  Repeat
BRE 4 0 Time to peak tension Plantar Flexor -3.4
46 Koryak 1997 0 120 2 0 CON 4 0 Half relaxation time Plantar Flexor -17 1
46 Koryak 1997 0 120 2 32832
4 day 
cycle
First day - force-velocity regime (70% force-velocity 
exercise, 15% velocity and force requiring exercise). 
Second day - velocity regime (70% velocity requiring 
exercise, 15% force and force-velocity exercise). 
Third day - force regime (70% force exercise, 15% 
velocit and force-velocity requiring exercise).  Fourth 
day rest.  Repeat
BRE 4 0 Half relaxation time Plantar Flexor -7.3 1
46 Koryak 1997 0 120 2 0 CON 4 0 Total contraction time Plantar Flexor -16.3 1
46 Koryak 1997 0 120 2 32832
4 day 
cycle
First day - force-velocity regime (70% force-velocity 
exercise, 15% velocity and force requiring exercise). 
Second day - velocity regime (70% velocity requiring 
exercise, 15% force and force-velocity exercise). 
Third day - force regime (70% force exercise, 15% 
velocit and force-velocity requiring exercise).  Fourth 
day rest.  Repeat
BRE 4 0 Total contraction time Plantar Flexor -19.2 1
47 Akima 2003 0 20 2 0 CON 0 6 Muscle Cross Section Area Plantar Flexor -11.6 1
47 Akima 2003 0 20 2 64
Twice / 
day
Morning - 5 sets of 10 reps leg press @ 70% 
maximal isometric force.  1 min between sets.  
Afternoon - plantar flexion training - 5 sets of 10 reps 
@ 70% max isometric force. 1 min between sets.
BRE 0 6 Muscle Cross Section Area Plantar Flexor -2.4




47 Akima 2003 0 20 2 64
Twice / 
day
Morning - 5 sets of 10 reps leg press @ 70% 
maximal isometric force.  1 min between sets.  
Afternoon - plantar flexion training - 5 sets of 10 reps 









47 Akima 2003 0 20 2 64
Twice / 
day
Morning - 5 sets of 10 reps leg press @ 70% 
maximal isometric force.  1 min between sets.  
Afternoon - plantar flexion training - 5 sets of 10 reps 
@ 70% max isometric force. 1 min between sets.
BRE 0 6 Delta in Exercise induced T2 Gastrocnemius 7.2
47 Akima 2003 0 20 2 0 CON 0 6 Delta in Exercise induced T2 Gastrocnemius 78.7 1
47 Akima 2003 0 20 2 64
Twice / 
day
Morning - 5 sets of 10 reps leg press @ 70% 
maximal isometric force.  1 min between sets.  
Afternoon - plantar flexion training - 5 sets of 10 reps 
@ 70% max isometric force. 1 min between sets.
BRE 0 6 Delta in Exercise induced T2 Gastrocnemius -3.8
47 Akima 2003 0 20 2 0 CON 0 6 Delta in Exercise induced T2 Soleus 50 1
47 Akima 2003 0 20 2 64
Twice / 
day
Morning - 5 sets of 10 reps leg press @ 70% 
maximal isometric force.  1 min between sets.  
Afternoon - plantar flexion training - 5 sets of 10 reps 
@ 70% max isometric force. 1 min between sets.
BRE 0 6 Delta in Exercise induced T2 Soleus -7.6
47 Akima 2003 0 20 2 0 CON 0 6 Delta in Exercise induced T2 Tibialis Anterior 200
47 Akima 2003 0 20 2 64
Twice / 
day
Morning - 5 sets of 10 reps leg press @ 70% 
maximal isometric force.  1 min between sets.  
Afternoon - plantar flexion training - 5 sets of 10 reps 
@ 70% max isometric force. 1 min between sets.
BRE 0 6 Delta in Exercise induced T2 Tibialis Anterior -66.6
47 Akima 2003 0 20 2 0 CON 0 6 Delta in Exercise induced T2 Libia Marrow 25
47 Akima 2003 0 20 2 64
Twice / 
day
Morning - 5 sets of 10 reps leg press @ 70% 
maximal isometric force.  1 min between sets.  
Afternoon - plantar flexion training - 5 sets of 10 reps 
@ 70% max isometric force. 1 min between sets.
BRE 0 6 Delta in Exercise induced T2 Libia Marrow 74.9
49 Guinet 2009 0 60 2 0 CON 8 0 Tolerance Time 80 Head-Up Tilt -50 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Tolerance Time 80 Head-Up Tilt -35 1
49 Guinet 2009 0 60 2 0 CON 8 0 Heart Rate (beats/min) Resting 19.7 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)








0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day









RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 VO2 (L/min) Max -8.3 1
51 Smith 2008 0 60 2 0 CON 8 0
Parathyroid Hormone (intact 
molecule)
Serum 18.4





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0
Parathyroid Hormone (intact 
molecule)
Serum 23.1
51 Smith 2008 0 60 2 0 CON 8 0 1,25(OH)-vitamin D Serum -19.4





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 1,25(OH)-vitamin D Serum -15
51 Smith 2008 0 60 2 0 CON 8 0 25(OH)-vitamin D Serum -11.4 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 25(OH)-vitamin D Serum -29.5 1









RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Calcium Serum 0 1
51 Smith 2008 0 60 2 0 CON 8 0 Calcium Urinary 35.9





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Calcium Urinary 0
51 Smith 2008 0 60 2 0 CON 8 0 Total Alkaline Phosphatase Serum 8.5





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Total Alkaline Phosphatase Serum 24 1
51 Smith 2008 0 60 2 0 CON 8 0
Bone specific alkaline 
phosphate
Serum 0





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0
Bone specific alkaline 
phosphate
Serum 27.3
51 Smith 2008 0 60 2 0 CON 8 0 Osteocalcin Serum 8.3





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Osteocalcin Serum 0
51 Smith 2008 0 60 2 0 CON 8 0
Procollagen type 1 N 
propeptide
Serum -5.5





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0
Procollagen type 1 N 
propeptide
Serum 32.5 1
51 Smith 2008 0 60 2 0 CON 8 0 n-telopeptide Urinary 45.3 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 n-telopeptide Urinary 29.7 1
51 Smith 2008 0 60 2 0 CON 8 0 c-telopeptide Urinary 75.6 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 c-telopeptide Urinary 40.6 1
51 Smith 2008 0 60 2 0 CON 8 0 Helical Peptide Urinary 72.8 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Helical Peptide Urinary 51.3 1
51 Smith 2008 0 60 2 0 CON 8 0 Deoxypyridinoline Urinary 20.4 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Deoxypyridinoline Urinary 26 1












RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-





51 Smith 2008 0 60 2 0 CON 8 0 Bone Mineral Density Trochanter -3.6 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Bone Mineral Density Trochanter -1.6 1
51 Smith 2008 0 60 2 0 CON 8 0 Bone Mineral Density Total Hip -4 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Bone Mineral Density Total Hip -2 1
51 Smith 2008 0 60 2 0 CON 8 0 Bone Mineral Density Legs -1.3 1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Bone Mineral Density Legs -0.3 1 1
51 Smith 2008 0 60 2 0 CON 8 0 Bone Mineral Density Femoral Neck -1.1





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Bone Mineral Density Femoral Neck 0.1
51 Smith 2008 0 60 2 0 CON 8 0 Bone Mineral Density Spine 0.3





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Bone Mineral Density Spine 1.1
53 Edgell 2007 0 60 2 0 CON 8 0 Mean Arterial Pressure Resting -1.7
53 Edgell 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Mean Arterial Pressure Resting -5.8





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Mean Arterial Pressure Resting 0.7
53 Edgell 2007 0 60 2 0 CON 8 0 Stroke Volume (mL) Resting -16.7
53 Edgell 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Stroke Volume (mL) Resting -12.7





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Stroke Volume (mL) Resting -0.2
53 Edgell 2007 0 60 2 0 CON 8 0 Cardiac Output Resting -6.7
53 Edgell 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Cardiac Output Resting -1.7





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Cardiac Output Resting -2.4




53 Edgell 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Total Peripheral Resistance Resting -8.7





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Total Peripheral Resistance Resting 7
53 Edgell 2007 0 60 2 0 CON 8 0 Leg Vascular Resistance Resting -48.8
53 Edgell 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Leg Vascular Resistance Resting -29





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Leg Vascular Resistance Resting 23
53 Edgell 2007 0 60 2 0 CON 8 0 Cerebral Vascular Resistance Resting 3.5
53 Edgell 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Cerebral Vascular Resistance Resting 12.2





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Cerebral Vascular Resistance Resting -3.8
53 Edgell 2007 0 60 2 0 CON 8 0 Epinephrine Resting 74.7
53 Edgell 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Epinephrine Resting 13.8





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Epinephrine Resting -30.7
53 Edgell 2007 0 60 2 0 CON 8 0 Norepinephrine Resting 18
53 Edgell 2007 0 60 2 2048
1.45g/kg BW/day protein, 3.6g/day free leucine, 
1.8g/day free valine, 1.8g/day free isoleucine (total 
protein intake was ~1.6g/kg BW/day whereas other 
two groups were 1.0g/kg BW/day
BRN 8 0 Norepinephrine Resting 0.7





RE: 4 sets of 7 supine squat reps and 4 sets of 14 
calf press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device. LBNP: 
40 min on vertical treadmill (40-80% Pre-BR 
VO2max) (~180 steps/min) 10 min LBNP at 52+-
3mmHg (~1 body wt.)
BRE 8 0 Norepinephrine Resting -16.6
54 Greenleaf 1989b 0 30 2 0 CON 0 5 VO2 (L/min) Max -20.5 1
54 Greenleaf 1989b 0 30 2 2 30
Twice daily 
/ 5 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
ITE 0 7 VO2 (L/min) Max 0.3
54 Greenleaf 1989b 0 30 2 1024 30
Twice daily 
/ 5 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg
IKE 0 7 VO2 (L/min) Max -10.5 1
54 Greenleaf 1989b 0 30 2 0 CON 0 5 Heart Rate (beats/min) Max -1.6
54 Greenleaf 1989b 0 30 2 2 30
Twice daily 
/ 5 days 
per week
7 min @ 40% VO2max, then 2 min @ 
60,70,80,90,80% VO2max each separated by 2 min 
@ 40% (supine ergometer)
ITE 0 7 Heart Rate (beats/min) Max 8.8 1
54 Greenleaf 1989b 0 30 2 1024 30
Twice daily 
/ 5 days 
per week
5 min warm-up, 5 peak knee flexions and extensions 
(90° arc) in 10s and rested remaining 50s. Repeat 10 
times, 4min cooling down, repeat with other leg












4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device















4 sets of 7 supine squat reps and 4 sets of 14 calf 
press reps.  2 min in between sets and 5 min 
between exercises.  Used a flywheel device
BRE 0 9 Muscle Volume Calf -14.7 1
56 Hughson 1994 0 28 2 0 CON 0 6 R-R Interval Resting -14.1




from day 7 
LBNP: 15 
min on day 
16, 18, 20, 
22-28
RE: cycling 15 min @ 25W, max isometric 
contraction for 5s, submax isom contraction for 30s, 
three reps max isokinetic contraction @ 30/s, seven 
reps max isok @ 180/s.  Sets varyied each day: one 
set day, four set day, three set day.  LBNP: -
40mmHg
BRE 0 6 R-R Interval Resting -15.5
56 Hughson 1994 0 28 2 0 CON 0 6
Systolic Blood Pressure 
(mmHg)
Resting -3.6 1




from day 7 
LBNP: 15 
min on day 
16, 18, 20, 
22-28
RE: cycling 15 min @ 25W, max isometric 
contraction for 5s, submax isom contraction for 30s, 
three reps max isokinetic contraction @ 30/s, seven 
reps max isok @ 180/s.  Sets varyied each day: one 
set day, four set day, three set day.  LBNP: -
40mmHg
BRE 0 6
Systolic Blood Pressure 
(mmHg)
Resting 5.8 1
56 Hughson 1994 0 28 2 0 CON 0 6 Plasme Volume (mL) Resting -2.2




from day 7 
LBNP: 15 
min on day 
16, 18, 20, 
22-28
RE: cycling 15 min @ 25W, max isometric 
contraction for 5s, submax isom contraction for 30s, 
three reps max isokinetic contraction @ 30/s, seven 
reps max isok @ 180/s.  Sets varyied each day: one 
set day, four set day, three set day.  LBNP: -
40mmHg
BRE 0 6 Plasme Volume (mL) Resting -11.2 1
56 Hughson 1994 0 28 2 0 CON 0 6 Norepinephrine Resting 30.9




from day 7 
LBNP: 15 
min on day 
16, 18, 20, 
22-28
RE: cycling 15 min @ 25W, max isometric 
contraction for 5s, submax isom contraction for 30s, 
three reps max isokinetic contraction @ 30/s, seven 
reps max isok @ 180/s.  Sets varyied each day: one 
set day, four set day, three set day.  LBNP: -
40mmHg
BRE 0 6 Norepinephrine Resting 18
56 Hughson 1994 0 28 2 0 CON 0 6 Epinephrine Resting 17.1




from day 7 
LBNP: 15 
min on day 
16, 18, 20, 
22-28
RE: cycling 15 min @ 25W, max isometric 
contraction for 5s, submax isom contraction for 30s, 
three reps max isokinetic contraction @ 30/s, seven 
reps max isok @ 180/s.  Sets varyied each day: one 
set day, four set day, three set day.  LBNP: -
40mmHg
BRE 0 6 Epinephrine Resting 1.3
57 Guell 1995 Series 1 0 28 2 0 CON 0 5 Heart Rate (beats/min) Resting 16.9









-28mmHg LBNP 0 5 Heart Rate (beats/min) Resting 11.9
57 Guell 1995 Series 1 0 28 2 0 CON 0 5 Mean Arterial Pressure Resting 5.8









-28mmHg LBNP 0 5 Mean Arterial Pressure Resting 5.1
58 Guell 1995 Series 2 0 28 2 0 Con 0 6 Heart Rate (beats/min) Resting 17.3
58 Guell 1995 Series 2 0 28 2 320 30
No CM first week, Exercise last 3 weeks, LBNP 
(15min@-28mmHg) every other day third week and 
every day last week




58 Guell 1995 Series 2 0 28 2 0 Con 0 6 Mean Arterial Pressure Resting -0.6
58 Guell 1995 Series 2 0 28 2 320 30
No CM first week, Exercise last 3 weeks, LBNP 
(15min@-28mmHg) every other day third week and 
every day last week
BRE 0 6 Mean Arterial Pressure Resting 4.1
59 Sun 2002 0 21 2 0 CON 0 6
Systolic Blood Pressure 
(mmHg)
Resting -5.3
59 Sun 2002 0 21 2 256 60
Daily from 
Day 15-21
-30mmHg in a Chinese LBNP suit LBNP 0 6
Systolic Blood Pressure 
(mmHg)
Resting 0.7
59 Sun 2002 0 21 2 0 CON 0 6
Diastolic Blood Pressure 
(mmHg)
Resting -14
59 Sun 2002 0 21 2 256 60
Daily from 
Day 15-21
-30mmHg in a Chinese LBNP suit LBNP 0 6
Diastolic Blood Pressure 
(mmHg)
Resting -9.9 1
59 Sun 2002 0 21 2 0 CON 0 6 Mean Arterial Pressure Resting -11.1
59 Sun 2002 0 21 2 256 60
Daily from 
Day 15-21
-30mmHg in a Chinese LBNP suit LBNP 0 6 Mean Arterial Pressure Resting -5.3
59 Sun 2002 0 21 2 0 CON 0 6 Heart Rate (beats/min) Resting 1.9
59 Sun 2002 0 21 2 256 60
Daily from 
Day 15-21
-30mmHg in a Chinese LBNP suit LBNP 0 6 Heart Rate (beats/min) Resting -7.2
59 Sun 2002 0 21 2 0 CON 0 6 Cardiac Output Resting -9.9
59 Sun 2002 0 21 2 256 60
Daily from 
Day 15-21
-30mmHg in a Chinese LBNP suit LBNP 0 6 Cardiac Output Resting -27 1
59 Sun 2002 0 21 2 0 CON 0 6 Total Peripheral Resistance Resting 8.5
59 Sun 2002 0 21 2 256 60
Daily from 
Day 15-21
-30mmHg in a Chinese LBNP suit LBNP 0 6 Total Peripheral Resistance Resting 34.5 1
59 Sun 2002 0 21 2 0 CON 0 6 Stroke Volume (mL) Resting -7.2
59 Sun 2002 0 21 2 256 60
Daily from 
Day 15-21
-30mmHg in a Chinese LBNP suit LBNP 0 6 Stroke Volume (mL) Resting -13.4
60 Schneider 2002 0 15 2 0 CON 0 7 Hematocrit Resting 6.5 1
60 Schneider 2002 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
@ 80%, 2 @ 50%, 3 @70%, 2 @ 40%, 3 @60%, 5 
@ 40%
BRE 0 7 Hematocrit Resting 0.5
60 Schneider 2002 0 15 2 0 CON 0 7 Tolerance Time Resting -38.3 1
60 Schneider 2002 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
@ 80%, 2 @ 50%, 3 @70%, 2 @ 40%, 3 @60%, 5 
@ 40%
BRE 0 7 Tolerance Time Resting -42.9 1
60 Schneider 2002 0 15 2 0 CON 0 7 Heart Rate (beats/min) Resting 18.7 1
60 Schneider 2002 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
@ 80%, 2 @ 50%, 3 @70%, 2 @ 40%, 3 @60%, 5 
@ 40%
BRE 0 7 Heart Rate (beats/min) Resting 11.9
60 Schneider 2002 0 15 2 0 CON 0 7
Systolic Blood Pressure 
(mmHg)
Resting
60 Schneider 2002 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
@ 80%, 2 @ 50%, 3 @70%, 2 @ 40%, 3 @60%, 5 
@ 40%
BRE 0 7
Systolic Blood Pressure 
(mmHg)
Resting
60 Schneider 2002 0 15 2 0 CON 0 7
Diastolic Blood Pressure 
(mmHg)
Resting
60 Schneider 2002 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
@ 80%, 2 @ 50%, 3 @70%, 2 @ 40%, 3 @60%, 5 
@ 40%
BRE 0 7
Diastolic Blood Pressure 
(mmHg)
Resting
60 Schneider 2002 0 15 2 0 CON 0 7 Mean Arterial Pressure Resting
60 Schneider 2002 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
@ 80%, 2 @ 50%, 3 @70%, 2 @ 40%, 3 @60%, 5 
@ 40%
BRE 0 7 Mean Arterial Pressure Resting
60 Schneider 2002 0 15 2 0 CON 0 7 Pulse Pressure Resting
60 Schneider 2002 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
@ 80%, 2 @ 50%, 3 @70%, 2 @ 40%, 3 @60%, 5 
@ 40%
BRE 0 7 Pulse Pressure Resting




60 Schneider 2002 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
@ 80%, 2 @ 50%, 3 @70%, 2 @ 40%, 3 @60%, 5 
@ 40%
BRE 0 7 Norepinephrine Resting
60 Schneider 2002 0 15 2 0 CON 0 7 Epinephrine Resting
60 Schneider 2002 0 15 2 260 40 Daily
LBNP at ~1 body weight.  40 min exercisewith 
LBNP.  7min @ 40% Pre-BR VO2max, 3 @ 60%, 2 
@ 40%, 3 @ 70%, 2 @ 50%, 3 @ 80%, 2 @60%, 3 
@ 80%, 2 @ 50%, 3 @70%, 2 @ 40%, 3 @60%, 5 
@ 40%
BRE 0 7 Epinephrine Resting
61 Wu (Unpublished) 0 30 2 0 CON 0 5 Tolerance Time 75 Head-Up Tilt -57.6 1
61 Wu (Unpublished) 0 30 2 2 20
5 days / 1 
rest
first two cycles - 5 sets of 5 reps for squat and 10 
reps for calf press 60-70% max   ||||   remaining 3 
cycles - 5 sets of 10 reps for squats and 15 reps for 
calf press 60-80% max
BRE 0 5 Tolerance Time 75 Head-Up Tilt -34.7
61 Wu (Unpublished) 0 30 2 192 30
5 days / 1 
rest
7min @50% VO2max, 2@60, 2%50, 2@70, 2@50, 
2@80, 2@50, 2@90, 2@50, 2@80, 3@50, 2@30
CYC 0 5 Tolerance Time 75 Head-Up Tilt -36.4
61 Wu (Unpublished) 0 30 2 0 CON 0 5 Exercise Time Max -17.7 1
61 Wu (Unpublished) 0 30 2 2 20
5 days / 1 
rest
first two cycles - 5 sets of 5 reps for squat and 10 
reps for calf press 60-70% max   ||||   remaining 3 
cycles - 5 sets of 10 reps for squats and 15 reps for 
calf press 60-80% max
BRE 0 5 Exercise Time Max -21.1 1
61 Wu (Unpublished) 0 30 2 192 30
5 days / 1 
rest
7min @50% VO2max, 2@60, 2%50, 2@70, 2@50, 
2@80, 2@50, 2@90, 2@50, 2@80, 3@50, 2@30
CYC 0 5 Exercise Time Max 1.2
61 Wu (Unpublished) 0 30 2 0 CON 0 5 Muscle Strength 90 degrees knee -6.81
61 Wu (Unpublished) 0 30 2 2 20
5 days / 1 
rest
first two cycles - 5 sets of 5 reps for squat and 10 
reps for calf press 60-70% max   ||||   remaining 3 
cycles - 5 sets of 10 reps for squats and 15 reps for 
calf press 60-80% max
BRE 0 5 Muscle Strength 90 degrees knee 10.7 1
61 Wu (Unpublished) 0 30 2 192 30
5 days / 1 
rest
7min @50% VO2max, 2@60, 2%50, 2@70, 2@50, 
2@80, 2@50, 2@90, 2@50, 2@80, 3@50, 2@30
CYC 0 5 Muscle Strength 90 degrees knee 3.88 1
62 Shibata 2010 0 18 2 32 Dextran 40  infusion on day 14 CON 1 6 Tolerance Time graded LBNP -25 1
62 Shibata 2010 0 18 2 2 30
3 / day / 
daily
75% max HR CYC 1 6 Tolerance Time graded LBNP -43 1
62 Shibata 2010 0 18 2 34 30
3 / day / 
daily
75% max HR, Dextran 40 infusion on day 14
CYC+D
EX
1 6 Tolerance Time graded LBNP -1.5
62 Shibata 2010 0 18 2 32 Dextran 40  infusion on day 14 CON 1 6 VO2 (L/min) Max -19 1
62 Shibata 2010 0 18 2 2 30
3 / day / 
daily
75% max HR CYC 1 6 VO2 (L/min) Max -6.8
62 Shibata 2010 0 18 2 34 30
3 / day / 
daily
75% max HR, Dextran 40 infusion on day 14
CYC+D
EX
1 6 VO2 (L/min) Max -1.4
62 Shibata 2010 0 18 2 32 Dextran 40  infusion on day 14 CON 1 6 Plasme Volume (mL) Resting -8.8 1
62 Shibata 2010 0 18 2 2 30
3 / day / 
daily
75% max HR CYC 1 6 Plasme Volume (mL) Resting -4.5 1
62 Shibata 2010 0 18 2 32 Dextran 40  infusion on day 14 CON 1 6 Stroke Volume (mL) Resting -15.8 1
62 Shibata 2010 0 18 2 32 Dextran 40  infusion on day 14 CON 1 6 Stroke Volume (mL) Resting 5.4
62 Shibata 2010 0 18 2 2 30
3 / day / 
daily
75% max HR CYC 1 6 Stroke Volume (mL) Resting -4.1 1
62 Shibata 2010 0 18 2 34 30
3 / day / 
daily
75% max HR, Dextran 40 infusion on day 14
CYC+D
EX
1 6 Stroke Volume (mL) Resting 6.1
62 Shibata 2010 0 18 2 32 Dextran 40  infusion on day 14 CON 1 6 Cardiac Output Resting -11.5 1
62 Shibata 2010 0 18 2 32 Dextran 40  infusion on day 14 CON 1 6 Cardiac Output Resting 11.8 1
62 Shibata 2010 0 18 2 2 30
3 / day / 
daily
75% max HR CYC 1 6 Cardiac Output Resting -5.6
62 Shibata 2010 0 18 2 34 30
3 / day / 
daily
75% max HR, Dextran 40 infusion on day 14
CYC+D
EX
1 6 Cardiac Output Resting 8.6
62 Shibata 2010 0 18 2 32 Dextran 40  infusion on day 14 CON 1 6 Mean Arterial Pressure Resting 0.4
62 Shibata 2010 0 18 2 32 Dextran 40  infusion on day 14 CON 1 6 Mean Arterial Pressure Resting 3.3
62 Shibata 2010 0 18 2 2 30
3 / day / 
daily
75% max HR CYC 1 6 Mean Arterial Pressure Resting 3.4
62 Shibata 2010 0 18 2 34 30
3 / day / 
daily
75% max HR, Dextran 40 infusion on day 14
CYC+D
EX
1 6 Mean Arterial Pressure Resting -0.7
62 Shibata 2010 0 18 2 32 Dextran 40  infusion on day 14 CON 1 6 Total Peripheral Resistance Resting 15.7 1
62 Shibata 2010 0 18 2 32 Dextran 40  infusion on day 14 CON 1 6 Total Peripheral Resistance Resting -6.8 1
62 Shibata 2010 0 18 2 2 30
3 / day / 
daily
75% max HR CYC 1 6 Total Peripheral Resistance Resting 11.5 1
62 Shibata 2010 0 18 2 34 30
3 / day / 
daily
75% max HR, Dextran 40 infusion on day 14
CYC+D
EX















2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 8 120 Daily
SUS+S
TD2




2 28 8 8 240 Daily
SUS+S
TD4
















2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 8 120 Daily
SUS+S
TD2






2 28 8 8 240 Daily
SUS+S
TD4














2 28 8 8 60 Daily
SUS+S
TD1




2 28 8 8 120 Daily
SUS+S
TD2




2 28 8 8 240 Daily
SUS+S
TD4














2 28 8 8 60 Daily
SUS+S
TD1








2 28 8 8 120 Daily
SUS+S
TD2








2 28 8 8 240 Daily
SUS+S
TD4
















2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 8 120 Daily
SUS+S
TD2






2 28 8 8 240 Daily
SUS+S
TD4














2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 8 120 Daily
SUS+S
TD2






2 28 8 8 240 Daily
SUS+S
TD4





















2 28 8 8 60 Daily
SUS+S
TD1









2 28 8 8 120 Daily
SUS+S
TD2









2 28 8 8 240 Daily
SUS+S
TD4






















2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 8 120 Daily
SUS+S
TD2




2 28 8 8 240 Daily
SUS+S
TD4














2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 8 120 Daily
SUS+S
TD2








2 28 8 8 240 Daily
SUS+S
TD4
















2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 8 120 Daily
SUS+S
TD2






2 28 8 8 240 Daily
SUS+S
TD4
















2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 8 120 Daily
SUS+S
TD2






2 28 8 8 240 Daily
SUS+S
TD4


















2 28 8 8 60 Daily
SUS+S
TD1








2 28 8 8 120 Daily
SUS+S
TD2








2 28 8 8 240 Daily
SUS+S
TD4


















2 28 8 8 60 Daily
SUS+S
TD1




2 28 8 8 120 Daily
SUS+S
TD2






2 28 8 8 240 Daily
SUS+S
TD4

















2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5






2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6
















2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5






2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6














2 28 8 8 60 Daily
SUS+S
TD1




2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5




2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6














2 28 8 8 60 Daily
SUS+S
TD1








2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5








2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6
















2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5






2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6


















2 28 8 8 60 Daily
SUS+S
TD1








2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5






2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6























2 28 8 8 60 Daily
SUS+S
TD1














2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5









2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6





















2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5






2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6
















2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5








2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6
















2 28 8 8 60 Daily
SUS+S
TD1






2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5








2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6
















2 28 8 8 60 Daily
SUS+S
TD1








2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5








2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6


















2 28 8 8 60 Daily
SUS+S
TD1








2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5








2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6





















2 28 8 8 60 Daily
SUS+S
TD1








2 28 8 1 1.5 1.5 60 Daily
SUS+C
EN1.5






2 28 8 1 2.6 2.6 60 Daily
SUS+C
EN2.6














2 28 8 8 1 Daily
SUS+S
TD1




2 28 8 8 2 Daily
SUS+S
TD2




2 28 8 8 4 Daily
SUS+S
TD4
0 10 Muscle Cross Section Area Papillary -3.7
84 Zhang 2008 2 28 0 0 CON 0 8 Wet Weight Whole Body
84 Zhang 2008 2 28 8 0 SUS 0 8 Wet Weight Whole Body -76.5
84 Zhang 2008 2 28 8 8 60 Daily
SUS+S
TD1
0 8 Wet Weight Whole Body -68.5
84 Zhang 2008 2 28 0 0 CON 0 8 Wet Weight Soleus 
84 Zhang 2008 2 28 8 0 SUS 0 8 Wet Weight Soleus -46
p<0.01 
vs. CON
84 Zhang 2008 2 28 8 8 60 Daily
SUS+S
TD1





84 Zhang 2008 2 28 0 0 CON 0 8 Length Tibia
84 Zhang 2008 2 28 8 0 SUS 0 8 Length Tibia -1.9
84 Zhang 2008 2 28 8 8 60 Daily
SUS+S
TD1
0 8 Length Tibia -3.2
84 Zhang 2008 2 28 0 0 CON 0 8
Systolic Blood Pressure 
(mmHg)
Resting
84 Zhang 2008 2 28 8 0 SUS 0 8














84 Zhang 2008 2 28 0 0 CON 0 8
Diastolic Blood Pressure 
(mmHg)
Resting
84 Zhang 2008 2 28 8 0 SUS 0 8









Diastolic Blood Pressure 
(mmHg)
Resting 8
84 Zhang 2008 2 28 0 0 CON 0 8 Heart Rate (beats/min) Resting
84 Zhang 2008 2 28 8 0 SUS 0 8 Heart Rate (beats/min) Resting 5
p<0.05 
vs. CON
84 Zhang 2008 2 28 8 8 60 Daily
SUS+S
TD1
0 8 Heart Rate (beats/min) Resting 4.1
p<0.05 
vs. CON
84 Zhang 2008 2 28 0 0 CON 0 8 Total Power Heart Rate Resting
84 Zhang 2008 2 28 8 0 SUS 0 8 Total Power Heart Rate Resting 195.7
p<0.01 
vs. CON
84 Zhang 2008 2 28 8 8 60 Daily
SUS+S
TD1
0 8 Total Power Heart Rate Resting 197.4
p<0.01 
vs. CON
84 Zhang 2008 2 28 0 0 CON 0 8
Low Frequency (LF) Heart 
Rate
Resting
84 Zhang 2008 2 28 8 0 SUS 0 8














84 Zhang 2008 2 28 0 0 CON 0 8
High Frequency (HF) Heart 
Rate
Resting
84 Zhang 2008 2 28 8 0 SUS 0 8
High Frequency (HF) Heart 
Rate
Resting 126.2




High Frequency (HF) Heart 
Rate
Resting 63.9
84 Zhang 2008 2 28 0 0 CON 0 8
HF sympathetic activity (SNS) 
(LF/HF)
Resting
84 Zhang 2008 2 28 8 0 SUS 0 8










HF sympathetic activity (SNS) 
(LF/HF)
Resting 0
84 Zhang 2008 2 28 0 0 CON 0 8 SBP Total Power Resting
84 Zhang 2008 2 28 8 0 SUS 0 8 SBP Total Power Resting 12.7
84 Zhang 2008 2 28 8 8 60 Daily
SUS+S
TD1
0 8 SBP Total Power Resting 12
84 Zhang 2008 2 28 0 0 CON 0 8 Low Frequency (LF) BP Resting
84 Zhang 2008 2 28 8 0 SUS 0 8 Low Frequency (LF) BP Resting 35.8
84 Zhang 2008 2 28 8 8 60 Daily
SUS+S
TD1
0 8 Low Frequency (LF) BP Resting 35.8
84 Zhang 2008 2 28 0 0 CON 0 8 High Frequency (HF) BP Resting
84 Zhang 2008 2 28 8 0 SUS 0 8 High Frequency (HF) BP Resting -64.5
84 Zhang 2008 2 28 8 8 60 Daily
SUS+S
TD1
0 8 High Frequency (HF) BP Resting -70.9
85 Sun 2003 2 28 0 0 CON 0 7 Wet Weight Soleus 
85 Sun 2003 2 28 8 0 SUS 0 7 Wet Weight Soleus -49.3
p<0.05 
vs. CON












85 Sun 2003 2 28 0 0 CON 0 7 Relative Weight Soleus 
85 Sun 2003 2 28 8 0 SUS 0 7 Relative Weight Soleus -45
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 120 Daily 45 degrees HUT2 0 7 Relative Weight Soleus -17.5
p<0.05 
vs. CON  
p<0.05 
vs. SUS







85 Sun 2003 2 28 0 0 CON 0 7 Wet Weight Gastrocnemius Medial
85 Sun 2003 2 28 8 0 SUS 0 7 Wet Weight Gastrocnemius Medial -9.3
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 120 Daily 45 degrees HUT2 0 7 Wet Weight Gastrocnemius Medial -12.6
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 240 Daily 45 degrees HUT4 0 7 Wet Weight Gastrocnemius Medial -6
85 Sun 2003 2 28 0 0 CON 0 7 Relative Weight Gastrocnemius Medial
85 Sun 2003 2 28 8 0 SUS 0 7 Relative Weight Gastrocnemius Medial -7.3
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 120 Daily 45 degrees HUT2 0 7 Relative Weight Gastrocnemius Medial -7.3
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 240 Daily 45 degrees HUT4 0 7 Relative Weight Gastrocnemius Medial 2.8
 p<0.05 
vs. SUS
85 Sun 2003 2 28 0 0 CON 0 7 Wet Weight Gastrocnemius Lateral
85 Sun 2003 2 28 8 0 SUS 0 7 Wet Weight Gastrocnemius Lateral -19.5
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 120 Daily 45 degrees HUT2 0 7 Wet Weight Gastrocnemius Lateral -16.7
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 240 Daily 45 degrees HUT4 0 7 Wet Weight Gastrocnemius Lateral -15.9
p<0.05 
vs. CON
85 Sun 2003 2 28 0 0 CON 0 7 Relative Weight Gastrocnemius Lateral
85 Sun 2003 2 28 8 0 SUS 0 7 Relative Weight Gastrocnemius Lateral -18.1
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 120 Daily 45 degrees HUT2 0 7 Relative Weight Gastrocnemius Lateral -13
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 240 Daily 45 degrees HUT4 0 7 Relative Weight Gastrocnemius Lateral -8
 p<0.05 
vs. SUS
85 Sun 2003 2 28 0 0 CON 0 7 Wet Weight
Extensor Digitorum 
Longus





















85 Sun 2003 2 28 0 0 CON 0 7 Relative Weight
Extensor Digitorum 
Longus


















85 Sun 2003 2 28 0 0 CON 0 7 Wet Weight Femur
85 Sun 2003 2 28 8 0 SUS 0 7 Wet Weight Femur -10.4
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 120 Daily 45 degrees HUT2 0 7 Wet Weight Femur -7.5
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 240 Daily 45 degrees HUT4 0 7 Wet Weight Femur -10.8
p<0.05 
vs. CON
85 Sun 2003 2 28 0 0 CON 0 7 Dry Weight Femur
85 Sun 2003 2 28 8 0 SUS 0 7 Dry Weight Femur -15
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 120 Daily 45 degrees HUT2 0 7 Dry Weight Femur -14.1
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 240 Daily 45 degrees HUT4 0 7 Dry Weight Femur -16.5
p<0.05 
vs. CON
85 Sun 2003 2 28 0 0 CON 0 7 Ash Weight Femur
85 Sun 2003 2 28 8 0 SUS 0 7 Ash Weight Femur -27.4
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 120 Daily 45 degrees HUT2 0 7 Ash Weight Femur -23.3
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 240 Daily 45 degrees HUT4 0 7 Ash Weight Femur -27.1
p<0.05 
vs. CON
85 Sun 2003 2 28 0 0 CON 0 7 Density Femur
85 Sun 2003 2 28 8 0 SUS 0 7 Density Femur -6
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 120 Daily 45 degrees HUT2 0 7 Density Femur -2
p<0.05 
vs. SUS





85 Sun 2003 2 28 0 0 CON 0 7 Bone Mineral Density Femur
85 Sun 2003 2 28 8 0 SUS 0 7 Bone Mineral Density Femur -29.2
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 120 Daily 45 degrees HUT2 0 7 Bone Mineral Density Femur -23.9
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 240 Daily 45 degrees HUT4 0 7 Bone Mineral Density Femur -25
p<0.05 
vs. CON
85 Sun 2003 2 28 0 0 CON 0 7 Elastic Load Femur
85 Sun 2003 2 28 8 0 SUS 0 7 Elastic Load Femur -27
p<0.05 
vs. CON










85 Sun 2003 2 28 0 0 CON 0 7 Maximum Load Femur
85 Sun 2003 2 28 8 0 SUS 0 7 Maximum Load Femur -32.3
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 120 Daily 45 degrees HUT2 0 7 Maximum Load Femur -25.1
p<0.05 
vs. CON





85 Sun 2003 2 28 0 0 CON 0 7 Bending Rigidity Coefficient Femur
85 Sun 2003 2 28 8 0 SUS 0 7 Bending Rigidity Coefficient Femur -30.9
p<0.05 
vs. CON
85 Sun 2003 2 28 8 512 120 Daily 45 degrees HUT2 0 7 Bending Rigidity Coefficient Femur -24.2
p<0.05 
vs. CON







Sun 2004 Protocol 
1 
2 28 0 0 CON 0 7 Wet Weight Whole Body 26.2
86
Sun 2004 Protocol 
1 
2 28 8 0 SUS 0 7 Wet Weight Whole Body 20.1
86
Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 
2 28 8 8 120 Daily STD2 0 7 Wet Weight Whole Body 15.3
86
Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 
2 28 0 0 CON 0 7 Contractile Response (100mM) Basilar Artery
86
Sun 2004 Protocol 
1 
2 28 8 0 SUS 0 7 Contractile Response (100mM) Basilar Artery 42.9
86
Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 
2 28 0 0 CON 0 7 Contractile Response (100mM) Femoral Artery
86
Sun 2004 Protocol 
1 
2 28 8 0 SUS 0 7 Contractile Response (100mM) Femoral Artery -20
86
Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 




Sun 2004 Protocol 
1 




Sun 2004 Protocol 
2 
2 28 0 0 COn 0 6 Wet Weight Whole Body 53.1
87
Sun 2004 Protocol 
2 
2 28 8 0 SUS 0 6 Wet Weight Whole Body 47.2
87
Sun 2004 Protocol 
2 
2 28 8 512 240 Daily 45 degrees HUT4 0 6 Wet Weight Whole Body 47.6
87
Sun 2004 Protocol 
2 
2 28 0 0 COn 0 6 Media Thickness Basilar Artery
87
Sun 2004 Protocol 
2 




Sun 2004 Protocol 
2 




Sun 2004 Protocol 
2 
2 28 0 0 COn 0 6 Cross Sectional Area Basilar Artery
87
Sun 2004 Protocol 
2 




Sun 2004 Protocol 
2 




Sun 2004 Protocol 
2 
2 28 0 0 COn 0 6 Intraluminal Diameter Basilar Artery
87
Sun 2004 Protocol 
2 
2 28 8 0 SUS 0 6 Intraluminal Diameter Basilar Artery
87
Sun 2004 Protocol 
2 
2 28 8 512 240 Daily 45 degrees HUT4 0 6 Intraluminal Diameter Basilar Artery
87
Sun 2004 Protocol 
2 
2 28 0 0 COn 0 6




Sun 2004 Protocol 
2 
2 28 8 0 SUS 0 6




Sun 2004 Protocol 
2 
2 28 8 512 240 Daily 45 degrees HUT4 0 6




Sun 2004 Protocol 
2 





Sun 2004 Protocol 
2 




Sun 2004 Protocol 
2 




Sun 2004 Protocol 
2 
2 28 0 0 COn 0 6 Media Thickness Anterior Tibial Artery
87
Sun 2004 Protocol 
2 




Sun 2004 Protocol 
2 




Sun 2004 Protocol 
2 
2 28 0 0 COn 0 6 Cross Sectional Area Anterior Tibial Artery
87
Sun 2004 Protocol 
2 




Sun 2004 Protocol 
2 




Sun 2004 Protocol 
2 
2 28 0 0 COn 0 6 Intraluminal Diameter Anterior Tibial Artery
87
Sun 2004 Protocol 
2 
2 28 8 0 SUS 0 6 Intraluminal Diameter Anterior Tibial Artery 8.4
87
Sun 2004 Protocol 
2 
2 28 8 512 240 Daily 45 degrees HUT4 0 6 Intraluminal Diameter Anterior Tibial Artery 12.2
87
Sun 2004 Protocol 
2 
2 28 0 0 COn 0 6




Sun 2004 Protocol 
2 
2 28 8 0 SUS 0 6
Cross Sectional Area of 
Smooth Cells
Anterior Tibial Artery -3.3
87
Sun 2004 Protocol 
2 
2 28 8 512 240 Daily 45 degrees HUT4 0 6
Cross Sectional Area of 
Smooth Cells
Anterior Tibial Artery 2
87
Sun 2004 Protocol 
2 
2 28 0 0 COn 0 6 Number of Smooth Cells Anterior Tibial Artery
87
Sun 2004 Protocol 
2 




Sun 2004 Protocol 
2 




Sun 2004 Protocol 
3, Ex. 1 
2 28 0 0 COn 0 5 Media Thickness Basilar Artery
88
Sun 2004 Protocol 
3, Ex. 1 




Sun 2004 Protocol 
3, Ex. 1 




Sun 2004 Protocol 
3, Ex. 1 
2 28 0 0 COn 0 5 Cross Sectional Area Basilar Artery
88
Sun 2004 Protocol 
3, Ex. 1 




Sun 2004 Protocol 
3, Ex. 1 




Sun 2004 Protocol 
3, Ex. 1 
2 28 0 0 COn 0 5 Intraluminal Diameter Basilar Artery
88
Sun 2004 Protocol 
3, Ex. 1 
2 28 8 0 SUS 0 5 Intraluminal Diameter Basilar Artery -0.4
88
Sun 2004 Protocol 
3, Ex. 1 
2 28 8 8 60 Daily HUT4 0 5 Intraluminal Diameter Basilar Artery -0.2
88
Sun 2004 Protocol 
3, Ex. 1 
2 28 0 0 COn 0 5




Sun 2004 Protocol 
3, Ex. 1 
2 28 8 0 SUS 0 5




Sun 2004 Protocol 
3, Ex. 1 
2 28 8 8 60 Daily HUT4 0 5




Sun 2004 Protocol 
3, Ex. 1 
2 28 0 0 COn 0 5 Number of Smooth Cells Basilar Artery
88
Sun 2004 Protocol 
3, Ex. 1 




Sun 2004 Protocol 
3, Ex. 1 




Sun 2004 Protocol 
3, Ex. 1 
2 28 0 0 COn 0 5 Media Thickness Anterior Tibial Artery
88
Sun 2004 Protocol 
3, Ex. 1 




Sun 2004 Protocol 
3, Ex. 1 




Sun 2004 Protocol 
3, Ex. 1 
2 28 0 0 COn 0 5 Cross Sectional Area Anterior Tibial Artery
88
Sun 2004 Protocol 
3, Ex. 1 







Sun 2004 Protocol 
3, Ex. 1 




Sun 2004 Protocol 
3, Ex. 1 
2 28 0 0 COn 0 5 Intraluminal Diameter Anterior Tibial Artery
88
Sun 2004 Protocol 
3, Ex. 1 
2 28 8 0 SUS 0 5 Intraluminal Diameter Anterior Tibial Artery 0
88
Sun 2004 Protocol 
3, Ex. 1 
2 28 8 8 60 Daily HUT4 0 5 Intraluminal Diameter Anterior Tibial Artery -0.3
88
Sun 2004 Protocol 
3, Ex. 1 
2 28 0 0 COn 0 5




Sun 2004 Protocol 
3, Ex. 1 
2 28 8 0 SUS 0 5
Cross Sectional Area of 
Smooth Cells
Anterior Tibial Artery 4.6
88
Sun 2004 Protocol 
3, Ex. 1 
2 28 8 8 60 Daily HUT4 0 5
Cross Sectional Area of 
Smooth Cells
Anterior Tibial Artery 1.5
88
Sun 2004 Protocol 
3, Ex. 1 
2 28 0 0 COn 0 5 Number of Smooth Cells Anterior Tibial Artery
88
Sun 2004 Protocol 
3, Ex. 1 




Sun 2004 Protocol 
3, Ex. 1 




Sun 2004 Protocol 
3, Ex. 2 
2 28 0 0 CON 0 7 Media Thickness Basilar Artery
89
Sun 2004 Protocol 
3, Ex. 2 
2 28 0 8 120 Daily CON2 0 7 Media Thickness Basilar Artery -5.6
89
Sun 2004 Protocol 
3, Ex. 2 







Sun 2004 Protocol 
3, Ex. 2 




Sun 2004 Protocol 
3, Ex. 2 
2 28 0 0 CON 0 7 Cross Sectional Area Basilar Artery
89
Sun 2004 Protocol 
3, Ex. 2 
2 28 0 8 120 Daily CON2 0 7 Cross Sectional Area Basilar Artery -4.9
89
Sun 2004 Protocol 
3, Ex. 2 







Sun 2004 Protocol 
3, Ex. 2 




Sun 2004 Protocol 
3, Ex. 2 
2 28 0 0 CON 0 7 Intraluminal Diameter Basilar Artery
89
Sun 2004 Protocol 
3, Ex. 2 
2 28 0 8 120 Daily CON2 0 7 Intraluminal Diameter Basilar Artery 0.9
89
Sun 2004 Protocol 
3, Ex. 2 
2 28 8 0 SUS 0 7 Intraluminal Diameter Basilar Artery 1.2
89
Sun 2004 Protocol 
3, Ex. 2 
2 28 8 8 120 Daily STD2 0 7 Intraluminal Diameter Basilar Artery 0.4
89
Sun 2004 Protocol 
3, Ex. 2 
2 28 0 0 CON 0 7 Media Thickness Anterior Tibial Artery
89
Sun 2004 Protocol 
3, Ex. 2 
2 28 0 8 120 Daily CON2 0 7 Media Thickness Anterior Tibial Artery -1.9
89
Sun 2004 Protocol 
3, Ex. 2 







Sun 2004 Protocol 
3, Ex. 2 




Sun 2004 Protocol 
3, Ex. 2 
2 28 0 0 CON 0 7 Cross Sectional Area Anterior Tibial Artery
89
Sun 2004 Protocol 
3, Ex. 2 
2 28 0 8 120 Daily CON2 0 7 Cross Sectional Area Anterior Tibial Artery -1.8
89
Sun 2004 Protocol 
3, Ex. 2 







Sun 2004 Protocol 
3, Ex. 2 




Sun 2004 Protocol 
3, Ex. 2 
2 28 0 0 CON 0 7 Intraluminal Diameter Anterior Tibial Artery
89
Sun 2004 Protocol 
3, Ex. 2 
2 28 0 8 120 Daily CON2 0 7 Intraluminal Diameter Anterior Tibial Artery 0.5
89
Sun 2004 Protocol 
3, Ex. 2 





Sun 2004 Protocol 
3, Ex. 2 
2 28 8 8 120 Daily STD2 0 7 Intraluminal Diameter Anterior Tibial Artery -0.9
90 Korolkov 2001 1 28 1 0 CON 0 6 VO2 (L/min) -16.1
90 Korolkov 2001 1 28 1 1 1.2-1.6 30
2-3 or 4-5 
per week
1.2G 2-3 times/week or 1.2, 1.4, 1.6 4-5 times per 
week
AG 0 6 VO2 (L/min) -6.7
90 Korolkov 2001 1 28 1 0 CON 0 6 Energy Cost of Regime -20
90 Korolkov 2001 1 28 1 1 1.2-1.6 30
2-3 or 4-5 
per week
1.2G 2-3 times/week or 1.2, 1.4, 1.6 4-5 times per 
week
AG 0 6 Energy Cost of Regime -14.3
90 Korolkov 2001 1 28 1 0 CON 0 6 Volume of Body Fluids -5
90 Korolkov 2001 1 28 1 1 1.2-1.6 30
2-3 or 4-5 
per week
1.2G 2-3 times/week or 1.2, 1.4, 1.6 4-5 times per 
week
AG 0 6 Volume of Body Fluids -5
90 Korolkov 2001 1 28 1 0 CON 0 6 Intracellular Fluid -4
90 Korolkov 2001 1 28 1 1 1.2-1.6 30
2-3 or 4-5 
per week
1.2G 2-3 times/week or 1.2, 1.4, 1.6 4-5 times per 
week
AG 0 6 Intracellular Fluid -4
90 Korolkov 2001 1 28 1 0 CON 0 6 Plasme Volume (mL) -6
90 Korolkov 2001 1 28 1 1 1.2-1.6 30
2-3 or 4-5 
per week
1.2G 2-3 times/week or 1.2, 1.4, 1.6 4-5 times per 
week
AG 0 6 Plasme Volume (mL) -7
90 Korolkov 2001 1 28 1 0 CON 0 6 Extracellular Fluid -11
90 Korolkov 2001 1 28 1 1 1.2-1.6 30
2-3 or 4-5 
per week
1.2G 2-3 times/week or 1.2, 1.4, 1.6 4-5 times per 
week
AG 0 6 Extracellular Fluid -6.5 1
90 Korolkov 2001 1 28 1 0 CON 0 6 Interstitial Fluid -11.5
90 Korolkov 2001 1 28 1 1 1.2-1.6 30
2-3 or 4-5 
per week
1.2G 2-3 times/week or 1.2, 1.4, 1.6 4-5 times per 
week
AG 0 6 Interstitial Fluid -6.5 1
90 Korolkov 2001 1 28 1 0 CON 0 6 Blood Flow Gastrocnemius Medial -40
90 Korolkov 2001 1 28 1 1 1.2-1.6 30
2-3 or 4-5 
per week
1.2G 2-3 times/week or 1.2, 1.4, 1.6 4-5 times per 
week
AG 0 6 Blood Flow Gastrocnemius Medial -19 1
91 Gurovsky 1980 3 18.5 0 0 CON 0 20 Wet Weight 43.3
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 Wet Weight 33.2
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 Wet Weight 29.7
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 Ve (L/min) lower
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 Ve (L/min) lower
91 Gurovsky 1980 3 18.5 0 0 CON 0 20
Total Renal Excretion of 
Potassium
91 Gurovsky 1980 3 18.5 9 0 ug 0 20
Total Renal Excretion of 
Potassium
53
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10
Total Renal Excretion of 
Potassium
14.9
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 Functioning Capillaries lower
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 Functioning Capillaries lower
91 Gurovsky 1980 3 18.5 0 0 CON 0 20 Hemoglobin
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 Hemoglobin 17.6
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 Hemoglobin 13
91 Gurovsky 1980 3 18.5 0 0 CON 0 20 Red Blood Cell Volume
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 Red Blood Cell Volume 20
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 Red Blood Cell Volume 13.8
91 Gurovsky 1980 3 18.5 0 0 CON 0 20 Hematocrit
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 Hematocrit 2
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 Hematocrit -4.1
91 Gurovsky 1980 3 18.5 0 0 CON 0 20 Reticulocytes
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 Reticulocytes -13.3
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 Reticulocytes 15
91 Gurovsky 1980 3 18.5 0 0 CON 0 20 Leucocytes
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 Leucocytes -27.1
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 Leucocytes 0
91 Gurovsky 1980 3 18.5 0 0 CON 0 20 Segmentonuclear Neutrophilis
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 Segmentonuclear Neutrophilis 181.2
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 Segmentonuclear Neutrophilis 37.5
91 Gurovsky 1980 3 18.5 0 0 CON 0 20 Lymphocytes
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 Lymphocytes -36.7
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 Lymphocytes -7.5
91 Gurovsky 1980 3 18.5 0 0 CON 0 20 Eosinophils
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 Eosinophils -69.2
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 Eosinophils -53.8
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 Sarcoplasmatic Proteins increase
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 Sarcoplasmatic Proteins no change
91 Gurovsky 1980 3 18.5 9 0 ug 0 20 ATPase activity of Myosin Myocardial large decrease
91 Gurovsky 1980 3 18.5 9 1 0.32 1 1 Continuous ug+AG 0 10 ATPase activity of Myosin Myocardial small decrease
93 Belozerova 2000 1 30 3 0 CON 0 6 Myofiber Cross Sectional Area MHC l Vastus Lateralis -26.4 1
93 Belozerova 2000 1 30 3 1 1.2 20-May
5 
days/week
AG 0 5 Myofiber Cross Sectional Area MHC l Vastus Lateralis -16.7 1




93 Belozerova 2000 1 30 3 1 1.2 20-May
5 
days/week
AG 0 5 Myofiber Cross Sectional Area MHC IIa / IIx -8.1
93 Belozerova 2000 1 30 3 0 CON 0 6
Area % Connective Tussue 
Compartment
113 1




Area % Connective Tussue 
Compartment
36
93 Belozerova 2000 1 30 3 0 CON 0 6 Capillary per fiber ratio -9.5
93 Belozerova 2000 1 30 3 1 1.2 20-May
5 
days/week
AG 0 5 Capillary per fiber ratio -9
93 Belozerova 2000 1 30 3 0 CON 0 6 capillary density 12.6
93 Belozerova 2000 1 30 3 1 1.2 20-May
5 
days/week
AG 0 5 capillary density -3.7
93 Belozerova 2000 1 30 3 0 CON 0 6 Succinate Dehydrogenase MHC l -2.6
93 Belozerova 2000 1 30 3 1 1.2 20-May
5 
days/week
AG 0 5 Succinate Dehydrogenase MHC l 22.2 1
93 Belozerova 2000 1 30 3 0 CON 0 6 Muscle weight-to-body ratio MHC IIa / IIx 9.9
93 Belozerova 2000 1 30 3 1 1.2 20-May
5 
days/week
AG 0 5 Muscle weight-to-body ratio MHC IIa / IIx 28.5 1
95 D'Aunno 1990 2 7 0 0 BAS 7 0 Wet Weight Soleus 
95 D'Aunno 1990 2 7 0 0 CON 8 0 Wet Weight Soleus 
95 D'Aunno 1990 2 7 8 0 SUS 12 0 Wet Weight Soleus -39.8 1
95 D'Aunno 1990 2 7 8 1 1.6 1.5 1.5 60 Daily AG1.5 8 0 Wet Weight Soleus -31.5
95 D'Aunno 1990 2 7 8 1 1.6 1.5 1.5 120 Daily AG1.5 8 0 Wet Weight Soleus -27.3 1
95 D'Aunno 1990 2 7 8 1 1.6 2.6 2.6 60 Daily AG2.6 6 0 Wet Weight Soleus -31.2
95 D'Aunno 1990 2 7 8 1 1.6 2.6 2.6 120 Daily AG2.6 7 0 Wet Weight Soleus -29.9 1
95 D'Aunno 1990 2 7 8 8 120 Daily STD2 6 0 Wet Weight Soleus -25.1 1
95 D'Aunno 1990 2 7 0 0 BAS 7 0 Sarcoplasmatic Proteins Soleus 
95 D'Aunno 1990 2 7 0 0 CON 8 0 Sarcoplasmatic Proteins Soleus 
95 D'Aunno 1990 2 7 8 0 SUS 12 0 Sarcoplasmatic Proteins Soleus -37.1 1
95 D'Aunno 1990 2 7 8 1 1.6 1.5 1.5 60 Daily AG1.5 8 0 Sarcoplasmatic Proteins Soleus -32
95 D'Aunno 1990 2 7 8 1 1.6 1.5 1.5 120 Daily AG1.5 8 0 Sarcoplasmatic Proteins Soleus -26.9
95 D'Aunno 1990 2 7 8 1 1.6 2.6 2.6 60 Daily AG2.6 6 0 Sarcoplasmatic Proteins Soleus -23
95 D'Aunno 1990 2 7 8 1 1.6 2.6 2.6 120 Daily AG2.6 7 0 Sarcoplasmatic Proteins Soleus -39.7
95 D'Aunno 1990 2 7 8 8 120 Daily STD2 6 0 Sarcoplasmatic Proteins Soleus -30.7
95 D'Aunno 1990 2 7 0 0 BAS 7 0 Muscle weight-to-body ratio Soleus 
95 D'Aunno 1990 2 7 0 0 CON 8 0 Muscle weight-to-body ratio Soleus 
95 D'Aunno 1990 2 7 8 0 SUS 12 0 Muscle weight-to-body ratio Soleus -23.5 1
95 D'Aunno 1990 2 7 8 1 1.6 1.5 1.5 60 Daily AG1.5 8 0 Muscle weight-to-body ratio Soleus -21.5
95 D'Aunno 1990 2 7 8 1 1.6 1.5 1.5 120 Daily AG1.5 8 0 Muscle weight-to-body ratio Soleus -18.6
95 D'Aunno 1990 2 7 8 1 1.6 2.6 2.6 60 Daily AG2.6 6 0 Muscle weight-to-body ratio Soleus -21.5
95 D'Aunno 1990 2 7 8 1 1.6 2.6 2.6 120 Daily AG2.6 7 0 Muscle weight-to-body ratio Soleus -17.6
95 D'Aunno 1990 2 7 8 8 120 Daily STD2 6 0 Muscle weight-to-body ratio Soleus -15.6
95 D'Aunno 1990 2 7 0 0 BAS 7 0 Wet Weight Whole Body
95 D'Aunno 1990 2 7 0 0 CON 8 0 Wet Weight Whole Body
95 D'Aunno 1990 2 7 8 0 SUS 12 0 Wet Weight Whole Body -13.3
95 D'Aunno 1990 2 7 8 1 1.6 1.5 1.5 60 Daily AG1.5 8 0 Wet Weight Whole Body -12.3
95 D'Aunno 1990 2 7 8 1 1.6 1.5 1.5 120 Daily AG1.5 8 0 Wet Weight Whole Body -11
95 D'Aunno 1990 2 7 8 1 1.6 2.6 2.6 60 Daily AG2.6 6 0 Wet Weight Whole Body -11.7
95 D'Aunno 1990 2 7 8 1 1.6 2.6 2.6 120 Daily AG2.6 7 0 Wet Weight Whole Body -14
95 D'Aunno 1990 2 7 8 8 120 Daily STD2 6 0 Wet Weight Whole Body -10.7
95 D'Aunno 1990 2 7 0 0 CON 8 0 Food Intake
95 D'Aunno 1990 2 7 8 0 SUS 12 0 Food Intake -6.1
95 D'Aunno 1990 2 7 8 1 1.6 1.5 1.5 60 Daily AG1.5 8 0 Food Intake -17.4
95 D'Aunno 1990 2 7 8 1 1.6 1.5 1.5 120 Daily AG1.5 8 0 Food Intake -5.1
95 D'Aunno 1990 2 7 8 1 1.6 2.6 2.6 60 Daily AG2.6 6 0 Food Intake -7.6
95 D'Aunno 1990 2 7 8 1 1.6 2.6 2.6 120 Daily AG2.6 7 0 Food Intake -22
95 D'Aunno 1990 2 7 8 8 120 Daily STD2 6 0 Food Intake -2.5
96 D'Aunno 1992 2 7 0 0 BAS 8 0 Wet Weight Soleus 
96 D'Aunno 1992 2 7 0 0 CON 7 0 Wet Weight Soleus 
96 D'Aunno 1992 2 7 8 0 SUS 6 0 Wet Weight Soleus -24.5
p<0.05 
vs CONS
96 D'Aunno 1992 2 7 8 8 15 4/day daily STD1 9 0 Wet Weight Soleus -8.1
p<0.05 
vs SUS
96 D'Aunno 1992 2 7 8 1 1.6 1.2 1.2 15 4/day daily AG1.6 5 0 Wet Weight Soleus -14.2
p<0.05 
vs CONS
96 D'Aunno 1992 2 7 0 0 BAS 8 0 Relative Sarcoplasmic protein Soleus 
96 D'Aunno 1992 2 7 0 0 CON 7 0 Relative Sarcoplasmic protein Soleus 
96 D'Aunno 1992 2 7 8 0 SUS 6 0 Relative Sarcoplasmic protein Soleus 8.5
96 D'Aunno 1992 2 7 8 8 15 4/day daily STD1 9 0 Relative Sarcoplasmic protein Soleus 25.7
96 D'Aunno 1992 2 7 8 1 1.6 1.2 1.2 15 4/day daily AG1.6 5 0 Relative Sarcoplasmic protein Soleus 0.5
96 D'Aunno 1992 2 7 0 0 BAS 8 0 Sarcoplasmatic Proteins Soleus 
96 D'Aunno 1992 2 7 0 0 CON 7 0 Sarcoplasmatic Proteins Soleus 
96 D'Aunno 1992 2 7 8 0 SUS 6 0 Sarcoplasmatic Proteins Soleus -22.6




96 D'Aunno 1992 2 7 8 1 1.6 1.2 1.2 15 4/day daily AG1.6 5 0 Sarcoplasmatic Proteins Soleus -20.7
96 D'Aunno 1992 2 7 0 0 BAS 8 0 Muscle weight-to-body ratio Soleus 
96 D'Aunno 1992 2 7 0 0 CON 7 0 Muscle weight-to-body ratio Soleus 
96 D'Aunno 1992 2 7 8 0 SUS 6 0 Muscle weight-to-body ratio Soleus -11.6
p<0.05 
vs CONS
96 D'Aunno 1992 2 7 8 8 15 4/day daily STD1 9 0 Muscle weight-to-body ratio Soleus 2.1
p<0.05 
vs SUS
96 D'Aunno 1992 2 7 8 1 1.6 1.2 1.2 15 4/day daily AG1.6 5 0 Muscle weight-to-body ratio Soleus -2.4
96 D'Aunno 1992 2 7 0 0 BAS 8 0 Wet Weight Whole Body
96 D'Aunno 1992 2 7 0 0 CON 7 0 Wet Weight Whole Body
96 D'Aunno 1992 2 7 8 0 SUS 6 0 Wet Weight Whole Body -17.2
p<0.05 
vs CON
96 D'Aunno 1992 2 7 8 8 15 4/day daily STD1 9 0 Wet Weight Whole Body -13
p<0.05 
vs CON
96 D'Aunno 1992 2 7 8 1 1.6 1.2 1.2 15 4/day daily AG1.6 5 0 Wet Weight Whole Body -14.6
p<0.05 
vs CON
96 D'Aunno 1992 2 7 0 0 BAS 8 0 Wet Weight Plantar Flexor
96 D'Aunno 1992 2 7 0 0 CON 7 0 Wet Weight Plantar Flexor
96 D'Aunno 1992 2 7 8 0 SUS 6 0 Wet Weight Plantar Flexor -23
p<0.05 
vs CON
96 D'Aunno 1992 2 7 8 8 15 4/day daily STD1 9 0 Wet Weight Plantar Flexor -14.5
p<0.05 
vs CON
96 D'Aunno 1992 2 7 8 1 1.6 1.2 1.2 15 4/day daily AG1.6 5 0 Wet Weight Plantar Flexor -21.5
p<0.05 
vs CON
96 D'Aunno 1992 2 7 0 0 BAS 8 0 Wet Weight Adrenal Gland
96 D'Aunno 1992 2 7 0 0 CON 7 0 Wet Weight Adrenal Gland
96 D'Aunno 1992 2 7 8 0 SUS 6 0 Wet Weight Adrenal Gland 8.7
96 D'Aunno 1992 2 7 8 8 15 4/day daily STD1 9 0 Wet Weight Adrenal Gland 24
96 D'Aunno 1992 2 7 8 1 1.6 1.2 1.2 15 4/day daily AG1.6 5 0 Wet Weight Adrenal Gland 20.6
96 D'Aunno 1992 2 7 0 0 CON 7 0 Food Intake
96 D'Aunno 1992 2 7 8 0 SUS 6 0 Food Intake -25
96 D'Aunno 1992 2 7 8 8 15 4/day daily STD1 9 0 Food Intake 0
96 D'Aunno 1992 2 7 8 1 1.6 1.2 1.2 15 4/day daily AG1.6 5 0 Food Intake -15
113 Wimalawansa 1999 4 14 0 0 BAS 0 10 #N/A
113 Wimalawansa 1999 4 14 0 0 CON 0 10 #N/A
113 Wimalawansa 1999 4 14 8 0 SUS 0 10 #N/A
113 Wimalawansa 1999 4 14 8 262144 Daily 80µg/kg/day PTH80 0 10 #N/A
97 Thomason 1987 2 28 0 0 CON 25 0 Wet Weight Soleus slow twitch
97 Thomason 1987 2 28 8 0 SUS 31 0 Wet Weight Soleus slow twitch
p<0.05 
vs CON








97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK




97 Thomason 1987 2 28 0 0 CON 25 0 Wet Weight Adductors slow twitch
97 Thomason 1987 2 28 8 0 SUS 31 0 Wet Weight Adductors slow twitch
p<0.05 
vs CON








97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK




97 Thomason 1987 2 28 0 0 CON 25 0 Wet Weight Vastus Intermedius slow twitch
97 Thomason 1987 2 28 8 0 SUS 31 0 Wet Weight Vastus Intermedius slow twitch
p<0.05 
vs CON
97 Thomason 1987 2 28 8 8 120 Daily STD2 6 0 Wet Weight Vastus Intermedius slow twitch
p<0.05 
vs CON
97 Thomason 1987 2 28 8 8 240 Daily STD4 7 0 Wet Weight Vastus Intermedius slow twitch
p<0.05 
vs CON
97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK







97 Thomason 1987 2 28 0 0 CON 25 0 Wet Weight Plantaris fast twitch
97 Thomason 1987 2 28 8 0 SUS 31 0 Wet Weight Plantaris fast twitch
p<0.05 
vs CON








97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK
8 0 Wet Weight Plantaris fast twitch
p<0.05 
vs CON
97 Thomason 1987 2 28 0 0 CON 25 0 Wet Weight Tibialis Anterior fast twitch
97 Thomason 1987 2 28 8 0 SUS 31 0 Wet Weight Tibialis Anterior fast twitch
p<0.05 
vs CON
97 Thomason 1987 2 28 8 8 120 Daily STD2 6 0 Wet Weight Tibialis Anterior fast twitch
p<0.05 
vs CON
97 Thomason 1987 2 28 8 8 240 Daily STD4 7 0 Wet Weight Tibialis Anterior fast twitch
p<0.05 
vs CON
97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK




97 Thomason 1987 2 28 0 0 CON 25 0 Wet Weight Vastus Lateralis fast twitch
97 Thomason 1987 2 28 8 0 SUS 31 0 Wet Weight Vastus Lateralis fast twitch
p<0.05 
vs CON








97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK
8 0 Wet Weight Vastus Lateralis fast twitch
p<0.05 
vs CON
97 Thomason 1987 2 28 0 0 CON 25 0 Wet Weight Whole Body
97 Thomason 1987 2 28 8 0 SUS 31 0 Wet Weight Whole Body
p<0.05 
vs CON
97 Thomason 1987 2 28 8 8 120 Daily STD2 6 0 Wet Weight Whole Body
p<0.05 
vs CON
97 Thomason 1987 2 28 8 8 240 Daily STD4 7 0 Wet Weight Whole Body
p<0.05 
vs CON
97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK
8 0 Wet Weight Whole Body
97 Thomason 1987 2 28 0 0 CON 25 0 Wet Weight Heart
97 Thomason 1987 2 28 8 0 SUS 31 0 Wet Weight Heart
97 Thomason 1987 2 28 8 8 120 Daily STD2 6 0 Wet Weight Heart
97 Thomason 1987 2 28 8 8 240 Daily STD4 7 0 Wet Weight Heart
97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK
8 0 Wet Weight Heart
p<0.05 
vs CON
97 Thomason 1987 2 28 0 0 CON 25 0 Wet Weight Adrenal Gland
97 Thomason 1987 2 28 8 0 SUS 31 0 Wet Weight Adrenal Gland
97 Thomason 1987 2 28 8 8 120 Daily STD2 6 0 Wet Weight Adrenal Gland
97 Thomason 1987 2 28 8 8 240 Daily STD4 7 0 Wet Weight Adrenal Gland
97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK




97 Thomason 1987 2 28 0 0 CON 25 0 Protein Soleus myofibril
97 Thomason 1987 2 28 8 0 SUS 31 0 Protein Soleus myofibril
p<0.05 
vs CON








97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK




97 Thomason 1987 2 28 0 0 CON 25 0 Protein Soleus myofibril - 



















97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK





97 Thomason 1987 2 28 0 0 CON 25 0
Relative ATPase activity of 
Myosin
Soleus 
97 Thomason 1987 2 28 8 0 SUS 31 0





97 Thomason 1987 2 28 8 8 120 Daily STD2 6 0





97 Thomason 1987 2 28 8 8 240 Daily STD4 7 0














97 Thomason 1987 2 28 0 0 CON 25 0 Myosin Isoform Content Soleus slow twitch
97 Thomason 1987 2 28 8 0 SUS 31 0 Myosin Isoform Content Soleus slow twitch
p<0.05 
vs CON
97 Thomason 1987 2 28 8 8 120 Daily STD2 6 0 Myosin Isoform Content Soleus slow twitch
p<0.05 
vs CON




97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK




97 Thomason 1987 2 28 0 0 CON 25 0 Myosin Isoform Content Soleus fast twitch
97 Thomason 1987 2 28 8 0 SUS 31 0 Myosin Isoform Content Soleus fast twitch
97 Thomason 1987 2 28 8 8 120 Daily STD2 6 0 Myosin Isoform Content Soleus fast twitch
97 Thomason 1987 2 28 8 8 240 Daily STD4 7 0 Myosin Isoform Content Soleus fast twitch
97 Thomason 1987 2 28 8 16 90 Daily 20m/min @ 30% grade
SUS+W
LK
8 0 Myosin Isoform Content Soleus fast twitch
98 Widrick 1996 2 14 0 0 CON 0 7 Wet Weight Soleus 
98 Widrick 1996 2 14 8 0 SUS 0 7 Wet Weight Soleus -40.2
p<0.05 
vs CON
98 Widrick 1996 2 14 8 8 10 4 / day STD 0 7 Wet Weight Soleus -35.7
p<0.05 
vs CON
98 Widrick 1996 2 14 0 0 CON 0 7 Relative Weight Soleus 
98 Widrick 1996 2 14 8 0 SUS 0 7 Relative Weight Soleus -45
p<0.05 
vs CON




98 Widrick 1996 2 14 0 0 CON 0 7 Myofiber Cross Sectional Area Soleus 
98 Widrick 1996 2 14 8 0 SUS 0 7 Myofiber Cross Sectional Area Soleus -28.1
p<0.05 
vs CON




98 Widrick 1996 2 14 0 0 CON 0 7 Po, Peak force MHC l Soleus
98 Widrick 1996 2 14 8 0 SUS 0 7 Po, Peak force MHC l Soleus -54.9
p<0.05 
vs CON




98 Widrick 1996 2 14 0 0 CON 0 7 Peak Tension Soleus 
98 Widrick 1996 2 14 8 0 SUS 0 7 Peak Tension Soleus -16.1
p<0.05 
vs CON
98 Widrick 1996 2 14 8 8 10 4 / day STD 0 7 Peak Tension Soleus -10
p<0.05 
vs CON
98 Widrick 1996 2 14 0 0 CON 0 7 Peak Elastic Modulus (Eo) Soleus 
98 Widrick 1996 2 14 8 0 SUS 0 7 Peak Elastic Modulus (Eo) Soleus -40.6
p<0.05 
vs CON
98 Widrick 1996 2 14 8 8 10 4 / day STD 0 7 Peak Elastic Modulus (Eo) Soleus -31.1
p<0.05 
vs CON
98 Widrick 1996 2 14 0 0 CON 0 7 Po / Eo Soleus 
98 Widrick 1996 2 14 8 0 SUS 0 7 Po / Eo Soleus 40
p<0.05 
vs CON
98 Widrick 1996 2 14 8 8 10 4 / day STD 0 7 Po / Eo Soleus 26.6
p<0.05 
vs CON
98 Widrick 1996 2 14 0 0 CON 0 7 Vo, shortening velocity Soleus 
98 Widrick 1996 2 14 8 0 SUS 0 7 Vo, shortening velocity Soleus 33.3
p<0.05 
vs CON







101 Pierotti 1990 2 7 0 0 CON 0 7 Wet Weight Whole Body
101 Pierotti 1990 2 7 8 0 SUS 0 9 Wet Weight Whole Body -8.8
p<0.05 
vs. CON
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Wet Weight Whole Body -13.4
p<0.05 
vs. CON
101 Pierotti 1990 2 7 0 0 CON 0 7 Wet Weight Soleus 
101 Pierotti 1990 2 7 8 0 SUS 0 9 Wet Weight Soleus -26.7
p<0.05 
vs. CON
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Wet Weight Soleus -19.7
p<0.05 
vs. CON
101 Pierotti 1990 2 7 0 0 CON 0 7 Relative Weight Soleus 
101 Pierotti 1990 2 7 8 0 SUS 0 9 Relative Weight Soleus -21.2
p<0.05 
vs. CON
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Relative Weight Soleus -8.5
101 Pierotti 1990 2 7 0 0 CON 0 7 Total contraction time Soleus 
101 Pierotti 1990 2 7 8 0 SUS 0 9 Total contraction time Soleus -24.7
p<0.05 
vs. CON
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK





101 Pierotti 1990 2 7 0 0 CON 0 7 Half relaxation time Soleus 
101 Pierotti 1990 2 7 8 0 SUS 0 9 Half relaxation time Soleus 2.7
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Half relaxation time Soleus -5.7
101 Pierotti 1990 2 7 0 0 CON 0 7 Pt, Isometric max twitch force Soleus 
101 Pierotti 1990 2 7 8 0 SUS 0 9 Pt, Isometric max twitch force Soleus -41.8
p<0.05 
vs. CON
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK





101 Pierotti 1990 2 7 0 0 CON 0 7 Po, Peak force Soleus 
101 Pierotti 1990 2 7 8 0 SUS 0 9 Po, Peak force Soleus -49.1
p<0.05 
vs. CON
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK





101 Pierotti 1990 2 7 0 0 CON 0 7 Pt / Po Soleus 
101 Pierotti 1990 2 7 8 0 SUS 0 9 Pt / Po Soleus 17.3
p<0.05 
vs. CON
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Pt / Po Soleus 8.6
101 Pierotti 1990 2 7 0 0 CON 0 7 Po / Muscle Weight Soleus 
101 Pierotti 1990 2 7 8 0 SUS 0 9 Po / Muscle Weight Soleus -30.5
p<0.05 
vs. CON
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Po / Muscle Weight Soleus -2.7
p<0.05 
vs. HS
101 Pierotti 1990 2 7 0 0 CON 0 7 Vo, shortening velocity Soleus 
101 Pierotti 1990 2 7 8 0 SUS 0 9 Vo, shortening velocity Soleus 4
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Vo, shortening velocity Soleus 10.2
101 Pierotti 1990 2 7 0 0 CON 0 7 Fatigue Index Soleus 
101 Pierotti 1990 2 7 8 0 SUS 0 9 Fatigue Index Soleus 0
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Fatigue Index Soleus -1
101 Pierotti 1990 2 7 0 0 CON 0 7 Wet Weight Gastrocnemius Medial
101 Pierotti 1990 2 7 8 0 SUS 0 9 Wet Weight Gastrocnemius Medial -26.2
p<0.05 
vs. CON
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Wet Weight Gastrocnemius Medial -23.1
p<0.05 
vs. CON
101 Pierotti 1990 2 7 0 0 CON 0 7 Relative Weight Gastrocnemius Medial
101 Pierotti 1990 2 7 8 0 SUS 0 9 Relative Weight Gastrocnemius Medial -18.6
p<0.05 
vs. CON
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Relative Weight Gastrocnemius Medial -10.3
p<0.05 
vs. CON
101 Pierotti 1990 2 7 0 0 CON 0 7 Total contraction time Gastrocnemius Medial
101 Pierotti 1990 2 7 8 0 SUS 0 9 Total contraction time Gastrocnemius Medial -1.5
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Total contraction time Gastrocnemius Medial 0.5
101 Pierotti 1990 2 7 0 0 CON 0 7 Half relaxation time Gastrocnemius Medial




101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Half relaxation time Gastrocnemius Medial -1.6
101 Pierotti 1990 2 7 0 0 CON 0 7 Pt, Isometric max twitch force Gastrocnemius Medial
101 Pierotti 1990 2 7 8 0 SUS 0 9 Pt, Isometric max twitch force Gastrocnemius Medial -1.5
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Pt, Isometric max twitch force Gastrocnemius Medial 0
101 Pierotti 1990 2 7 0 0 CON 0 7 Po, Peak force Gastrocnemius Medial
101 Pierotti 1990 2 7 8 0 SUS 0 9 Po, Peak force Gastrocnemius Medial -19.7
p<0.05 
vs. CON
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Po, Peak force Gastrocnemius Medial -11.1
101 Pierotti 1990 2 7 0 0 CON 0 7 Pt / Po Gastrocnemius Medial
101 Pierotti 1990 2 7 8 0 SUS 0 9 Pt / Po Gastrocnemius Medial 21.4
p<0.05 
vs. CON
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Pt / Po Gastrocnemius Medial 7.1
101 Pierotti 1990 2 7 0 0 CON 0 7 Po / Muscle Weight Gastrocnemius Medial
101 Pierotti 1990 2 7 8 0 SUS 0 9 Po / Muscle Weight Gastrocnemius Medial 8.8
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Po / Muscle Weight Gastrocnemius Medial 15.3
p<0.05 
vs. CON
101 Pierotti 1990 2 7 0 0 CON 0 7 Vo, shortening velocity Gastrocnemius Medial
101 Pierotti 1990 2 7 8 0 SUS 0 9 Vo, shortening velocity Gastrocnemius Medial -3
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Vo, shortening velocity Gastrocnemius Medial -6.4
101 Pierotti 1990 2 7 0 0 CON 0 7 Fatigue Index Gastrocnemius Medial
101 Pierotti 1990 2 7 8 0 SUS 0 9 Fatigue Index Gastrocnemius Medial -5.1
101 Pierotti 1990 2 7 8 16 10 4 / day
12m/min @ 19% grade on treadmill  (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 8 Fatigue Index Gastrocnemius Medial 0
102 Graham 1989a 2 28 0 0 CON 7 0 Wet Weight Soleus 
102 Graham 1989a 2 28 8 0 SUS 7 0 Wet Weight Soleus -69.1
p<0.05 
vs. CON
102 Graham 1989a 2 28 8 16 10 to 90 Daily
started at 10min/day, increased by 5min/day until 
1hr/day, then increased by 10min/day until 
90min/day.  Speed was 20m/min at 30% grade
SUS+W
LK





102 Graham 1989a 2 28 0 0 CON 7 0 Wet Weight Adrenal Gland
102 Graham 1989a 2 28 8 0 SUS 7 0 Wet Weight Adrenal Gland 5
102 Graham 1989a 2 28 8 16 10 to 90 Daily
started at 10min/day, increased by 5min/day until 
1hr/day, then increased by 10min/day until 
90min/day.  Speed was 20m/min at 30% grade
SUS+W
LK





102 Graham 1989a 2 28 0 0 CON 7 0 Myofiber distribution % Soleus fast twitch
102 Graham 1989a 2 28 8 0 SUS 7 0 Myofiber distribution % Soleus fast twitch 90
102 Graham 1989a 2 28 8 16 10 to 90 Daily
started at 10min/day, increased by 5min/day until 
1hr/day, then increased by 10min/day until 
90min/day.  Speed was 20m/min at 30% grade
SUS+W
LK
7 0 Myofiber distribution % Soleus fast twitch 70
102 Graham 1989a 2 28 0 0 CON 7 0 Myofiber Cross Sectional Area Soleus slow twitch
102 Graham 1989a 2 28 8 0 SUS 7 0 Myofiber Cross Sectional Area Soleus slow twitch -69
p<0.05 
vs. CON
102 Graham 1989a 2 28 8 16 10 to 90 Daily
started at 10min/day, increased by 5min/day until 
1hr/day, then increased by 10min/day until 
90min/day.  Speed was 20m/min at 30% grade
SUS+W
LK





102 Graham 1989a 2 28 0 0 CON 7 0 Myofiber Cross Sectional Area Soleus fast twitch
102 Graham 1989a 2 28 8 0 SUS 7 0 Myofiber Cross Sectional Area Soleus fast twitch -46
p<0.05 
vs. CON
102 Graham 1989a 2 28 8 16 10 to 90 Daily
started at 10min/day, increased by 5min/day until 
1hr/day, then increased by 10min/day until 
90min/day.  Speed was 20m/min at 30% grade
SUS+W
LK





102 Graham 1989a 2 28 0 0 CON 7 0 Succinate Dehydrogenase Soleus slow twitch
102 Graham 1989a 2 28 8 0 SUS 7 0 Succinate Dehydrogenase Soleus slow twitch 40.2
102 Graham 1989a 2 28 8 16 10 to 90 Daily
started at 10min/day, increased by 5min/day until 
1hr/day, then increased by 10min/day until 
90min/day.  Speed was 20m/min at 30% grade
SUS+W
LK
7 0 Succinate Dehydrogenase Soleus slow twitch 39.7
102 Graham 1989a 2 28 0 0 CON 7 0 Succinate Dehydrogenase Soleus fast twitch
102 Graham 1989a 2 28 8 0 SUS 7 0 Succinate Dehydrogenase Soleus fast twitch 11.3
102 Graham 1989a 2 28 8 16 10 to 90 Daily
started at 10min/day, increased by 5min/day until 
1hr/day, then increased by 10min/day until 
90min/day.  Speed was 20m/min at 30% grade
SUS+W
LK
7 0 Succinate Dehydrogenase Soleus fast twitch 19.5







102 Graham 1989a 2 28 8 0 SUS 7 0
Integrated Succinate 
Dehydrogenase (ISDH)
Soleus slow twitch -55.9
102 Graham 1989a 2 28 8 16 10 to 90 Daily
started at 10min/day, increased by 5min/day until 
1hr/day, then increased by 10min/day until 






Soleus slow twitch -26.4




102 Graham 1989a 2 28 8 0 SUS 7 0
Integrated Succinate 
Dehydrogenase (ISDH)
Soleus fast twitch -37.8
102 Graham 1989a 2 28 8 16 10 to 90 Daily
started at 10min/day, increased by 5min/day until 
1hr/day, then increased by 10min/day until 






Soleus fast twitch 2.5
103 Hauschka 1988 2 7 0 0 CON 0 10 Wet Weight Adrenal Gland
103 Hauschka 1988 2 7 8 0 SUS 0 11 Wet Weight Adrenal Gland 6.8
103 Hauschka 1988 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Wet Weight Adrenal Gland -4.5
103 Hauschka 1988 2 7 0 0 CON 0 10 Length Tibia
103 Hauschka 1988 2 7 8 0 SUS 0 11 Length Tibia -1.5
103 Hauschka 1988 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Length Tibia -1.8
103 Hauschka 1988 2 7 0 0 CON 0 10 Length Femur
103 Hauschka 1988 2 7 8 0 SUS 0 11 Length Femur -0.8
103 Hauschka 1988 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Length Femur -0.2
103 Hauschka 1988 2 7 0 0 CON 0 10 Wet Weight Soleus 
103 Hauschka 1988 2 7 8 0 SUS 0 11 Wet Weight Soleus -35
p<0.05 
vs. CON
103 Hauschka 1988 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK





103 Hauschka 1988 2 7 0 0 CON 0 10 Relative Weight Soleus 
103 Hauschka 1988 2 7 8 0 SUS 0 11 Relative Weight Soleus -27.5
p<0.05 
vs. CON
103 Hauschka 1988 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Relative Weight Soleus -7.5
p<0.05 
vs. HS
103 Hauschka 1988 2 7 0 0 CON 0 10 Myofiber distribution % Soleus fast twitch
103 Hauschka 1988 2 7 8 0 SUS 0 11 Myofiber distribution % Soleus fast twitch -2.7
103 Hauschka 1988 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Myofiber distribution % Soleus fast twitch 2.7
103 Hauschka 1988 2 7 0 0 CON 0 10 Succinate Dehydrogenase Soleus slow twitch
103 Hauschka 1988 2 7 8 0 SUS 0 11 Succinate Dehydrogenase Soleus slow twitch 9.7
103 Hauschka 1988 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Succinate Dehydrogenase Soleus slow twitch -8.7
103 Hauschka 1988 2 7 0 0 CON 0 10 Succinate Dehydrogenase Soleus fast twitch
103 Hauschka 1988 2 7 8 0 SUS 0 11 Succinate Dehydrogenase Soleus fast twitch 26.6
103 Hauschka 1988 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Succinate Dehydrogenase Soleus fast twitch 5.7




103 Hauschka 1988 2 7 8 0 SUS 0 11
Integrated Succinate 
Dehydrogenase (ISDH)
Soleus slow twitch -28.1
103 Hauschka 1988 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 






Soleus slow twitch -24.5




103 Hauschka 1988 2 7 8 0 SUS 0 11
Integrated Succinate 
Dehydrogenase (ISDH)
Soleus fast twitch -14.5
103 Hauschka 1988 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 






Soleus fast twitch -5.1
103 Hauschka 1988 2 7 0 0 CON 0 10 Myofiber Cross Sectional Area Soleus slow twitch
103 Hauschka 1988 2 7 8 0 SUS 0 11 Myofiber Cross Sectional Area Soleus slow twitch -36.1
p<0.05 
vs. CON
103 Hauschka 1988 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Myofiber Cross Sectional Area Soleus slow twitch -20
p<0.05 
vs. CON
103 Hauschka 1988 2 7 0 0 CON 0 10 Myofiber Cross Sectional Area Soleus fast twitch
103 Hauschka 1988 2 7 8 0 SUS 0 11 Myofiber Cross Sectional Area Soleus fast twitch -33.5
p<0.05 
vs. CON
103 Hauschka 1988 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Myofiber Cross Sectional Area Soleus fast twitch -12.1
p<0.05 
vs. SUS
104 Graham 1989b 2 7 0 0 CON 0 10 Wet Weight Gastrocnemius Medial






104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Wet Weight Gastrocnemius Medial -24.4
p<0.05 
vs. CON
104 Graham 1989b 2 7 0 0 CON 0 10 Relative Weight Gastrocnemius Medial
104 Graham 1989b 2 7 8 0 SUS 0 11 Relative Weight Gastrocnemius Medial -16.9
p<0.05 
vs. CON
104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Relative Weight Gastrocnemius Medial -13.3
p<0.05 
vs. CON
104 Graham 1989b 2 7 0 0 CON 0 10 Myofiber distribution % Gastrocnemius Superficial Dark
104 Graham 1989b 2 7 8 0 SUS 0 11 Myofiber distribution % Gastrocnemius Superficial Dark 0
104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Myofiber distribution % Gastrocnemius Superficial Dark 0
104 Graham 1989b 2 7 0 0 CON 0 10 Myofiber distribution % Gastrocnemius Deep Dark
104 Graham 1989b 2 7 8 0 SUS 0 11 Myofiber distribution % Gastrocnemius Deep Dark -1.3
104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Myofiber distribution % Gastrocnemius Deep Dark -5
104 Graham 1989b 2 7 0 0 CON 0 10 Myofiber Cross Sectional Area Gastrocnemius Deep Light
104 Graham 1989b 2 7 8 0 SUS 0 11 Myofiber Cross Sectional Area Gastrocnemius Deep Light
104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Myofiber Cross Sectional Area Gastrocnemius Deep Light
104 Graham 1989b 2 7 0 0 CON 0 10 Myofiber Cross Sectional Area Gastrocnemius Deep Dark
104 Graham 1989b 2 7 8 0 SUS 0 11 Myofiber Cross Sectional Area Gastrocnemius Deep Dark
104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Myofiber Cross Sectional Area Gastrocnemius Deep Dark
104 Graham 1989b 2 7 0 0 CON 0 10 Myofiber Cross Sectional Area Gastrocnemius Superficial Dark
104 Graham 1989b 2 7 8 0 SUS 0 11 Myofiber Cross Sectional Area Gastrocnemius Superficial Dark
104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Myofiber Cross Sectional Area Gastrocnemius Superficial Dark
104 Graham 1989b 2 7 0 0 CON 0 10 Succinate Dehydrogenase Gastrocnemius Deep Light
104 Graham 1989b 2 7 8 0 SUS 0 11 Succinate Dehydrogenase Gastrocnemius Deep Light
104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Succinate Dehydrogenase Gastrocnemius Deep Light
104 Graham 1989b 2 7 0 0 CON 0 10 Succinate Dehydrogenase Gastrocnemius Deep Dark
104 Graham 1989b 2 7 8 0 SUS 0 11 Succinate Dehydrogenase Gastrocnemius Deep Dark
104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Succinate Dehydrogenase Gastrocnemius Deep Dark
104 Graham 1989b 2 7 0 0 CON 0 10 Succinate Dehydrogenase Gastrocnemius Superficial Dark
104 Graham 1989b 2 7 8 0 SUS 0 11 Succinate Dehydrogenase Gastrocnemius Superficial Dark
104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 
weighed 15g and provided extra loading on treadmill)
SUS+W
LK
0 12 Succinate Dehydrogenase Gastrocnemius Superficial Dark








104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 















104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 















104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 















104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 


















104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 















104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 















104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 















104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 















104 Graham 1989b 2 7 8 16 10 4 / day
Walked 5m/min at 19% grade on treadmill (Tail cast 







105 Herbert 1988 2 7 0 0 CON 0 7 Wet Weight Adrenal Gland
105 Herbert 1988 2 7 8 0 SUS 0 7 Wet Weight Adrenal Gland -4.1
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Wet Weight Adrenal Gland 4.1
105 Herbert 1988 2 7 0 0 CON 0 7 Length Tibia
105 Herbert 1988 2 7 8 0 SUS 0 7 Length Tibia -1
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Length Tibia -1.3
105 Herbert 1988 2 7 0 0 CON 0 7 Wet Weight Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7 Wet Weight Soleus -41.9
p<0.05 
vs. CON
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 









105 Herbert 1988 2 7 0 0 CON 0 7 Relative Weight Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7 Relative Weight Soleus -32.8
p<0.05 
vs. CON
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 









105 Herbert 1988 2 7 0 0 CON 0 7 Po / Muscle Weight Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7 Po / Muscle Weight Soleus -4.1
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Po / Muscle Weight Soleus -4.9
105 Herbert 1988 2 7 0 0 CON 0 7 Wet / Dry Weight Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7 Wet / Dry Weight Soleus -6.2
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Wet / Dry Weight Soleus -2.5
105 Herbert 1988 2 7 0 0 CON 0 7 Relative Sarcoplasmic protein Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7 Relative Sarcoplasmic protein Soleus -11.8
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Relative Sarcoplasmic protein Soleus -14.6
105 Herbert 1988 2 7 0 0 CON 0 7 Total contraction time Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7 Total contraction time Soleus -12.3
p<0.05 
vs. CON
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Total contraction time Soleus -20
p<0.05 
vs. CON
105 Herbert 1988 2 7 0 0 CON 0 7 Half relaxation time Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7 Half relaxation time Soleus -4.8
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 












105 Herbert 1988 2 7 0 0 CON 0 7 Pt, Isometric max twitch force Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7 Pt, Isometric max twitch force Soleus -34.2
p<0.05 
vs. CON
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Pt, Isometric max twitch force Soleus -26.3
p<0.05 
vs. CON
105 Herbert 1988 2 7 0 0 CON 0 7 Po, Peak force Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7 Po, Peak force Soleus -44.1
p<0.05 
vs. CON
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 









105 Herbert 1988 2 7 0 0 CON 0 7 Pt / Po Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7 Pt / Po Soleus 17.3
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Pt / Po Soleus 0
105 Herbert 1988 2 7 0 0 CON 0 7
P20 / Po (Max Tension at 
20Hz / Po)
Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7





105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 










105 Herbert 1988 2 7 0 0 CON 0 7 Vo, shortening velocity Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7 Vo, shortening velocity Soleus 13.3
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Vo, shortening velocity Soleus 6.6
105 Herbert 1988 2 7 0 0 CON 0 7 Fatigue Index Soleus 
105 Herbert 1988 2 7 8 0 SUS 0 7 Fatigue Index Soleus -2
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Fatigue Index Soleus -1
105 Herbert 1988 2 7 0 0 CON 0 7 Wet Weight Gastrocnemius Medial
105 Herbert 1988 2 7 8 0 SUS 0 7 Wet Weight Gastrocnemius Medial -28.1
p<0.05 
vs. CON
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Wet Weight Gastrocnemius Medial -25.8
p<0.05 
vs. CON
105 Herbert 1988 2 7 0 0 CON 0 7 Relative Weight Gastrocnemius Medial
105 Herbert 1988 2 7 8 0 SUS 0 7 Relative Weight Gastrocnemius Medial -17.4
p<0.05 
vs. CON
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Relative Weight Gastrocnemius Medial -11.3
p<0.05 
vs. CON
105 Herbert 1988 2 7 0 0 CON 0 7 Po / Muscle Weight Gastrocnemius Medial
105 Herbert 1988 2 7 8 0 SUS 0 7 Po / Muscle Weight Gastrocnemius Medial 7.1
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Po / Muscle Weight Gastrocnemius Medial 13.6
p<0.05 
vs. CON
105 Herbert 1988 2 7 0 0 CON 0 7 Wet / Dry Weight Gastrocnemius Medial
105 Herbert 1988 2 7 8 0 SUS 0 7 Wet / Dry Weight Gastrocnemius Medial -4.1
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Wet / Dry Weight Gastrocnemius Medial -6
p<0.05 
vs. CON
105 Herbert 1988 2 7 0 0 CON 0 7 Relative Sarcoplasmic protein Gastrocnemius Medial
105 Herbert 1988 2 7 8 0 SUS 0 7 Relative Sarcoplasmic protein Gastrocnemius Medial 5.4
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Relative Sarcoplasmic protein Gastrocnemius Medial 0
105 Herbert 1988 2 7 0 0 CON 0 7 Total contraction time Gastrocnemius Medial
105 Herbert 1988 2 7 8 0 SUS 0 7 Total contraction time Gastrocnemius Medial -9.1
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Total contraction time Gastrocnemius Medial -6
105 Herbert 1988 2 7 0 0 CON 0 7 Half relaxation time Gastrocnemius Medial
105 Herbert 1988 2 7 8 0 SUS 0 7 Half relaxation time Gastrocnemius Medial -7.6
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Half relaxation time Gastrocnemius Medial -5.1
105 Herbert 1988 2 7 0 0 CON 0 7 Pt, Isometric max twitch force Gastrocnemius Medial




105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Pt, Isometric max twitch force Gastrocnemius Medial -6.8
105 Herbert 1988 2 7 0 0 CON 0 7 Po, Peak force Gastrocnemius Medial
105 Herbert 1988 2 7 8 0 SUS 0 7 Po, Peak force Gastrocnemius Medial -23
p<0.05 
vs. CON
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Po, Peak force Gastrocnemius Medial -15.7
p<0.05 
vs. CON
105 Herbert 1988 2 7 0 0 CON 0 7 Pt / Po Gastrocnemius Medial
105 Herbert 1988 2 7 8 0 SUS 0 7 Pt / Po Gastrocnemius Medial 5.5
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Pt / Po Gastrocnemius Medial 5.5
105 Herbert 1988 2 7 0 0 CON 0 7
P20 / Po (Max Tension at 
20Hz / Po)
Gastrocnemius Medial
105 Herbert 1988 2 7 8 0 SUS 0 7
P20 / Po (Max Tension at 
20Hz / Po)
Gastrocnemius Medial -4.3
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 





P20 / Po (Max Tension at 
20Hz / Po)
Gastrocnemius Medial 2.1
105 Herbert 1988 2 7 0 0 CON 0 7 Vo, shortening velocity Gastrocnemius Medial
105 Herbert 1988 2 7 8 0 SUS 0 7 Vo, shortening velocity Gastrocnemius Medial -6
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Vo, shortening velocity Gastrocnemius Medial -7.2
105 Herbert 1988 2 7 0 0 CON 0 7 Fatigue Index Gastrocnemius Medial
105 Herbert 1988 2 7 8 0 SUS 0 7 Fatigue Index Gastrocnemius Medial 11.1
105 Herbert 1988 2 7 8 524288 1.5 4 / day
Climbed 1-m grid inclined to 85° for 8 reps.  Rats 




0 8 Fatigue Index Gastrocnemius Medial 11.1
106 Hauschka 1987 2 28 0 0 CON 7 0 Wet Weight Whole Body
106 Hauschka 1987 2 28 8 0 SUS 8 0 Wet Weight Whole Body -1.4
106 Hauschka 1987 2 28 8 65536 10 / day
Rats dropped from 58cm angled at 45° so HL 
absorbed majority of force
SUS+D
RP
5 0 Wet Weight Whole Body -17.7
106 Hauschka 1987 2 28 0 0 CON 7 0 Wet Weight Soleus 
106 Hauschka 1987 2 28 8 0 SUS 8 0 Wet Weight Soleus -68.7
p<0.05 
vs. CON
106 Hauschka 1987 2 28 8 65536 10 / day
Rats dropped from 58cm angled at 45° so HL 
absorbed majority of force
SUS+D
RP
5 0 Wet Weight Soleus -68.7
p<0.05 
vs. CON
106 Hauschka 1987 2 28 0 0 CON 7 0 Myofiber distribution % Soleus fast twitch
106 Hauschka 1987 2 28 8 0 SUS 8 0 Myofiber distribution % Soleus fast twitch 30.7
p<0.05 
vs. CON
106 Hauschka 1987 2 28 8 65536 10 / day
Rats dropped from 58cm angled at 45° so HL 
absorbed majority of force
SUS+D
RP
5 0 Myofiber distribution % Soleus fast twitch 65.3
p<0.05 
vs. CON
106 Hauschka 1987 2 28 0 0 CON 7 0 Succinate Dehydrogenase Soleus slow twitch
106 Hauschka 1987 2 28 8 0 SUS 8 0 Succinate Dehydrogenase Soleus slow twitch 26.6
p<0.05 
vs. CON
106 Hauschka 1987 2 28 8 65536 10 / day
Rats dropped from 58cm angled at 45° so HL 
absorbed majority of force
SUS+D
RP









106 Hauschka 1987 2 28 8 0 SUS 8 0
a-glycerophosphate 
Dehydrogenase (GDP)
Soleus slow twitch 113
p<0.05 
vs. CON
106 Hauschka 1987 2 28 8 65536 10 / day
Rats dropped from 58cm angled at 45° so HL 






Soleus slow twitch 82.4
p<0.05 
vs. CON
106 Hauschka 1987 2 28 0 0 CON 7 0 Myofiber Cross Sectional Area Soleus slow twitch
106 Hauschka 1987 2 28 8 0 SUS 8 0 Myofiber Cross Sectional Area Soleus slow twitch -67.3
p<0.05 
vs. CON
106 Hauschka 1987 2 28 8 65536 10 / day
Rats dropped from 58cm angled at 45° so HL 
absorbed majority of force
SUS+D
RP





106 Hauschka 1987 2 28 0 0 CON 7 0 SDH / GDP Soleus slow twitch
106 Hauschka 1987 2 28 8 0 SUS 8 0 SDH / GDP Soleus slow twitch -43.6
p<0.05 
vs. CON
106 Hauschka 1987 2 28 8 65536 10 / day
Rats dropped from 58cm angled at 45° so HL 
absorbed majority of force
SUS+D
RP
5 0 SDH / GDP Soleus slow twitch -54.6
p<0.05 
vs. CON
106 Hauschka 1987 2 28 0 0 CON 7 0 Succinate Dehydrogenase Soleus fast twitch






106 Hauschka 1987 2 28 8 65536 10 / day
Rats dropped from 58cm angled at 45° so HL 
absorbed majority of force
SUS+D
RP









106 Hauschka 1987 2 28 8 0 SUS 8 0
a-glycerophosphate 
Dehydrogenase (GDP)
Soleus fast twitch 128.3
p<0.05 
vs. CON
106 Hauschka 1987 2 28 8 65536 10 / day
Rats dropped from 58cm angled at 45° so HL 











106 Hauschka 1987 2 28 0 0 CON 7 0 Myofiber Cross Sectional Area Soleus fast twitch
106 Hauschka 1987 2 28 8 0 SUS 8 0 Myofiber Cross Sectional Area Soleus fast twitch -50.3
p<0.05 
vs. CON
106 Hauschka 1987 2 28 8 65536 10 / day
Rats dropped from 58cm angled at 45° so HL 
absorbed majority of force
SUS+D
RP
5 0 Myofiber Cross Sectional Area Soleus fast twitch -53.2
p<0.05 
vs. CON
106 Hauschka 1987 2 28 0 0 CON 7 0 SDH / GDP Soleus fast twitch
106 Hauschka 1987 2 28 8 0 SUS 8 0 SDH / GDP Soleus fast twitch -57.1
p<0.05 
vs. CON
106 Hauschka 1987 2 28 8 65536 10 / day
Rats dropped from 58cm angled at 45° so HL 
absorbed majority of force
SUS+D
RP
5 0 SDH / GDP Soleus fast twitch -69.5
p<0.05 
vs. CON
107 Haddad 2006 2 6 0 0 CON 7 0 Wet Weight Gastrocnemius Medial
107 Haddad 2006 2 6 8 0 SUS 7 0 Wet Weight Gastrocnemius Medial -20
p<0.05 
vs. CON
107 Haddad 2006 2 6 8 16384 27
Days 1, 2, 
4, 5, 
electrodes placed in R. leg of anesthetized rat.  4 
sets of contractions of 10 reps against a footplate to 
produce maximal isometric tension
SUS+IS
M





107 Haddad 2006 2 6 0 0 CON 7 0 Relative Weight Gastrocnemius Medial
107 Haddad 2006 2 6 8 0 SUS 7 0 Relative Weight Gastrocnemius Medial -11
p<0.05 
vs. CON
107 Haddad 2006 2 6 8 16384 27
Days 1, 2, 
4, 5, 
electrodes placed in R. leg of anesthetized rat.  4 
sets of contractions of 10 reps against a footplate to 
produce maximal isometric tension
SUS+IS
M
7 0 Relative Weight Gastrocnemius Medial -4
107 Haddad 2006 2 6 0 0 CON 7 0 Protein Gastrocnemius Medial
107 Haddad 2006 2 6 8 0 SUS 7 0 Protein Gastrocnemius Medial 5
107 Haddad 2006 2 6 8 16384 27
Days 1, 2, 
4, 5, 
electrodes placed in R. leg of anesthetized rat.  4 
sets of contractions of 10 reps against a footplate to 
produce maximal isometric tension
SUS+IS
M
7 0 Protein Gastrocnemius Medial 12.7
p<0.05 
vs. SUS
107 Haddad 2006 2 6 0 0 CON 7 0 Myofibril Concentration Gastrocnemius Medial
107 Haddad 2006 2 6 8 0 SUS 7 0 Myofibril Concentration Gastrocnemius Medial -5
107 Haddad 2006 2 6 8 16384 27
Days 1, 2, 
4, 5, 
electrodes placed in R. leg of anesthetized rat.  4 
sets of contractions of 10 reps against a footplate to 
produce maximal isometric tension
SUS+IS
M
7 0 Myofibril Concentration Gastrocnemius Medial -10
107 Haddad 2006 2 6 0 0 CON 7 0 Myofibril Content Gastrocnemius Medial
107 Haddad 2006 2 6 8 0 SUS 7 0 Myofibril Content Gastrocnemius Medial -16
p<0.05 
vs. CON
107 Haddad 2006 2 6 8 16384 27
Days 1, 2, 
4, 5, 
electrodes placed in R. leg of anesthetized rat.  4 
sets of contractions of 10 reps against a footplate to 
produce maximal isometric tension
SUS+IS
M
7 0 Myofibril Content Gastrocnemius Medial -14
p<0.05 
vs. CON
107 Haddad 2006 2 6 0 0 CON 7 0 Total RNA Concentration Gastrocnemius Medial
107 Haddad 2006 2 6 8 0 SUS 7 0 Total RNA Concentration Gastrocnemius Medial -24
p<0.05 
vs. CON
107 Haddad 2006 2 6 8 16384 27
Days 1, 2, 
4, 5, 
electrodes placed in R. leg of anesthetized rat.  4 
sets of contractions of 10 reps against a footplate to 
produce maximal isometric tension
SUS+IS
M
7 0 Total RNA Concentration Gastrocnemius Medial 0
p<0.05 
vs. SUS
107 Haddad 2006 2 6 0 0 CON 7 0 Myostatin Levels Gastrocnemius Medial
107 Haddad 2006 2 6 8 0 SUS 7 0 Myostatin Levels Gastrocnemius Medial 400
p<0.05 
vs. CON
107 Haddad 2006 2 6 8 16384 27
Days 1, 2, 
4, 5, 
electrodes placed in R. leg of anesthetized rat.  4 
sets of contractions of 10 reps against a footplate to 
produce maximal isometric tension
SUS+IS
M
7 0 Myostatin Levels Gastrocnemius Medial 7
p<0.05 
vs. SUS
107 Haddad 2006 2 6 0 0 CON 7 0 Atrogin Levels Gastrocnemius Medial
107 Haddad 2006 2 6 8 0 SUS 7 0 Atrogin Levels Gastrocnemius Medial 230
p<0.05 
vs. CON
107 Haddad 2006 2 6 8 16384 27
Days 1, 2, 
4, 5, 
electrodes placed in R. leg of anesthetized rat.  4 
sets of contractions of 10 reps against a footplate to 
produce maximal isometric tension
SUS+IS
M
7 0 Atrogin Levels Gastrocnemius Medial 26
107 Haddad 2006 2 6 0 0 CON 7 0 MURF-1 mRNA Gastrocnemius Medial










107 Haddad 2006 2 6 8 16384 27
Days 1, 2, 
4, 5, 
electrodes placed in R. leg of anesthetized rat.  4 
sets of contractions of 10 reps against a footplate to 
produce maximal isometric tension
SUS+IS
M
7 0 MURF-1 mRNA Gastrocnemius Medial 23
108 Baek 2009 2 28 0 0 CON 0 10 Marrow Area Tibia 0
108 Baek 2009 2 28 8 0 SUS 0 12 Marrow Area Tibia 7.4
108 Baek 2009 2 28 0 1048576 Daily 250 ug/kg/hr CONBB 0 10 Marrow Area Tibia 0
108 Baek 2009 2 28 8 1048576 Daily 250 ug/kg/hr SUSBB 0 12 Marrow Area Tibia 2.9
108 Baek 2009 2 28 0 2097152 Daily 0.35 mg/kg/d CONLE 0 10 Marrow Area Tibia -4.6
108 Baek 2009 2 28 8 2097152 Daily 0.35 mg/kg/d SUSLE 0 12 Marrow Area Tibia -4.9
108 Baek 2009 2 28 0 0 CON 0 10 Cortical Shell Area Tibia 1.1
108 Baek 2009 2 28 8 0 SUS 0 12 Cortical Shell Area Tibia -14.8
p<0.05 
vs. PRE
108 Baek 2009 2 28 0 1048576 Daily 250 ug/kg/hr CONBB 0 10 Cortical Shell Area Tibia -2.5
108 Baek 2009 2 28 8 1048576 Daily 250 ug/kg/hr SUSBB 0 12 Cortical Shell Area Tibia -16.8
p<0.05 
vs. PRE
108 Baek 2009 2 28 0 2097152 Daily 0.35 mg/kg/d CONLE 0 10 Cortical Shell Area Tibia -4.8
108 Baek 2009 2 28 8 2097152 Daily 0.35 mg/kg/d
SUSLE
P
0 12 Cortical Shell Area Tibia -12.1
p<0.05 
vs. PRE
108 Baek 2009 2 28 0 0 CON 0 10 Total Area Tibia 0.4
108 Baek 2009 2 28 8 0 SUS 0 12 Total Area Tibia -2
108 Baek 2009 2 28 0 1048576 Daily 250 ug/kg/hr CONBB 0 10 Total Area Tibia -1.1
108 Baek 2009 2 28 8 1048576 Daily 250 ug/kg/hr SUSBB 0 12 Total Area Tibia -2.5
108 Baek 2009 2 28 0 2097152 Daily 0.35 mg/kg/d CONLE 0 10 Total Area Tibia -5.1
108 Baek 2009 2 28 8 2097152 Daily 0.35 mg/kg/d SUSLE 0 12 Total Area Tibia -7.9
110 Fluckey 2002 2 28 0 0 CON 0 4 Wet Weight Soleus 
110 Fluckey 2002 2 28 8 0 SUS 0 5 Wet Weight Soleus 
p<0.05 
vs. CON
110 Fluckey 2002 2 28 8 64
3 times / 
week





110 Fluckey 2002 2 28 0 0 CON 0 4 Fractional Synthesis Rate
110 Fluckey 2002 2 28 8 0 SUS 0 5 Fractional Synthesis Rate
p<0.05 
vs. CON
110 Fluckey 2002 2 28 8 64
3 times / 
week
2 sets of a maximum of 25 reps (or point of failure) SUSEX 0 5 Fractional Synthesis Rate
p<0.05 
vs. SUS
110 Fluckey 2002 2 28 0 0 CON 0 4 Bone Mineral Density Distal Femur
110 Fluckey 2002 2 28 8 0 SUS 0 5 Bone Mineral Density Distal Femur -7.7
p<0.05 
vs. CON
110 Fluckey 2002 2 28 8 64
3 times / 
week
2 sets of a maximum of 25 reps (or point of failure) SUSEX 0 5 Bone Mineral Density Distal Femur
110 Fluckey 2002 2 28 0 0 CON 0 4 Bone Mineral Density Mid-shaft Femur
110 Fluckey 2002 2 28 8 0 SUS 0 5 Bone Mineral Density Mid-shaft Femur
110 Fluckey 2002 2 28 8 64
3 times / 
week
2 sets of a maximum of 25 reps (or point of failure) SUSEX 0 5 Bone Mineral Density Mid-shaft Femur
